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Abstract 
Rift Valley fever phlebovirus (RVFV) is an ongoing threat to both humans and 
animals across the continent of Africa. RVFV is a member of the Phlebovirus 
genus and Phenuviridae family, within the Bunyavirales order. Members of the 
Phlebovirus genus are characterised by a negative sense tripartite RNA genome. 
The large (L) segment encodes the RNA-dependent RNA polymerase (L), the 
medium (M) segment encodes the two glycoproteins Gn and Gc, and the small 
segment (S) encodes the nucleocapsid (N) protein and the non-structural protein 
NSs. The N protein performs a number of important functions, including 
encapsidation of the viral genome allowing viral RNA replication and 
transcription. Research into N protein-protein interactions has been  limited. 
The work presented in this thesis characterises previously unidentified functional 
residues of RVFV N protein and describes new insights into virus-host protein-
protein interactions. Two previously uncharacterized N protein residues, F11 and 
F149, when substituted for alanine, performed all its known functions; 
Encapsidation of the viral genome, N-N multimerisation and L protein 
interaction. However, utilising a minigenome assay still showed these mutants 
lack replication capacity. This indicates that currently unknown interactions 
with these residues are disrupted. Furthermore, a proteomics study on N protein 
immunoprecipitated from lung epithelial A549 cell infections was performed to 
identify RVFV N interaction partners, revealing 23 potential candidates. A 
subsequent siRNA knockdown of candidates identified β-catenin, Polyadenylate 
binding protein 1 and 4, Annexin 1 and 2, and Scaffold attachment factor B as 
important for functional viral replication. Previous research indicated β-catenin, 
the effector molecule of the WNT pathway, was involved with RVFV replication. 
Utilising a TOPFlash reporter assay, it was determined that the WNT pathway, of 
which β-catenin is the effector molecule, was inhibited by RVFV infection. The 
generation of a CRISPR-Cas9 β-catenin knockout cell line provided a useful tool 
for further study into N protein-protein and RVFV-β-catenin interactions. The 
knockout of β-catenin significantly reduced RVFV replication, similarly to siRNA-
mediated knock down. Additionally, it was observed through the use of confocal 
microscopy that upon infection with RVFV, β-catenin relocalised from the 
plasma membrane to a diffuse pattern across the cytoplasm. Furthermore, 
during the course of this study, it was investigated whether RVFV N protein can 
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affect mosquito antiviral pathway(s), similarly to yellow fever virus (genus 
flavivirus) capsid protein. Using alphavirus Semliki Forest virus (SFV) as a model, 
allowing work to be carried out in a CL-2 lab setting, it was found that N protein 
does not possess such properties. However, Zika virus (genus flavivirus) capsid 
protein (ZIKV C) showed significant proviral properties, however, this effect did 
not occur via disruption of the siRNA pathway, the most efficient mosquito 
antiviral mechanism, as evidenced by ZIKV C having no effect within our siRNA 
assay. To summarise, the data in this thesis reveals new interactions between 
RVFV nucleocapsid protein and mammalian host proteins that are important for 
RVFV replication. It provides a basis for future research on RVFV (or 
phleboviruses, in general) nucleocapsid research. The disruption of RVFV N-host 
protein interactions or direct disruption of N function could lead to new 
therapeutic strategies against this important emerging virus.  
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Chapter 1 Introduction 
1.1 Bunyavirales molecular biology 
1.1.1 Bunyavirales order classification 
The Bunyavirales order is a large order of RNA viruses. The International 
Committee on Taxonomy of Viruses (ICTV)  updated the relevant taxonomy of 
the formally known as Bunyaviridae family in 2017. The Bunyavirales order 
includes 9 distinct families; Feraviridae, Fimoviridae, Hantaviridae, Jonviridae, 
Nairoviridae, Peribunyaviridae, Phasmaviridae, Phenuviridae and Tospoviridae. 
The members of the Bunyavirales order all share some common characteristics; 
virions are spherical or pleomorphic and between 80-120 nm in diameter. Virions 
are enveloped and display glycoproteins on the surface of the envelope. The 
viral genome consists of three negative or ambisense single stranded RNA 
segments and all stages of virus replication occur in the cytoplasm 
(https://talk.ictvonline.org/taxonomy/). 
The families within the Bunyavirales order are further categorised into 13 
genera; Hantaviridae has one classified genus Orthohantavirus, Peribunyaviridae 
has two: Herbevirus and Orthobunyavirus. Phenuviridae has a further four 
genus; Goukovirus, Phasivirus, Phlebovirus and Tenuivirus. These distinct genera 
were identified through Bayesian modelling of sequence data and contain a 
number of important human and animal pathogens. 
The Bunyavirales order consists primarily of arthropod borne viruses 
(arboviruses); that is, viruses transmitted through the bite of an arthropod 
vector including mosquitos, ticks, thrips and biting midges. With the exception 
of the Hantaviridae, which are transmitted through aerosolization of virus 
particles within rodent urine, saliva or faeces (Watson et al., 2014). 
Hantaviridae are also distinguished by the incidental nature of vertebrate 
infections that are almost always a dead-end host, resulting in the end of the 
virus infection chain. Not all members of the Bunyavirales order infect 
vertebrates, Tenuiviruses of the family Phenuiviridae and the Tospoviridae 
family are transmitted by thrips and are pathogenic to plants. 
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The transmission cycle of most bunyaviruses is maintained in nature through the 
invertebrate host, which can include Phlebotominae (commonly referred to as 
sandflies), mosquitoes, ticks, biting midge or thrips. Rift Valley fever phlebovirus 
of the Phenuviridae family is transmitted primarily by mosquitos and follows an 
enzootic cycle between ruminants, wild vertebrates and humans (Figure 1-1). 
Bunyaviruses multiply within the host after oral feeding or injection by the 
vector, though some members of the Orthobunyaviridae and Phenuviridae 
families are also transmitted transovarially by their vectors (Watts et al., 1973, 
Endris et al., 1983). Tick-borne arboviruses such as those found in the 
Phlebovirus genus can be transferred through transstadial transmission to the 
next development stage of the tick life cycle (Zhuang et al., 2018). The broad 
range of hosts, vectors and transmission cycles highlight the diversity of the 
Bunyavirales order and the importance of unveiling molecular mechanisms of 
each of its members.  
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Figure 1-1. Mosquito-transmitted bunyavirus transmission cycle 
The transmission cycle of Rift Valley fever phlebovirus (RVFV). Solid arrows 
represent confirmed routes of transmission through experimental data and 
dotted lines represent suspected routes of transmission. Adapted from (Lumley 
et al., 2017). 
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1.1.2 Classification and geographical distribution of 
Phenuiviridae. 
The Phenuiviridae family is comprised of 4 genera: Goukovirus, Phasivirus, 
Tenuivirus and Phlebovirus. The Goukovirus genus prototype is Gouleako 
goukovirus, was thought to have prevalence in pigs throughout South Korea 
(Chung et al., 2014), however is now considered to be insect specific (Junglen et 
al., 2015). The Phasivirus prototype is Badu phasivirus, a recently discovered 
insect specific virus (Hobson-Peters et al., 2016). Viruses of the Tenuivirus genus 
are plant specific, characterised by the Rice stripe tenuivirus. The Phlebovirus 
genus is the largest and most widely studied genus of the Phenuiviridae family. 
The genus contains 10 virus species that are broadly divided into two specific 
groups based primarily on their genomic and vector similarities (Figure 1-2). The 
Phlebotomus group of viruses are transmitted by phlebotomines or mosquitoes 
however the Uukuniemi-like group are transmitted by ticks. Another important 
observation between the two groups is the lack of non-structural gene NSm in 
the Uukuniemi-like group, though there is no evidence of this distinction 
impacting vector specificity. 
The Phlebotomine group consists of a number of important pathogens, including 
the prototype Phlebovirus, Rift Valley fever phlebovirus (RVFV, as described 
previously), Punta Toro phlebovirus (PTV), Sandfly fever Naples phlebovirus 
(SFNV) and Sandfly fever Sicilian virus (SFSV). The Uukuniemi-like group is based 
on Uukuniemi phlebovirus (UUKV) but also includes SFTS phlebovirus (SFTSV; 
previously known as severe fever with thrombocytopenia syndrome virus).These 
groups now include strains such as Toscana (TOSV), Heartland (HRTV) and Lone 
Star phleboviruses (LSV) that were previously assigned as species. The recent 
reorganisation of taxonomy has streamlined phylogeny allowing easier 
categorisation of emerging Phenuiviridae, particular as a growing number of 
novel Phenuiviridae have been identified. Phleboviruses have a global 
distribution determined by their specific vectors. TOSV is distributed across the 
Mediterranean basin, with seroprevalence in countries including Italy, France, 
Spain, Portugal and Cyprus in correspondence with its mosquito vector (Cusi et 
al., 2010). The distribution of vectors is evolving with climate change and 
globalization which is likely to result in further spread of phleboviruses into new 
ecological niches (Cusi et al., 2010, Gould et al., 2017).   
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Figure 1-2. Phylogenetic analysis of phleboviruses. 
Phylogenetic relationships between phleboviruses with highlighted vector groups 
analysed by nucleotide sequence modelling. (A) L segment RNA, (B) M segment 
RNA and (C) S segment RNA were analysed. Figure taken from (Matsuno et al., 
2013).  
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1.1.3 Genome structure 
The Bunyavirales is an order of viruses that are characterised by negative sense 
or ambisense single stranded RNA genome consisting of three unique segments. 
These segments are identified and named as large (L), medium (M) and small (S) 
based on their relative size (in base pairs). The size of each segment varies 
widely between different genera and strains of the Bunyavirales as highlighted in 
Figure 1-3. Genome structure of Bunyavirales members.Each segment is flanked 
by viral untranslated regions (UTR), the nt of each UTR are complementary, 
resulting in a characteristic pan-handle structure essential for the formation of 
viral ribonucleoproteins (RNP) (Lowen and Elliott, 2005, Gauliard et al., 2006). 
The viral genomic segments encode four structural proteins: the negative sense 
L RNA segment encodes the RNA-dependent RNA polymerase (L). The negative 
sense, M RNA segment encodes the polyprotein precursor that is cleaved to 
produce the two glycoproteins, Gn and Gc. The S segment encodes the 
nucleocapsid (N) protein. Many of the Bunyavirales also encode for non-
structural proteins as important virulence factors (Figure 1-3). The Phenuiviridae 
and Tospoviridae families uniquely employ an ambisense strategy on the viral S 
segment, encoding for the non-structural protein S (NSs). Bunyavirales members 
encode another non-structural protein NSm. Tospoviridae family uniquely utilises 
an ambisense M segment to encode NSm. 
As bunyaviruses primarily have a negative sense single stranded RNA genome, 
upon infection each segment is used to transcribe a positive sense mRNA 
allowing the translation of viral proteins. In addition, each segment is copied in 
to an antigenomic RNA which is used as a template for the replication to 
generate nascent negative sense RNA genomes. However, the ambisense coding 
strategy employed in the S segment of some families also allows the generation 
of separate subgenomic RNAs. The generation of N subgenomic RNA occurs from 
the transcription of the negative sense genomic RNA however the NSs 
subgenomic RNA is transcribed from the antigenomic RNA (Figure 1-4)(Bouloy 
and Weber, 2010) This coding strategy was thought to function to temporally 
regulate the expression of N and NSs during infection, as the negative sense 
genomic RNA can be directly transcribed into mRNA, N protein expression occurs 
earlier in infection. The positive sense genomic RNA however has a further step 
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of transcription to negative sense anti-genome before generation of mRNA 
transcripts. The function of NSs as an interferon antagonist would indicate the 
need to be expressed early for successful infection and overcoming the host 
immune response. As such, RVFV packages positive sense NSs transcripts into 
virions that allow early expression of NSs in infection (Brennan et al., 2014). 
With RVFV, the transcriptional efficiency and promotor strength has also been 
shown to be higher for the negative sense N sequence than for the positive sense 
NSs sequence (Brennan et al., 2014). Bunyavirus morphology is characterised by 
three pan-handle RNP segments encased in an envelope studded with the 
glycoproteins Gn and Gc (Figure 1-4). Bunyavirus structure and morphology is 
further described in 1.1.5.   
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Figure 1-3. Genome structure of Bunyavirales members. 
A schematic depicting the genome structure of members of the Bunyavirales 
order, including BUNV, HTNV, DUGV, RVFV and TSWV representing 
Peribunyaviridae, Hantaviridae, Nairoviridae, Phenuviridae and Tospoviridae 
respectively. All segments are presented in a 3’ to 5’ orientation as is 
convention for negative strand viruses, with arrows depicting the direction of 
transcription. Genome lengths are depicted above each viral segment and 
molecular weight of viral proteins is shown.  
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Figure 1-4. Viral structure and genome coding strategy of RVFV  
Schematic representation of the organisation of the RVFV viral particle and its 
ambisense genome coding strategy. (A) A representation of the viral particle 
with the glycoproteins studding the viral envelope and the formation of “pan-
handle” RNP complexes. (B) The negative sense genome is transcribed into a 
positive sense antigenome which is used as a template for genome replication, 
or it can be transcribed into mRNA for translation of the L or M precursors. The 
ambisense genome transcribes the N mRNA in the negative sense as above, 
however mRNA production of the NSs gene requires the generation of an 
intermediate antigenome RNA before transcription of NSs mRNA. Red dotted 
arrows represent mRNA.  
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1.1.4 Bunyavirus gene products: expression and function 
1.1.4.1 RNA-Dependent RNA polymerase 
The RNA-dependent RNA polymerase, commonly referred to as RdRp or L protein 
is encoded by the large segment of the genome. The molecular weight (m.w.) of 
L varies according to genus, and is found to be between 240 – 460 kDa. The L 
protein of the Bunyavirales order and Arenaviridae family contain a unique 
conserved region found between the premotif A and polymerase module A that 
can only be found in negative-stranded RNA viruses (Müller et al., 1994). The 
polymerase contains 6 polymerase modules labelled from PreA to A-E common 
between all RNA-dependent RNA polymerases. The L protein has also been 
identified to contain cap-snatching domains, a function exclusive to single 
stranded negative sense viruses (Reguera et al., 2010). La Crosse virus (LACV) 
These domains function to recognise capped cellular mRNAs and cleave 10-14 
nucleotides downstream to prime viral mRNA transcription. This mechanism has 
been identified in Orthobunyaviridae, Arenaviridae and Phenuiviridae (Reguera 
et al., 2016, Brennan et al., 2011a, Shi and Elliott, 2009).  
1.1.4.2 Nucleocapsid 
The nucleocapsid (N) protein is the most abundant viral protein detected during 
bunyaviral infection. The size of N monomers varies between different members 
of the Bunyavirales order. A key function of N is multimerisation, where N binds 
to adjacent monomers to form multimeric structures (Ferron et al., 2011). The 
number of monomers required to form a functional multimeric structure again 
varies between Bunyavirales members (Table 1-1). N protein has two key 
structural elements that aid in the formation of multimeric structures. Primarily, 
it has a flexible N-terminal arm that can rotate through differing degrees in 
order to bind adjacent N proteins (Raymond et al., 2012). The binding of the N-
terminal arm occurs in a hydrophobic globular binding pocket near the C-
terminus of N. By observation of the crystal structure, it was shown that in the 
absence of bound RNA, the N-terminal arm binds into its own globular binding 
pocket resulting in a low-energy closed conformation, thus hinting that this 
process is strongly linked to the second primary function of N, the encapsidation 
of the viral genomic segments (Raymond et al., 2010).  
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The formation of N protein into multimeric structures allows the binding of the 
RNA genome into a positively charged RNA binding cleft (Figure 1-5). The binding 
cleft has a varied capacity depending on the size of the nucleocapsid, with RVFV 
N having the capacity to bind 6 nucleotides per monomer, thus 36 per hexamer 
(Raymond et al., 2012, Ferron et al., 2011). This encapsidation process is 
essential for the formation of RNP complexes, allowing the recruitment of L and 
the further transcription and replication of the genome. While the mechanism of 
this is relatively understudied, it has been shown in the related phlebovirus 
TOSV that the binding of RNA to TOSV N results in an inter-subunit rotation 
allowing the formation of a helical shape characteristic of many negative-strand 
viruses (Olal et al., 2014). In addition, the encapsidation process also functions 
to protect the viral genome from harsh cytoplasmic conditions including RNA 
degradation through RNase enzymes. N protein also plays an important role in 
packaging of genome into virions by interacting with the cytoplasmic tails of 
RVFV glycoproteins (Overby et al., 2007). As replication takes place in the 
cytoplasm during infection, both L protein and N protein are typically observed 
with a diffuse localisation throughout the cytoplasm. 
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Figure 1-5. RVFV N protein monomeric and multimeric structure and electrostatic potential. 
(A) A ribbon structure of RVFV N protein with highlighted subdomains; N-
terminal arm in red, globular domains in brown and green and C-terminus in 
blue. (B) A surface structure of RVFV N protein with highlighted oligomerisation 
groove and RNA binding cleft. (C) The positively charged residues of N are 
evident on the internal ring of the multimeric structure. Taken from (Ferron et 
al., 2011).  
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Virus  Nucleocapsid 
size 
Multimeric units 
RVFV 27 kDa 6 units 
RV 56 kDa 11 units 
VSV 47 kDa 10 units 
RSV 43 kDa 10 units 
IVA 56 kDa 9 units 
BUNV 26 kDa 4 units 
HTNV 50 kDa 3 units 
 
Table 1-1 N protein size and unit variation between –ve sense RNA viruses. 
1.1.4.3 Glycoproteins 
Bunyavirales order members encode for a single polyprotein on the M genomic 
RNA segment. This transcript encodes a polyprotein that is post translationally 
cleaved into two glycoproteins, Gn and Gc. In the case of RVFV, there is an 
additional cleavage event resulting in the production of a small non-structural 
protein termed (NSm) that is translated through alternative start codon usage of 
5 AUG sites within the transcript. This alternative codon usage, potentially 
through a leaky scanning mechanism, results in the translation of two further 
non-structural proteins, NSm’ and P78 (Figure 1-6)(Kreher et al., 2014). Gn and 
Gc are integral for virus attachment to the cell membrane and viral entry (De 
Boer et al., 2012b). They are type-I membrane glycoproteins that form 
functional heterodimers. Gn has been identified to contain a Golgi localisation 
signal and Gc an endoplasmic reticulum retention signal thus Gn-Gc 
heterodimers are formed in the ER before subsequent relocalisation to the Golgi 
apparatus (Andersson and Pettersson, 1998). The targeting signals found on Gn 
vary widely between different Bunyavirales members (Carnec et al., 2014). As 
bunyaviruses do not encode a matrix protein, the interaction between the C-
terminal cytoplasmic tail of Gn and the nucleocapsid allows the assembly of RNP 
complexes into the virion and allows the budding of mature virions from the 
lumen of the Golgi (Piper et al., 2011, Hepojoki et al., 2010).  
Glycoprotein Gc is composed mainly of β-sheets and thus has been proposed to 
be a class II viral fusion protein (Garry and Garry, 2004), similar to those 
encoded by the Flaviviridae and Arenaviridae. Thus, Gc acts as the fusion 
molecule between the viral envelope and the host cell membrane. For the 
Phenuiviridae, the primary receptor for Gn has been identified as the 
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interceullar adhesion molecule-3-grabbing non-integrin (DC-SIGN) (Hofmann et 
al., 2013, Phoenix et al., 2016b). With RVFV, N-glycans on the surface of Gn 
have been shown to bind DC-SIGN. There is also evidence showing the C-type 
lectin (77% homology) L-SIGN can also be used as a receptor for entry of these 
viruses (Léger et al., 2016).  
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Figure 1-6 RVFV M segment polyprotein post processing and cleavage.  
The polypeptide 78kD-Gc and NSm-Gn-Gc are transcribed from the 1st AUG and 
2nd AUG respectively. There are two signal peptidase cleavage sites. The first 
cleavage site at 477-482 allows the cleavage of NSm-Gn-Gc into NSm and Gn. 
The second cleavage site resides at position 2088-2093 and functions to cleave 
the 78kD-Gc (Phoenix et al., 2016a). This site also cleaves NSm-Gn-Gc into NSm-
Gn and Gc. Adapted from (Kreher et al., 2014).  
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1.1.4.4 Non-structural NSs proteins 
The S segment of some bunyaviruses, including RVFV, encodes for a non-
structural protein (NSs) in the positive sense orientation (Figure 1-3), whereas 
other bunyaviruses encode NSs from within the N ORF. In RVFV, the NSs protein 
is 265 aa long and 31 kDa in size. The primary function of vertebrate infecting 
bunyavirus NSs is believed to be the antagonism of the interferon system (Eifan 
et al., 2013). This function is conserved across bunyaviruses despite little 
sequence homology as evidenced by the sand-fly fever group of phleboviruses, 
where NSs amino acid sequence homology ranges between 7.5 and 28.6%, 
despite carrying out broadly similar functions (Xu et al., 2007). NSs is non-
essential for replication, however non-functional NSs-deletant viruses (delNSs) 
often show an attenuated phenotype and reduced viral growth kinetics (Bird et 
al., 2008). RVFV NSs has been identified to inhibit the JAK/STAT signalling 
pathway; dysregulating the inflammatory response (Benferhat et al., 2012). 
However, most research focuses on NSs protein’s inhibitory effect on general 
host transcription (Billecocq et al., 2004). Additionally, RVFV NSs specifically 
targets IFN-β for transcriptional inhibition through the formation of a 
multiprotein repression complex that binds to the IFN-β promoter (Figure 1-7) 
(Le May et al., 2008). NSs protein localises and accumulates in the nucleus 
through use of two PXXP motifs (Proline.any.any.Proline) present within the 
encoded amino acid sequence at positions 29 to 32 and 82 to 85. These motifs 
are absent in the RVFV clone 13 NSs and requires nuclear localisation to carry 
out its inhibitory functions (Billecocq et al., 2004). In RVFV specifically, it was 
previously considered that the highly acidic 17aa C-terminus of NSs functions, 
along with a ΩXaV (Aromatic.any.acidic.valine) motif to form distinct 
filamentous structures (Yadani et al., 1999, Cyr et al., 2015), however a 
crystallisation study of NSs with N and C terminal deletions still formed 
filamentous structures (Barski et al., 2017); this discrepancy is considered to be 
an artefact of single terminal deletions resulting in non-native self-interactions 
and destabilization of the filaments, an effect lost in N,C double mutants. These 
filamentous structures are an important virulence factor. The formation of 
filamentous structures requires a direct interaction between the terminal region 
of the NSs protein and p44 subunit of general transcription factor IIH (TFIIH) (Le 
May et al., 2004). By sequestering p44, the TFIIH complex components p62 and 
Xeroderma pigmentosum group D (XPD) subunits were degraded. RVFV NSs 
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protein binds p62 through the use of aa ΩXaV motif (Cyr et al., 2015) and F-box 
ubiquitin ligase (FBXO3) resulting in ubiquination of p62 and subsequent 
degradation and suppression of the IFN response (Kalveram et al., 2011, 
Kainulainen et al., 2014).  
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Figure 1-7. Schematic detailing the mechanism of NSs-mediated TFIIH suppression. 
The TFIIH complex is inhibited either through the sequestration of p44 by the 
NSs protein or through NSs interaction with FBXO3 and subsequent ubiquitination 
and proteosomal degradation of p62. Adapted from (Ly and Ikegami, 2016).  
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1.1.4.5 Non-structural proteins NSm, Nsm’ and P78 
During the replication of RVFV, the leaky scanning and differential cleavage of 
the M segment polyprotein results in the expression of three non-structural 
proteins NSm, a 14-kDa cytosolic protein and P78 (NSm’) and a 78 kDa 
glycoprotein (P78). Translation from the first AUG and further differential 
cleavage results in production of the NSm-Gn fusion protein known as P78 
(Figure 1-6). The translation from AUG2 results in the expression of NSm and the 
translation from AUG3? results in NSm’. The translation from AUG4 and AUG5 
express just the glycoproteins Gn and Gc. Both NSm and P78 are non-essential 
for viral replication, maturation and infection in cell culture (Won et al., 2006, 
Gerrard et al., 2007). NSm localises to the mitochondrial membrane and 
prevents early cellular apoptosis through inhibition of caspase 8, potentially 
caspase 9, and caspase 3 (Terasaki et al., 2013, Won et al., 2007). In addition, 
NSm is important for regulating reactive oxygen species (ROS) potentially 
through the activation of p38 MAPK (Narayanan et al., 2011). P78 however 
localises to the Golgi complex (Wasmoen et al., 1988) and forms heterodimers 
with Gc, resulting in packaging within the virus particle. However, despite 
expression within mammalian cells, packaging of P78 has only been observed in 
mosquito cell culture (Weingartl et al., 2014). NSm and NSm’ are important for 
replication in the vector host and P78 has been identified as an important for 
virus dissemination within mosquitos (Kading et al., 2014, Kreher et al., 2014). 
1.1.5 Virion structure 
The virion structure of bunyaviruses are composed of four structural proteins. 
The nucleocapsid protein and the RNA-dependent RNA polymerase, which form 
the functional units of the ribonucleoprotein complex when bound the three RNA 
genomic segment and the glycoproteins Gn and Gc which are studded on the 
surface of the lipid envelope. The RNP complexes have a distinct shape within 
the cytoplasm and virion, displaying a circular panhandle structure important for 
replication in the infected cell (Obijeski et al., 1976). The average replication 
time for a genomic segment was estimated to be 40 min (Wichgers Schreur and 
Kortekaas, 2016). These RNPs are packaged into the virion in a non-selective 
process, resulting in many virions lacking genome segments. As expected with 
non-selective packaging, the intracellular genome segments average a S:M:L 
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ratio of 1:1:1 yet individual cells had major variation in genome segment ratio 
(Wichgers Schreur and Kortekaas, 2016). It is also evident that while the 
majority of packaged segments are genomic there are a proportion of 
antigenomic segments packaged in RVFV virions (Brennan et al., 2014).  
Virion morphology and size varies between different members of the 
Bunyavirales. The virion diameter has been observed for a number of 
bunyaviruses including Bunyamwera orthobunyavirus (BUNV) at 108 ± 8 nm 
(Bowden et al., 2013), UUKV at 95-125 nm (Overby et al., 2008) and RVFV at 102 
± 3 nm (Bowden et al., 2013, Freiberg et al., 2008). The lipid envelope 
surrounding RVFV RNP complexes is studded with 350-375 glycoprotein spikes 
which measure 10 to 18 nm in length and approximately 5 nm in diameter (Ellis 
et al., 1988). RVFV and UUKV have both been found to have an icosahedral 
lattice of glycoproteins where T=12 (Freiberg et al., 2008, Overby et al., 2008). 
BUNV however was found to be pleomorphic (Bowden et al., 2013) and Tula 
orthohantavirus can form both spherical and elongated virions (Huiskonen et al., 
2010) thus highlighting the diversity of morphologies seen within bunyaviruses 
virions.  
1.1.6 Replication cycle 
1.1.6.1 Viral Entry 
Bunyaviruses have a similar entry mechanism to other enveloped viruses, 
utilising the virally-encoded glycoproteins Gn and Gc (1.1.4.3) in a 
heterodimeric conformation to bind to receptors on the host cell surface. 
Different bunyaviruses make use of varying receptors and cellular factors to gain 
entry to a multitude of different cell types from different host species. 
Arthropod-borne bunyavirus entry classically begins with the bite of an infected 
arthropod into the dermis of its vertebrate host. At the bite site, bunyaviruses 
first encounter dendritic cells and dermal macrophages (Albornoz et al., 2016), a 
process common to arboviruses that provides new cellular targets for infection 
(Pingen et al., 2016). To gain access to the intracellular environment, RVFV and 
other Phleboviruses utilise the glycosaminoglycan (GAG) heparin sulfate to dock 
to the membrane of the cell using electrostatic interactions (Figure 1-8 part 1) 
(De Boer et al., 2012a, Riblett et al., 2016). This was evidenced by 
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competitively inhibiting GAGs reduced Phlebovirus infection (Pietrantoni et al., 
2015). As mentioned previously (1.1.4.3) RVFV and other members of the 
Phlebovirus genus utilise the C-type lectin DC-SIGN for infection and entry of 
dendritic cells. By overexpressing DC-SIGN on the surface of cells that do not 
effectively support bunyavirus infection, one can significantly improve infection 
with RVFV, UUKV and TOSV (Lozach et al., 2011). In addition to DC-SIGN, RVFV, 
TOSV and UUKV have been shown to exploit a second C-type lectin L-SIGN as a 
receptor (Léger et al., 2016). Hantavirus receptor-mediated entry is vastly 
different from other bunyaviruses due to the nature of Hantavirus aerosol 
transmission. Hantaviruses first cellular contact is with lung epithelium and 
Hantaviruses utilise intergrins β1, β2 (CD18) found on endothelial neutrophils, and 
β3 found on platelets and endothelial cells, to gain entry to the intracellular 
space (Raftery et al., 2014, Gavrilovskaya et al., 1998). Additionally, receptors 
decay-accelerating factor (DAF)/CD55 and the receptor for the global domain of 
complement C1q (gC1qR)/p32 are also important for Hantavirus entry 
(Krautkrämer and Zeier, 2008, Choi et al., 2008).  
Once bound to the receptor, bunyaviruses must be endocytosed to gain entry to 
the intracellular environment. It was determined using a UUKV model system 
that receptors are recruited to virus particles to form a receptor-rich 
microdomain on the plasma membrane at the site of virus entry (Lozach et al., 
2011). DC-SIGN was identified as an important endocytic receptor as well as 
attachment factor in UUKV infection, in contrast L-SIGN was not used during 
endocytosis indicating its role as purely an attachment factor (Léger et al., 
2016). Bunyaviruses have been shown to utilise different endocytic methods to 
gain cellular entry. Orthobunyaviruses and nairoviruses primarily use clathrin-
mediated endocytosis to infect cells, however the mechanism of Phlebovirus 
entry still remains unclear. UUKV entry has been associated with clathrin-coated 
pits and vesicles however clathrin silencing had no effect on the ability of UUKV 
to infect cells in culture (Lozach et al., 2011, Lozach et al., 2010). RVFV has 
been suggested in numerous studies to use a variety of different cellular entry 
methods, including clathrin, caveolin-dependent and micropinocytosis (Figure 
1-8 part 2) (Harmon et al., 2012, De Boer et al., 2012b, Filone et al., 2010) thus 
bunyavirus entry may be cell, tissue or virus strain specific. 
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Upon uptake, bunyavirus particles are transported via vesicles through the 
endocytic machinery before subsequent fusion and penetration into the cytosol. 
Bunyaviruses transit through early endosomes (EE) to late endosomes (LE), 
encountering a pH ranging from ~6.5 in EEs to ~5.5-5 in LE. Endosomal 
acidification is thought to be the trigger for bunyavirus activation and 
penetration (Figure 1-8 part 3) (Harmon et al., 2012, De Boer et al., 2012b, 
Shtanko et al., 2014). The blocking of trafficking and maturation of EEs blocks 
infection of many bunyaviruses including UUKV and CCHFV (Shtanko et al., 2014, 
Hollidge et al., 2012, Lozach et al., 2010). RVFV and UUKV are late penetrating 
viruses, meaning that they penetrate between 20-40 min after internalisation 
which corresponds with the maturation of the late endosome (Lozach et al., 
2010, De Boer et al., 2012b). In addition, bunyaviruses require an intact 
microtubule network for successful infection, allowing the trafficking of the LE 
towards the nucleus (Simon et al., 2009, Lozach et al., 2010).  
Endocytosed viruses must fuse with the endosomal vesicle membrane to release 
their genome into the cytosol (Figure 1-8 part 4). This fusion event, as 
mentioned previously (1.1.4.3), is primarily mediated by the envelope 
glycoproteins Gn and Gc. In RVFV and UUKV infection, changes in glycoprotein 
conformation and resulting fusion event is triggered by low pH acidic conditions 
(Overby et al., 2007, De Boer et al., 2012b). Thus, upon conformational change, 
glycoproteins harpoon the endosomal lipid bilayer resulting in hemifusion and 
fusion pore formation allowing the viral RNA to be delivered into the cytoplasm 
(Albornoz et al., 2016). 
1.1.6.2 Transcription and translation 
Following entry of the viral genomic RNPs into the cytosol, transcription from 
genomic RNA occurs (Figure 1-8 part 5). This process involves the viral L protein 
utilising its cap-snatching mechanism of cleaving the 10-18 nucleotide long 7-
methylguanosine (m7G) cap from host cell pre-mRNA (Shatkin, 1976, Topisirovic 
et al., 2011). The host cell pre-mRNA caps are transferred to the 5’ end of the 
viral transcript by L protein activity allowing recognition of viral mRNA by host 
cell ribosomes (Patterson et al., 1984, Garcin et al., 1995). The complementary 
regions of the viral genomic segments UTR regions are important for the 
formation of panhandle RNP structures; however they are also involved in the 
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binding of L to the RNP and crucial in determining promoter strength, therefore 
are important for regulating viral RNA synthesis (Kohl et al., 2004, Mir and 
Panganiban, 2004). The S, M and L mRNAs are bound by free ribosomes in the 
cytoplasm for translation, while M transcription is initiated in the cytoplasm, it 
is hypothesised that Gn subsequently recruits M complexes to membrane bound 
ribosomes at the ER (Wichgers Schreur and Kortekaas, 2016).  
Bunyaviral mRNAs do not contain a poly(A) tail nor any U-rich sequences. 
Transcription termination signals are variable between segments but are 
generally located upstream of the 3’ end of the genomic mRNA. Some 
termination signals have been identified such as a purine-rich region for M 
segment mRNA of RVFV and a C-rich motif for the S segment mRNA of SNV 
(Collett, 1986, Hutchinson et al., 1996). There have been two nucleotide motifs, 
3’-GUCGAC-5’ and 3’-UGUCG-5’ identified in BUNV S segment mRNA that are 
critical to signalling termination (Barr et al., 2006). The intergenic region of 
Phlebovirus S segments termination signals vary between species. RVFV has been 
shown to contain a 5’-GCUGC-3’ motif which plays a role in transcription 
termination (Lara et al., 2011, Ikegami et al., 2007, Albariño et al., 2007). UUKV 
however terminates the N signal at the end of the 3’ NSs gene, whereas the NSs 
gene terminates within the N gene in the opposite orientation (Simons and 
Pettersson, 1991). SFTSV was found to contain overlapping termination signals in 
both N and NSs genes and termination occurred upstream of a 5’-GCCAGCC-3’ 
motif (Brennan et al., 2017).  
Bunyaviruses have been shown to have a unique coupled transcription-
translation mechanism. As there are multiple transcription termination sites 
within the genomic sequence, the mRNA can hybridize to the genome at these 
sites resulting in premature termination. However, translocating ribosomes 
trailing the viral polymerase can prevent these hybridization events until the 
termination sequence is reached in the UTR (Barr, 2007). 
1.1.6.3 Genome replication 
Replication of the viral genome requires the generation of complementary 
antigenomic RNAs (cRNA) which are then used as a template to generate 
genomic RNA (gRNA) which can be further used as a transcription template or 
37 
 
packaged into virions (Figure 1-8 part 6). The mechanism that governs the switch 
between mRNA transcription and full length replication is unclear. There may be 
a link to the level of N to allow encapsidation of the cRNA and gRNA during 
replication, particularly as the cRNA is always found encapsidated (Elliott, 
2014). Additionally, cRNAs and gRNAs can be identified by their lack of cap 
structure. During infection with RVFV, the transcription factor TFIIH interacting 
with NSs (1.1.4.4) may help balance transcription and replication during 
infection by limiting primers for transcription and thus favouring primer-
independent replication (Le May et al., 2004). Interestingly, the M RNA is the 
most abundant viral RNA present within the infected cell during replication, 
followed by the L RNA and then S RNA (Barr et al., 2003), despite transcription 
and replication only requiring L and N proteins. Encapsidation of the genome by 
N protein is essential for genome replication, possibly through keeping the 
genome in a linear form, thereby allowing full genome synthesis (Guu et al., 
2012). In hantaviruses, it has been proposed that a polymerase slippage 
mechanism, where the polymerase realigns on the RNA, removing an 
overhanging guanosine triphosphate group leaving a 5’ uridine monophosphate 
allowing elongation to continue to generate a full length sequence (Garcin et 
al., 1995). Additionally, during replication it is key for bunyaviruses sequence 
integrity to be preserved. The L protein has been shown to be capable of 
repairing insertions and deletions during RNA replication (Walter and Barr, 
2010). 
1.1.6.4 Viral budding and release 
The generation of infectious bunyavirus particles within the natural life cycle 
requires the packaging of all the genome segments into a single virion (Wichgers 
Schreur and Kortekaas, 2016), however it is possible to generate 2 segmented 
viruses expressing all the structural proteins through manipulation of the viral 
genome (Brennan et al., 2011b). Packaging has been shown to be a non-selective 
process which can result in the generation of virions missing one or multiple 
genome segments rendering the particles inert (Wichgers Schreur and Kortekaas, 
2016). The intermolecular interactions between UTRs and genome segments may 
be important in the packaging process (Terasaki et al., 2011) though evidence of 
packaging in 2 segmented viruses lacking these regions indicate these 
intermolecular interactions are not essential (Brennan et al., 2011b).  
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Virus assembly takes place in the Golgi apparatus (Figure 1-8 part 7), as 
evidenced by the targeting signal of Gn, identified to be a 48 amino acid region 
spanning a transmembrane domain and the second hydrophobic domain in the 
cytoplasmic tail (Andersson and Pettersson, 1998, Gerrard and Nichol, 2002). 
The mechanism behind the retention of Gn in the Golgi is unknown, but may 
follow one of two models; the oligomerisation of Gn into structures too large to 
be secreted or the short transmembrane domains of Gn result in segregation 
from sterol- or sphingolipid rich transport vesicles (Gerrard and Nichol, 2002). 
The Golgi is also the site of viral factories, tubular structures and an actin matrix 
that functions to provide a stable scaffold for viral replication and budding 
(Fontana et al., 2008). Additionally, RNPs have been shown to target 
glycoprotein-rich regions of the Golgi through the interaction with Gn and Gc 
before budding (Overby et al., 2007, Rusu et al., 2012). Virions are transported 
from the Golgi apparatus to the plasma membrane via vesicles via exocytic 
release (Figure 1-8 part 8 and 9) (Shi et al., 2010).   
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Figure 1-8. Schematic of RVFV life cycle. 
(1) Attachment occurs with the interaction of cell surface receptors and RVFV 
Gn and Gc. (2) Entry occurs via clathrin-dependent or independent endocytosis. 
(3) The acidification of early endosomes results in the dissociation of clathrin 
and the uncoating of the virus particle. (4) Fusion occurs in the late endosome 
allowing release of the viral RNPs into the cytosol. (5,6) The RNPs are used as 
templates for transcription and replication. The S and L segments bind free 
ribosomes for translation in the cytoplasm, the M segment is translated by 
membrane bound ribosomes at the endoplasmic reticulum (ER). The formation of 
additional RNPs results in replication of the genomic segments. (7) The 
association of GnGc complex and RNPs recruits viral components to the Golgi. (8) 
RNPs accumulate at the Golgi and are non-specifically packaged into virions by 
budding from the Golgi lumen. (9) Mature virus particles are exocytosed from 
the cell. Taken from (Wichgers Schreur and Kortekaas, 2016).  
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1.2 Phlebovirus genus family 
1.2.1 Phlebovirus infection and disease 
Phleboviruses cause a multitude of different diseases in both humans and 
animals, of varying severity. Many of the phlebotomine group of viruses 
generally cause mild symptoms in humans. SFSV and SFNV infections for example 
are self-limiting and characterised by fever myalgia and headache (Cusi et al., 
2010). TOSV also can cause febrile erythema or influenza like symptoms 
(Portolani et al., 2002). However can be a major cause of aseptic meningitis, 
particularly in the summer months when mosquito populations are most 
prevalent (Valassina et al., 2000).  
Infection with the Uukuniemi-like group of viruses also has a wide variation in 
disease outcomes in animals and man. UUKV-infected individuals show no clinical 
signs of disease however the closely related Heartland phlebovirus is highly 
pathogenic resulting in a widely disseminated infection with multiple organ 
failure (Fill et al., 2017). Since its emergence, SFTSV has become a significant 
issue across China, Japan and South Korea. SFTSV causes fever, 
thromobytopenia, gastrointestinal symptoms and leukocytopenia amongst other 
symptoms (Liu et al., 2014). Infection with SFTSV leads to SFTS-like disease 
which has a mortality rate between 12-30% (Silvas and Aguilar, 2017). 
1.2.2 RVFV disease 
RVFV was first isolated in the Rift Valley, Kenya in 1930 after an outbreak 
displaying signs of enzootic hepatitis resulting in death of adult ruminants and 
pregnant ruminants abortion storms (Daubney et al., 1931). RVFV is primarily 
transmitted by Aedes albopictus and Culex pipiens mosquitos however the virus 
is replication competent in a large number of mosquito species including 
Anopheles species such as An. pharonesis, An. stephensi and Cx. antennatus 
among others (Nepomichene et al., 2018, Turell et al., 1996). Despite these 
mosquitos being susceptible, there is lack of evidence showing viral release in 
saliva and thus the role of these species in transmission is unknown. Since its 
identification, RVFV’s geographical distribution has spread significantly to 
include most of the African continent and more recently spread to the Arabian 
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Peninsula in 2000-2001 (Madani et al., 2003). The gradual spread of RVFV may be 
related to the distribution of RVFV vector species that has been undergoing 
range expansion (Kraemer et al., 2015). There have been several severe 
outbreaks associated with RVFV including South Africa in 1950, Egypt in 1977 
(Gear, 1979) and Saudi Arabia in 2000 (Madani et al., 2003). The Egyptian 
outbreak had a reported 200,000 human cases and 598 deaths with a estimated 
impact of $115 million. The outbreak in Egypt signified the first time RVFV had 
crossed the Sahara desert, an important geographical barrier. In 1979, RVFV was 
isolated from Madagascar, crossing the Mozambique channel, thus indicating the 
breakdown of another geographical barrier in the spread of the virus (Morvan et 
al., 1991). The outbreak in Saudi Arabia and Yemen showed RVFV’s ability to 
spread across the Red Sea ((Cdc), 2000a, (Cdc), 2000b).The most recent 
significant outbreak in Kenya 2007 had an estimated 75,000 human cases 
however only 684 were reported and there were 158 deaths indicating a large 
discrepancy between the reporting of RVFV and predicted cases, likely due to 
lack of healthcare infrastructure and the classical febrile symptoms of RVFV 
being similar to other reportable diseases. The yearly rate of infection is 
unknown, however the average of reported cases across Africa between 2006-
2012 was 459, with 101 case fatalities, though this excludes estimated cases 
within outbreaks (Nanyingi et al., 2015).  
RVFV strains can be categorised into 7 main lineages based on molecular 
genotyping. This molecular epidemiology highlights the spread of RVFV 
throughout the African continent (Figure 1-9); particularly there are long 
distance translocations of RVFV species indicating human influence on the 
spread of RVFV between distant regions as evidenced by phylogenetic analysis of 
isolates. This is particularly apparent with the phylogenetic similarity between 
the Egyptian isolates of 1977-1979 and the Madagascar isolate 1979 (Pepin et al., 
2010).  
RVFV is primarily transmitted through mosquito bite; however there is evidence 
of infection from raw milk, contaminated bodily fluids and animal blood, thus 
abattoir workers are at higher risk of infection (Nyakarahuka et al., 2018, 
Labeaud et al., 2011). There has been no reported cases of horizontal 
transmission between humans, however, horizontal transmission has been shown 
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to occur spontaneously though rarely results in disease (Busquets et al., 2010). A 
case study in 2008 indicated that RVFV can be vertically transmitted (Adam and 
Karsany, 2008). RVFV infection in humans has an incubation period of between 
2-6 days and most commonly manifests as a febrile illness with diarrhoea and 
malaise recovering within two days to one week after symptoms occur, however 
in approximately 1% of cases (largely dependent on strain and outbreak) 
infection can result in severe symptoms such as hepatitis, retinitis and 
haemorrhagic fever (Ikegami and Makino, 2011, Laughlin et al., 1979). Through 
the use of a mouse model, it was shown that pathogenesis begins early in the 
liver through the apoptosis of hepatocytes. Mice that survive hepatitis later 
develop meningoencephalitis. The virus exhibits a wide tissue and cell type 
tropism.  
RVFV infection in ruminants has a more severe clinical outcome. RVFV primarily 
infects ruminants, including cattle, sheep, goats and camels. The virus has a 
varying seroprevalence of between 2-16% across endemic areas (Cêtre-Sossah et 
al., 2012, Nyakarahuka et al., 2018, Georges et al., 2018). RVFV has a 30% 
mortality rate in adult ruminants (Bird et al., 2009) and between 90-100% 
mortality in newborn lambs. The virus also causes a high abortion rate in 
pregnant ruminants (Coetzer, 1982). Thus, the impact of RVFV on rural 
communities can be devastating causing significant socio-economic problems 
(Chengula et al., 2013, Sindato et al., 2011). While there is evidence of low-
level circulation of RVFV within wildlife, shown through virus detection and 
clinical signs of infection (Capobianco Dondona et al., 2016), there is no 
experimental evidence for a mammalian reservoir host (Rostal et al., 2017).  
Research on RVFV has focused on a number of key strains. Pathogenic strains 
ZH501 and ZH548 were isolated from human cases during the Egyptian outbreak 
of RVF in 1977; the largest human outbreak of RVFV that resulted in acute 
febrile, ocular, encephalitic and fatal haemorrhagic disease (Gear, 1979). ZH501 
was isolated from a fatal case of haemorrhagic fever, whereas ZH548 was 
isolated from a febrile self-limiting case. As RVFV is a significant human 
pathogen with no fully licensed vaccines or antiviral treatments, the virus 
requires handling in a high containment biosafety level 3 (CL-3) laboratory. 
Additionally, pathogenic RVFV has been recognised as a potential bioterrorism 
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agent and thus falls under additional legislation (Mandell and Flick, 2010). The 
strain used throughout this study was MP12, a vaccine strain derived from the 
serial plaque passage of ZH548 strain 12 times in the presence of the mutagen 5-
fluorouracil (Caplen et al., 1985). The resulting MP12 strain encodes 25 
mutations (11 aa substitutions) across the genome. Of these mutations, the 
attenuation of MP12 is by 7 amino acid changes in the M segment and 3 amino 
acid changes in the L segment (Lokugamage et al., 2012), the S segment encodes 
for N with only synonymous mutations and a moderately functional NSs protein 
with 1 non-synonymous mutation (Billecocq et al., 2008, Ikegami et al., 2015). 
The MP12 vaccine is conditionally licensed in the United States for veterinary use 
(Ikegami, 2017). Vaccination of livestock is the most effective way to reduce the 
economic impact of RVFV infection and while there are a number of vaccines, 
including the live attenuated MP12 and Smithburn vaccines, many of them come 
with inherent risks and the lack of ability to differentiate between infected and 
vaccinated animals (Smithburn, 1949, Botros et al., 2006). There are currently 
no policies in place supporting routine vaccination of livestock in any endemic 
countries for RVFV and thus the vaccine is used reactively to outbreaks, reducing 
the vaccines overall effectiveness (Bird and Nichol, 2012). The efficacy of 
individual vaccines varies greatly between human, adult ruminant and newborn 
ruminant application, as well as between different experimental models used 
such as mice and non-human primates. The formalin-inactivated RVFV vaccine 
had an efficacy of 67% in adult sheep however challenge induced abortion in 2 of 
2 pregnant ewes (Harrington et al., 1980). The MP12 vaccine in comparison 
resulted in no abnormal effects when given to 3 pregnant ewes in one study 
(Morrill et al., 1987) however a separate study found that four month old calves 
vaccinated with MP12 resulted in necrotic lesions in the liver (Wilson et al., 
2014). Further evaluation of efficacy and safety of these vaccines may allow for 
increased confidence for policymakers to implement scheduled vaccination 
programs in endemic areas reducing the overall economic burden of the disease.  
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Figure 1-9. Distribution of RVFV as of 2018. 
The dark blue areas indicate significant outbreaks, the lighter blue areas 
indicate serological evidence or virus isolation. Years of outbreaks are shown and 
updated from the CDC. Adapted from (Ikegami, 2012).  
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1.2.3 RVFV reverse genetics 
The first reverse genetics system for bunyaviruses was developed in 1996 
(Bridgen and Elliott, 1996) based upon a system described for rabies virus 
(Schnell et al., 1994). The bunyavirus rescue system involves the expression of 
“helper” plasmids encoding the viral structural proteins N and L, which assist in 
the formation of viral RNPs, in addition cDNA copies of each of the three viral 
segments in the antigenomic sense have a bacteriophage T7 RNA polymerase 
promoter before the 5’UTR of the viral antigenomic RNA; and simplified later 
(Lowen et al., 2004). After the 3’ UTR sits a hepatitis δ virus ribozyme (Hδr) and 
the T7 terminator. The Hδr functions to allow the self-cleavage of the 
antigenomic RNA transcript generating the correct viral transcript size and 
sequence. The three plasmids, containing cDNA copies of either the S, M or L 
antigenomic RNA segments are transfected into cells expressing the T7 RNA 
polymerase such as BSR-T7/5 or Huh-T7-Lunets (Buchholz et al., 1999, Kaul et 
al., 2007). Upon transfection, the antigenomes are transcribed by the T7 RNA 
polymerase generating positive-sense or antigenomic RNA transcripts. These RNA 
transcripts can then be translated to produce the virally encoded proteins. The 
viral proteins (specifically N & L) form RNP complexes which can initiate the 
replication of the antigenomic RNA into genomic RNA, which can be further 
packaged into virions and released from the cell. The additional helper plasmids 
encoding N and L cDNA under the T7 promoter allow more efficient formation of 
RNPs thereby increasing the success of viral rescue. 
The 5’-triphosphorylated transcripts produced by the T7 polymerase induce high 
levels of IFN through RIG-I (Hornung et al., 2006) and thus, may interfere with 
the successful rescue of RVFV, in particular attenuated viruses lacking IFN-
antagonism. However, analysis of a Pol-I/II based rescue system showed a similar 
efficiency regardless of interferon antagonism (Habjan et al., 2008). Further 
research showed BSR-T7/5 cells have a compromised RIG-I pathway and thus is 
not stimulated by T7-derived RNA transcripts (Habjan et al., 2008).  
The T7-based system is versatile, allowing reverse genetics and phenotypic 
experiments that been used in a number of RVFV studies. Reverse genetic 
systems of RVFV have been used to  generate a two-segmented RVFV virus 
(Brennan et al., 2011b) and the rescue of RVFV containing a V5 tagged L protein 
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(Brennan et al., 2011a). It was also used in mutagenesis studies investigating the 
RVFV glycoprotein Gn (Phoenix et al., 2016a). The T7 system is also widely used 
across the bunyaviruses, such as investigating cellular roles for BUNV NSs (Weber 
et al., 2002) and demonstrating the flexibility of the BUNV genome through 
rescue of an ambisense S segment virus (Van Knippenberg and Elliott, 2015).  
In order to breakdown the study of bunyaviruses into their component processes, 
minigenome systems have also been developed. The minigenome system allows 
studies of such viruses including BSL-3 and BSL-4 pathogens to be carried out at 
lower safety levels. The system is similar to the reverse genetics system 
previously described. Briefly, cDNA expression plasmid encoding RVFV N and L 
proteins are transfected into T7 RNA polymerase-expressing cells along with a 
reporter plasmid that expresses a reporter gene in the negative sense (replacing 
the virally encoded ORF), flanked by viral genomic UTRs. The expression of N 
and L form functional RNP complexes recognising the UTRs flanking the reporter 
gene, thus by binding the viral UTRs the RNPs are transcribed and replicated, 
resulting in the production of the reporter protein (usually luciferase or GFP). 
This system allows an assessment of the functionality of the N and L proteins as 
well as their ability to recognise the cognate UTR of the virus in question. There 
have been many studies that have utilised this system such as studying the 
effects of protein phosphatase-1 on RVFV replication (Baer et al., 2016), the 
assessment of MP12 N and L proteins to replicate different virus species (GOLV & 
AMTV) M segment minigenomes (Ly et al., 2017) and to evaluate the importance 
of the non-coding regions of the viral segments and their involvement in 
regulating RNA synthesis (Gauliard et al., 2006). 
The minigenome system can be adapted further through the addition of a 
plasmid expressing the gene M segment viral glycoprotein polyprotein precursor. 
This allows viral assembly, maturation, packaging and egress to occur, 
generating virus-like particles (VLPs). These VLPs are capable of delivering 
packaged RNPs into recipient cells for a single-cycle of replication, as there is no 
genomic template for further transcription of the viral glycoproteins within the 
recipient. Pre-transfection of recipient cells with N and L can allow 
measurement of luciferase reporter genes transferred from the donor cells via 
VLPs. The morphology of the VLPs in UUKV are identical to authentic virions 
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(Overby et al., 2008). VLP systems have been used for assessing inhibitors of 
RVFV replication (Piper and Gerrard, 2010), for identifying the packaging signals 
within the coding and non-coding regions of RVFV genomic segments (Murakami 
et al., 2012). 
Utilising these molecular tools it was possible to explore the molecular 
interactions governing RVFV nucleocapsid during viral replication and thus 
informing on unknown functions. Understanding these interactions will allow 
future study focused on novel intervention strategies for this emerging viral 
threat.   
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Figure 1-10. Schematic of RVFV reporter systems. 
A schematic of minigenome and VLP reporter systems for RVFV. (A) Minigenome 
assay system with the transfection of four plasmids and subsequent reading of 
Renilla luciferase (Rluc) and Firefly luciferase (Fluc). (B) A schematic of the 
reporter Ren plasmid use in minigenome and VLP assays, contains the Rluc ORF 
flanked by RVFV M segment UTRs in the genome-sense orientation. (C) Virus-like 
particle (VLP) assay similar to the minigenome assay however with the addition 
of M plasmid expressing viral glycoproteins Gn and Gc. Thus, VLPs can form and 
be used to transduce indicator cells pre-transfected with RVFV N and L plasmids 
before measurement of Rluc. Adapted from (Habjan et al., 2009).  
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Chapter 2 Aims 
Previous research on RVFV has primarily focused on the non-structural protein 
NSs with regards to the interaction of viral proteins with host cell proteins. 
Information on the function of RVFV N proteins, not including the formation of 
RNPs, is largely unknown. 
The aim of this project was to gain insights into the N protein of RVFV in order 
to understand the basic processes undertaken during the virus life cycle.  
These aims included:  
(i) To perform a mutagenesis study on RVFV N to assess any potential 
functional residues. 
(ii) Perform a proteomics study of RVFV N protein to identify host protein 
interactors and validate interactions through experimentation. 
(iii) Assess importance of interactors through siRNA experiments using 
minigenome and reporter virus systems. 
(iv) Further investigate the WNT pathways effect on RVFV replication. 
(v) Assess RVFVs impact on the WNT pathway, and vice versa. 
(vi) Determine RVFV N protein effect on mosquito antiviral RNA 
interference pathways. 
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Chapter 3 Materials 
3.1 Cell Culture 
3.1.1 Eukaryotic Cell Lines 
 A549: derived from adenocarcinomic human alveolar basal epithelial cells 
(86012804, Public Health England). The cells were maintained in DMEM 
supplemented with 10% (v/v) Heat-inactivated fetal bovine serum (FBS) 
(Gibco). A549 β-catenin knockout cells are a CRISPR knockout single cell 
clone generated using a CRISPRcas9 lentivirus construct (A gift from 
Isabelle Dietrich, Oxford University, UK) in the course of this project. 
A549 β-catenin knockout control cells are a CRISPRcas9 lentivirus cell line 
with non-functional guide RNA. Knockout and control cells are 
supplemented with puromycin (100 µg/ml) for selection.  
 Aag2: derived from Ae. aegypti (Received from P. Eggleston, Keele 
University, UK) and were grown in L-15+Glutamax (Life Technologies) 
supplemented with 10% Tryptose Phosphate Broth (Life Technologies), 10% 
Heat-inactivated FBS (Gibco) and 100 units/mL of penicillin and 100 
µg/mL of streptomycin. AF5 cells are a single cell clone derived from the 
Aag2 cells (Varjak et al., 2017b) with a confirmed functional RNAi 
pathway. The cell line AF319, is a derivative of AF5 cells however they 
have the key RNAi effector protein Dicer 2 (Dcr2) knocked out which 
blocks the cleavage of dsRNA into siRNAs(Varjak et al., 2017b). 
 BHK-21: a baby hamster kidney derived cell line (Macpherson and Stoker, 
1962). Maintained in Glasgow modified Eagle’s medium (GMEM) (Gibco) 
with 10% (v/v) Heat-inactivated FBS, 10% (v/v) Tryptose Phosphate Broth 
and 100 units/mL of penicillin and 100 µg/mL of streptomycin.  
 BSR-T7/5: A BHK-21 derived clone constitutively expressing bacteriophage 
T7 RNA polymerase (Buchholz et al., 1999). Provided by Dr Karl-Klaus 
Conzelmann (Ludwig-Maximilians-Universitӓt München). Cells were 
maintained in Glasgow modified Eagle’s medium (GMEM) (Gibco) with 10% 
(v/v) Heat-inactivated FBS, 10% (v/v) Tryptose Phosphate Broth and 100 
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units/mL of penicillin and 100 µg/mL of streptomycin supplemented with 
1mg/ml G418 (Promega) to maintain selection pressure for cells 
expressing T7 RNA polymerase.  
 BSR-T7/5 (clone 21): A derivative single cell clone of BSR-T7/5 showing 
increased expression of T7 RNA polymerase (Mottram et al., 2017). 
 HEK-293FT: Human embryonic kidney derived cell line. Maintained in 
DMEM with 10% (v/v) Heat-inactivated FBS, supplemented with 0.1 mM 
non-essential amino acids and 100 units/mL of penicillin and 100 µg/mL of 
streptomycin. 
 Huh7-Lunet-T7: Derivative of Huh-7 cells, generated from liver carcinoma 
cells (Nakabayashi et al., 1982), constitutively expressing the 
bacteriophage T7 RNA polymerase (Kaul et al., 2007). Provided by Dr Ralf 
Bartenschlager (Universitӓtsklinikum Heidelberg). Maintained in DMEM 
with 10% (v/v) FBS and 0.1 mM non-essential amino acids supplemented 
with Zeocin (100 µg/ml) (Thermo Fisher Scientific) to maintain selection. 
 Vero E6: African green monkey kidney cells provided by Prof Richard M. 
Elliott. Maintained in DMEM, supplemented with 10% (v/v) FBS. 
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3.1.2 Competent Bacteria 
Plasmid amplified for stocks and through general cloning techniques were 
generated through the use of DH5α competent cells genotype; F- Φ80lacZΔM15 
Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ-thi-
1 gyrA96 relA1 (Thermo Fisher Scientific). Plasmids generated through In-Fusion 
cloning kit (Clontech) were amplified in supplied Stellar Competent cells 
genotype; F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA, Φ80d lacZΔ 
M15, Δ (lacZYA - argF) U169, Δ (mrr - hsdRMS - mcrBC), ΔmcrA, λ–. Bacteria were 
grown at 37˚C on either Luria-Bertani (LB) broth or LB agar plates under the 
selection of either ampicillin (100 µg/ml) or kanamycin (100 µg/ml). 
3.1.3 Virus Strains 
Recombinant RVFV strain MP12 (Caplen et al., 1985) used in this project was 
derived from plasmids supplied by Prof Richard M. Elliott. Working stocks of 
RVFV rMP12 and RVFV rMP12delNSs:eGFP were generated by passaging the virus 
in BHK-21 cells (4.1.8). RVFV rMP12delNSs:hren was also previously described 
and provided by Prof Richard M. Elliott. 
pCMV-SFV6-RLuc-2SG plasmid was generated in Prof Andres Merits laboratory 
(University of Tartu, Estonia), it was used to rescue SFV6(3H)-RLuc-2SG virus 
(Tamberg et al., 2007, Saul et al., 2015) (Rodriguez-Andres et al., 2012). This 
plasmid served as a backbone to generate new viruses during this project and 
virus was rescued using a previously described protocol in BHK-21 cells (4.1.8). 
BUNV, rBUNVdelNSs2 and BUNVNanoLuc (provided by Prof Richard M. Elliott) 
were used in this study to assess the impact of β-catenin on bunyavirus 
replication. Working stocks were generated by passaging the virus in BHK-21 
cells (4.1.8). 
3.2 Molecular Biology 
3.2.1 Oligonucleotides 
A list of oligonucleotides used throughout this project is provided in the 
supplementary material (9.1). 
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3.2.2 Plasmids 
Plasmid Description Reference 
pTM1 RVFV L3V5 pTM1 plasmid backbone 
containing a T7 promoter to 
drive transcription followed 
by an Internal Ribosome 
Entry Site (IRES) driving 
translation. Plasmid 
encodes the modified RVFV 
MP12 RNA-dependent-RNA 
polymerase (L) sequence 
containing an inserted V5 
sequence towards the 3’ 
terminus.  
Provided by Benjamin 
Brennan (Brennan et al., 
2011a). 
pTM1 RVFV MP12 N 
 
pTM1 RVFV MP12 L 
pTM1 plasmid encoding 
RVFV MP12 nucleocapsid (N) 
protein or L protein. 
Provided by Richard Elliott. 
pTVT7 M-Hren-M pTV plasmid expression of 
negative sense Humanized 
Renilla (hRen) under T7 
promoter flanked by RVFV M 
segment UTRs  
Provided by Benjamin 
Brennan. 
pTM1 FF Luc pTM1 plasmid encoding 
Firefly luciferase. 
Provided by Isabelle 
Dietrich. 
pTM1 UUKV N 
 
pTM1 UUKV L 
pTM1 plasmid encoding 
UUKV N protein or L 
protein.  
Provided by Richard Elliott / 
Veronica Rezelj. 
pTM1 UUKV N RVFV motif pTM1 plasmid encoding 
UUKV N protein with a tick-
borne phenuviridae specific 
motif replaced with the 
motif found in RVFV. 
Generated during this 
project. 
pTM1 RVFV MP12 N Mutant 
Gly32Ala 
 
pTM1 RVFV MP12 N Mutant 
Asp34Ala 
 
pTM1 RVFV MP12 N Mutant 
Trp125Ala 
 
pTM1 RVFV MP12 N Mutant 
Ser148Ala 
 
pTM1 RVFV MP12 N Mutant 
Phe149Ala 
 
pTM1 RVFV MP12 N Mutant 
Asp181Ala 
 
pTM1 RVFV MP12 N Mutant 
Pro182Ala 
 
pTM1 RVFV MP12 N Mutant 
Arg185Ala 
 
pTM1 RVFV MP12 N Mutant 
Phe11Ala 
pTM1 plasmid encoding 
RVFV MP12 N protein with 
an alanine or glycine 
substitution point mutation.  
Generated during this 
project (5.2.1). 
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pTM1 RVFV MP12 N Mutant 
Phe11Gly 
pTM1 HB29 N pTM1 plasmid encoding 
SFTSV N protein or L protein 
(Strain Hubei 29; HB29). 
Provided by Benjamin 
Brennan 
pTM1 TOSV N pTM1 plasmid encoding 
TOSV N protein or L protein. 
Provided by Benjamin 
Brennan 
pCMV RVFV N pTM1 plasmid encoding 
RVFV N under CMV promoter 
Generated during this 
project. 
pTVT7 RVFV MP12 S 
Segment 
 
pTVT7 RVFV MP12 M 
Segment 
 
pTVT7 RVFV MP12 L 
Segment  
Full length RVFV MP12 
antigenomic Small (S), 
Medium (M) and Large (L) 
segments cloned into the 
pTVT7 backbone driven by a 
bacteriophage T7 promoter 
and flanked at the 3’ by a 
hepatitis Δ ribozyme 
facilitating self-clevage.  
Provided by Benjamin 
Brennan 
pTVT7 RVFV S Segment N 
Mutant 2-14 
 
pTVT7 RVFV S Segment N 
Mutant 2-31 
 
pTVT7 RVFV S Segment N 
Mutant F11A 
 
pTVT7 RVFV S Segment N 
Mutant Y30A 
 
pTVT7 RVFV S Segment N 
Mutant Asp34Ala 
 
pTVT7 RVFV S Segment N 
Mutant Phe149Ala 
 
pTVT7 RVFV S Segment N 
Mutant Arg185Ala 
Full length RVFV MP12 
antigenomic S segment in 
the pTVT7 backbone with 
specific point mutations to 
the N sequence.  
Generated during this 
project. 
p14 RVFV MP12 p14 backbone encoding His-
6 tagged RVFV N protein 
Provided by Ping Li. 
p14 RVFV MP12 N Mutant 
2-14AA 
 
p14 RVFV MP12 N Mutant 
2-30AA 
 
p14 RVFV MP12 N Mutant 
Phe11Ala 
 
p14 RVFV MP12 N Mutant 
Phe11Gly 
 
p14 RVFV MP12 N Mutant 
Y30A 
 
p14 RVFV MP12 N Mutant 
Gly32Ala 
 
p14 RVFV MP12 N Mutant 
Asp34Ala 
p14 backbone encoding His-
6 tagged mutant RVFV N 
protein 
Generated during this 
project (5.2.1). 
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p14 RVFV MP12 N Mutant 
Trp125Ala 
 
p14 RVFV MP12 N Mutant 
Ser148Ala 
 
p14 RVFV MP12 N Mutant 
Phe149Ala 
 
p14 RVFV MP12 N Mutant 
Asp181Ala 
 
p14 RVFV MP12 N Mutant 
Arg185Ala 
 
pCMV-SFV(Rluc-H)6-2SG Full length viral SFV6 
genome containing Rluc ORF 
and two subgenomic 
promoters used as a 
backbone for cloning. 
Constructed by Prof Andres 
Merits (University of Tartu, 
Estonia). 
pCMV-SFV(Rluc-H)6-p19 
 
Full length viral SFV6 
genome containing Rluc ORF 
and Tombusvirus p19 ORF 
under the subgenomic 
promoter.  
Generated during this 
project (7.2). 
pCMV-SFV(Rluc-H)6-BUNVN 
 
Full length viral SFV6 
genome containing Rluc ORF 
and the BUNV N ORF under 
the subgenomic promoter. 
Generated during this 
project (7.2). 
pCMV-SFV(Rluc-H)6-RVFVN 
 
Full length viral SFV6 
genome containing Rluc ORF 
and the RVFV N ORF under 
the subgenomic promoter.  
Generated during this 
project (7.2). 
pCMV-SFV(Rluc-H)6-ZIKVC 
 
Full length viral SFV6 
genome containing Rluc ORF 
and ZIKV C ORF under the 
subgenomic promoter. 
Generated during this 
project (7.2). 
pCMV-SFV(Rluc-H)6-eGFP 
 
Full length viral SFV6 
genome containing Rluc ORF 
and the eGFP ORF under the 
subgenomic promoter. 
Generated during this 
project (7.2). 
pCCI-SP6-Zika   pCCI-SP6 plasmid containing 
full length Zika genome 
used as a template to 
generate Zika C DNA during 
cloning. 
Constructed by Prof Andres 
Merits (University of Tartu, 
Estonia)(Mutso et al., 2017). 
 
SFV4(3H)-Rluc-p19 SFV4 full length viral DNA 
containing the Rluc ORF and 
Tombusvirus p19 ORF under 
specific sub-genomic 
promoters, used as a 
template during cloning. 
Previously generated in the 
Kohl lab (Attarzadeh-Yazdi 
et al., 2009). 
LentiCRISPR v2 CRISPRcas9 lentiviral vector Provided as a gift from Feng 
Zhang (Addgene plasmid # 
52961). 
Human Beta-catenin GFP Expression of mammalian β-
catenin GFP under a CMV 
promoter 
Human Beta-catenin GFP 
was a gift from Alpha Yap 
(Addgene plasmid # 71367). 
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M50 Super 8x TOPFlash Beta-catenin reporter 
containing TCF/LEF 
promoter sites upstream of 
a firefly luciferase reporter.  
M50 Super 8x TOPFlash was 
a gift from Randall Moon 
(Addgene plasmid # 12456). 
 
3.2.3 Enzymes 
3.2.3.1 Modifying enzymes  
Benzonase was used for digestion of transfected template plasmid in VLP assays 
was purchased from Merck Millipore. For PCR, GoTaq G2 Flexi DNA polymerase 
(Promega) or KOD Hot start DNA polymerase (Merck Millipore) were used. 
3.2.3.2 Restriction enzymes 
Restriction enzymes used for checking successful insertion of gene products 
during cloning were purchased from New England Biolabs.  
3.2.4 Antibodies 
Primary Dilution 
Antibody Primary 
Target 
WB IP IF 
Rabbit anti-
RVFV MP12 N 
(Provided by 
Richard M. 
Elliott). 
RVFV MP12 N 1:5000 1:500 1:250 
Rabbit anti-
BUNV N 
(Provided by 
Richard M. 
Elliott). 
BUNV N   1:250 
Rabbit anti-β-
Actin (Abcam, 
#ab8227). 
β-Actin 1:2000   
Rabbit anti-β-
Catenin (R&D 
Systems). 
β-Catenin 1:1000   
Mouse anti-β-
Catenin (Cell 
Signalling 
#2677). 
β-Catenin 1:1000  1:250 
Mouse anti-
Annexin-A1 
(R&D Systems 
#MAB3770). 
Annexin-A1   1:100 
Mouse anti-
Annexin-A2 
(R&D Systems 
#MAB3928). 
Annexin-A2   1:100 
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Secondary Dilution 
Antibody Target WB IP IF 
Anti-rabbit 
Alexa Fluor 405 
(Invitrogen #A-
35551). 
Rabbit IgG   1:500 
Anti-rabbit 
Alexa Fluor 488 
(Invitrogen 
#35552). 
Rabbit IgG   1:500 
Anti-mouse 
Alexa Fluor 568 
(Invitrogen #A-
11019). 
Mouse IgG   1:500 
Anti-rabbit IgG 
HRP-linked 
(Abcam 
#ab205718). 
Rabbit IgG 
 
1:2000   
Anti-mouse IgG 
HRP-linked 
(Thermo Fisher 
Scientific 
#31430). 
Mouse IgG 1:2000   
Anti-rabbit 
Veriblot (Abcam 
#ab131366). 
IgG 1:2000   
Anti-rabbit IgG 
(H and L) 
DyLight 680 
(Thermo Fisher 
Scientific 
#35568).  
Rabbit IgG 1:10000   
Anti-mouse IgG 
(H and L) 
DyLight 800 4x 
PEG (Thermo 
Fisher Scientific 
#SA5-35521). 
Mouse IgG 1:5000   
 
3.3 Reagents 
3.3.1 Cell Culture 
 Glasgow Minimal Essential Medium (GMEM), Dulbecco Modified Eagle 
Medium (DMEM), 2x Temin’s Modified Eagle Medium (MEM) and Tryptose 
Phosphate Broth (TPB) were purchased from Gibco. 
 Versene (E&O Laboratories).  
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 Trypsin solution: Versene (E&O Laboratories) supplemented with 10x 
trypsin. 
 Heat-inactivated fetal bovine serum (FBS) (Gibco) 
 Dulbecco’s phosphate buffered saline (DPBS) 10x purchased from Sigma. 
 0.6% Avicel overlay: Avicel 1.2% (w/v) in H2O diluted 1:1 with 2x MEM 
supplemented with 4% FBS.  
 Formaldehyde fixing solution: 8% (v/v) formaldeyde (Sigma) in PBS. 
 TransIT-LT1 transfection reagent purchased from MirusBio. 
 Lipofectamine 2000 and Lipofectamine RNAMax purchased from Thermo 
Fisher Scientific. 
 Dharmacon purchased from GE Healthcare. 
 Opti-Minimum Essential Medium (Opti-MEM) purchased from Thermo 
Fisher Scientific. 
 Antibiotic G418 sulfate (G418) purchased from Promega and used at 100 
mg/ml. 
 Zeocin purchased from Invivogen and used at 100 mg/ml. 
3.3.2 Bacterial Culture 
 Ampicillin sodium salt (Amp) purchased from Fisher. 
 Kanamycin sulfate (Kan) purchased from Sigma. 
 LB agar (Miller) purchased from E&O Laboratories.  
 LB broth purchased from E&O Laboratories.  
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3.3.3 DNA/RNA Analysis 
 Plasmid isolation from bacterial culture was carried out using either a 
Maxiprep kit (Thermo Fisher Scientific) or Miniprep kit (Bioline). 
 Cloning was performed using In-Fusing cloning tools purchased from 
Clontech. 
 Agarose gel used in DNA gels: 1% (w/v) UltraPure agarose (Invitrogen) in 
TAE buffer (Thermo Fisher Scientific). 
 Agarose gel used in RNA gels: 1% (w/v) NuSieve GTG agarose (Lonza) in 
TBE buffer (Novex). 
 TAE buffer was purchased from Thermo Fisher Scientific. 
 TBE buffer was purchased from Thermo Fisher Scientific. 
 GeneRuler 1kb Plus ladder and 6x DNA Loading Dye used in DNA gels 
purchased from Thermo Fisher Scientific. 
 100bp ladder used in RNA gels purchased from Thermo Fisher Scientific. 
 Purification and extraction of DNA from agarose gels was performed using 
a gel extraction kit purchased from GE Healthcare. 
 Ethidium bromide used in DNA visualisation was purchased from Promega. 
 Gel Red used in RNA visualisation was purchased from Biotium. 
 Human Wnt3a recombinant protein was purchased from R&D Systems. 
3.3.4 Western Blotting 
 SeeBlue Plus2 protein ladder was purchased from Thermo Fisher 
Scientific. 
60 
 
 Bolt LDS 4x, Bolt Sample reducing agent 10x, Bolt 4-12% Bis Tris and Bolt 
MES buffer were purchased from Thermo Fisher Scientific. 
 Amersham Protran 0.45 nitrocellulose membrane was purchased from GE 
Healthcare. 
 Semi-dry blotting buffer: 48 mM Tris, 39 mM glycine, 20% (v/v) methanol  
 Blocking buffer: 2% (w/v) skimmed milk powder (Marvel) in PBS/0.1% (v/v) 
Tween-20. 
 Wash buffer: PBS/0.1% (v/v) Tween-20. 
 Pierce ECL western blotting substrate was purchased from Thermo Fisher 
Scientific. 
3.3.5 Immunofluoresence 
 Permeabilisation solution: 0.5% (v/v) Triton X-100 in PBS. 
 Prolong Diamond Antifade Mountant (Thermo Fisher Scientific). 
 KPL TrueBlue Peroxidase substrate for focus forming assay was purchased 
from Seracare. 
 DRAQ7™ DNA dye (Abcam). 
 Microscope (LSM 710, Zeiss). 
3.3.6 Immunoprecipitation 
 Lysis/Wash buffer – 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5% 
Triton X-100, Halt™ Protease inhibitor cocktail (Thermo Fisher Scientific). 
 Lysis buffer Proteomics – 50 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 
10% glycerol, 1ul/ml Benzonase (Merck Millipore), protease inhibitor 
cocktail (Thermo Fisher Scientific) 1% Np-40. 
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 Wash buffer Proteomics – 50 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 
1% Np-40 (Sigma). 
 Pierce™ Protein A magnetic beads were purchased from Thermo Fisher 
Scientific. 
3.3.7 Protein Purification 
 Wash buffer: 40 mM Imidazole, 0.3M NaCl, 50 mM Tris pH 8.0, 10% 
glycerol. 
 Elution buffer: 200 mM Imidazole, 0.3 NaCl, 10 mM Tris pH 8.0, 10% 
glycerol.  
 Protein storage buffer: 10mM Tris pH 8.0, 150mM NaCl, 10% glycerol. 
 Vivaspin 6 centrifugal concentrators were purchased from Sigma. 
 HisPur Ni-NTA resin was purchased from Thermo Fisher Scientific  
3.3.8 Luciferase Assay 
 Dual Luciferase kit (Promega). 
 Steady Glo Luciferase kit (Promega). 
 Firefly Luciferase kit (Promega). 
3.4 Software 
 CLC Genomics or Geneious software packages were used for sequence 
analysis and primer design. 
 ZEN software (Zeiss) was used for analysis of immunofluorescence images. 
 Irfanview (Irfan Skiljan, 2017) and ImageStudio (LI-COR, 2017) were used 
for image processing. 
62 
 
 Graphpad Prism version 6 (GraphPad Software, 2017) was used for graphic 
design and statistical analysis. 
 Inkscape was used for figure production. 
 Molecular graphics and analyses were performed with the UCSF Chimera 
package. Chimera is developed by the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San 
Francisco (supported by NIGMS P41-GM103311). 
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Chapter 4 Methods 
4.1 Cell Culture 
4.1.1 Maintenance of eukaryotic cell lines 
Mammalian cells were maintained in either T25, T75, T150 or T225 vented flasks 
at 37 °C with 5% CO2 and were split either 1:5 or 1:10 after confluency. To 
maintain, cells were washed with 5 ml PBS versene before adding trypsin and 
incubating for 5 minutes at 37 °C. Subsequently, cells were transferred into a 
falcon tube and centrifuged at 1000 x g for 5 minutes. Following centrifugation, 
cells were resuspended in fresh cell culture media. Mosquito cells were 
maintained in T25 non-vented flasks at 28 °C with no CO2; once confluent, the 
cells were scraped and were split 1:5.  
4.1.2 Transfection of eukaryotic cell lines 
At approximately 24 hours post seeding (or 70-80% confluency) cells were 
transfected using either Lipofectamine 2000 (Thermo Fisher Scientific), LT1 
(Mirus Bio), RNAiMax (Thermo Fisher Scientific) or Dharmafect (GE Healthcare). 
Volumes of Opti-MEM and transfection reagent varies dependent on plate size, 
reagent used and was occasionally varied further based on quantity of 
transfected DNA (According to manufacturer’s instructions).  
Lipofectamine 2000 & LT1 
Cell culture plate Media volume per 
well/flask (ml) 
Transfection 
reagent volume 
per well/flask (µl) 
Total Opti-MEM 
volume per 
well/flask (µl) 
T25 4 5 500 
6-well plate 2 4 400 
12-well plate 1 2 200 
24-well plate 1 1 100 
 
Dharmafect & RNAimax 
Cell culture plate Media volume per 
well (ml) 
Transfection 
reagent volume 
per well (µl) 
Total Opti-MEM 
volume per well 
(µl) 
24-well plate 1 2 100 
 
Half of the total Opti-MEM volume was supplemented with the total volume of 
transfection reagent and mixed gently; the second half was mixed separately 
with the required DNA, siRNA and/or dsRNA in a microcentrifuge tube. The Opti-
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MEM transfection reagent mix was combined with the DNA or siRNA and 
incubated for 20 minutes at room temperature before being applied directly 
onto the well containing fresh cell culture media. 
4.1.3 Minigenome assays 
BSR-T7/5, BSR-T7/5 CL21 or Huh7-T7-Lunet cells were seeded in a 24-well plate 
at approximately 1 x105 cells per well. At 24 hours post seeding, cells were 
transfected with 25 ng pTM1-FF-Luc (a firefly luciferase expressing plasmid 
under the T7 promotor, used as an internal control to normalise variations in 
transfection efficiency and total cell count), 0.5 µg of the Renilla based reporter 
plasmid pTVT7-GM:hRen, 0.2 µg pTM1-L and 1 µg pTM1-N (RVFV MP12 based), 
empty pTM1 or one of the N protein mutant clones using either Lipofectamine 
2000 or LT1 transfection reagent. The total amount of DNA added per well was 
kept constant by the addition of empty pTM1. At 24 hours post-transfection, cell 
culture supernatant was removed and cells were lysed with 100 µl passive lysis 
buffer (PLB; Promega). Firefly and Renilla luciferase activity was measure using 
the Dual Luciferase Reporter Assay system (Promega), as per the manufacturer’s 
instructions. 
4.1.4 Virus-like particle assay 
BSR-T7/5 CL21 cells were seeded in a 12-well plate at approximately 2 x105 cells 
per well. At 24 hours post seeding, cells were transfected in a similar manner to 
the minigenome assay with RVFV MP12 based plasmids; 25 ng pTM1-FF-Luc, 0.5 
µg pTVT7-GM:hRen, 0.25 µg pTM1-L and 0.5 µg pTM1-N, empty pTM1 or one of 
the N protein mutant clones. Additionally, DNA mixtures were supplemented 
with 0.5 µg pTM1-M encoding the Open Reading Frame (ORF) for the RVFV viral 
glycoproteins Gn and Gc. After 48 hours, the supernatant was removed and 
treated with 2 µl Benzonase nuclease (Merck Millipore) for 4 h at 37 °C to 
eliminate any plasmid DNA not encapsidated into viral particles. Of the treated 
supernatant, 160 µl was subsequently added to a 12-well plate of BSR-T7/5 CL21 
cells pre-transfected 24 h prior with 0.5 µg pTM1-N and 0.5 µg pTM1-L. At 24 h 
post VLP infection, cells were lysed in 200 µl PLB. Firefly and Renilla luciferase 
activity was measured as above. 
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4.1.5 TOPFlash reporter assay 
Huh7-Lunet-T7, A549 or HEK-293FT cells were seeded in a 24 well plate at 
approximately 6 x104 cells per well. After 24 hours, cells were transfected with 
290 ng M50 Super 8x TOPFlash per well. At 24 hours post transfection, cells were 
infected with rMP12, rMP12delNSs, rBUNV or rBUNVdelNSs at MOI 1. Samples 
were taken at the timepoints indicated, cells were lysed with 100 µl 2x passive 
lysis buffer (Promega) and luciferase signal was measured. 
4.1.6 CRISPR-Cas9 knockouts 
A stock of β-catenin knockout A549 cells were generated using the lentiCRISPRv2 
system Guide RNAs (gRNA1 GAAACAGCTCGTTGTACCGC, gRNA2 
AGAACGCATGATAGCGTGTC) were cloned through restriction digest with BsmBI 
into lentiCRISPRv2 plasmid by Isabelle Dietrich, University of Oxford. HEK 293T 
cells were transduced with lentiCRISPRv2-gRNA plasmids, p8.91 and pVSV-G. 
After 48 hours, supernatant was harvested, filtered and supernatant applied to 
A549 cells allowing transduction of the generated lentiviruses. Lentivirus 
integrated cells were selected for by the addition of 1 µg/ml Puromycin. In the 
course of this thesis, these mixed cell cultures were cloned and purified by 
serially diluting into 6 well plates. After 7 days, formed single cell clones were 
transferred by scraping to a 24 well plate containing appropriate media. After 7 
days, cultures were scraped and transferred into T25 flasks. At 4 days post 
seeding, the absence of β-catenin was confirmed by Western blot (4.3.2).  A 
culture containing integrated lentivirus but maintained presence of β-catenin 
was used as a control. 
4.1.7 siRNA knockdowns 
4.1.7.1 Virus infection 
A549 were plated at a density of 6 x104 cells per ml in a 24 well plate. After 24 
hours, triplicate wells were transfected with 5 pmol Silencer Select siRNA (Life 
Technologies) targeting CTNB1, ANXA1, ANXA2, PABP1, PABP4, SAFB or DCD 
using 1 µl RNAimax transfection reagent (GE Healthcare). At 72 hours post-
transfection, A549 cells were infected with rMP12delNSs:hRen at MOI 0.01. After 
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24 h post infection, cells were lysed in 100 µl 2x passive lysis buffer (Promega). 
Rluc activity was measured according to manufacturer’s instructions (4.3.4.1). 
4.1.7.2 Minigenome Assay 
Huh7-Lunet-T7s were plated at 1x105 cells per ml in a 24 well plate. siRNA was 
transfected as previously described in 4.1.7.1. At 72 hours post-transfection of 
the siRNA, cells were transfected with 0.5 µg pTM1 N, 0.25 µg pTM1 L, 25 ng 
pTM1-FF-Luc, and 0.5 µg pTVT7-GM:hRen. After 24 h, cells were lysed in 100 µl 
passive lysis buffer. Dual luciferase was measured according to manufacturer’s 
instructions (4.3.4.1). 
4.1.8 Generation of virus stocks 
Stocks of wild-type and recombinant RVFV, BUNV and SFV were generated by 
passaging the virus at a low multiplicity of infection (MOI) (0.01 plaque forming 
units [PFU]/cell) in either BHK-21 or Vero E6 cells. Cell media was removed and 
replaced with virus inoculum in 2% (v/v) FBS in PBS. After 1 h incubation at 37 
°C, fresh media containing 2% (v/v) FBS was added. The propagation of SFV 
viruses was performed in BHK cells at 37 °C as above and harvested at 6 days 
p.i. Generation of RVFV and BUNV virus stocks were performed in Vero E6 cells 
at 33 °C with the same method as above.. Harvested supernatant was then 
clarified by centrifugation at 4,000 x g for 10 min, aliquoted and stored at -80 °C 
for further use. All experimentation with RVFV was conducted under 
containment level 3 conditions. 
4.1.9 Virus infections 
Cells were seeded in 24 well, 96 well plates or T225 flasks and allowed to reach 
approximately 70% confluence. Virus dilutions were made in 2% (v/v) FBS/PBS. 
Cell culture media was removed and replaced with 100 µl, 200 µl or 10 ml virus 
inoculum for a 96 well, 24 well or T225 flask respectively. Virus inoculum was 
adsorbed onto cells at 37°C for 1 h. Following virus adsorption, the flasks or 
plates were topped up with appropriate cell culture medium. Application of 
infectious material onto cells was considered time point 0 h p.i.  
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4.1.10 Plaque forming assay and focus forming assay 
Plaque assays were performed on monolayers of confluent BHK-21 cells in 12 or 6 
well plates. The cell media was removed and 10-fold serial dilutions of virus 
inoculum (in 2% (v/v) FBS/PBS) was added to the monolayer. Following 1 h 
incubation at 37 °C, an overlay of MEM supplemented with 2% (v/v) FBS and 0.6% 
(v/v) Avicel was added. The plates were incubated at 37 °C for 5 days after 
which they were fixed with formaldehyde solution for 1 h. After fixation, the 
formaldehyde fixing solution was removed and 0.1% (v/v) Toluene blue staining 
agent was added. The plates were incubated for 30 minutes at room 
temperature after which the staining agent was removed, the plates were 
washed with distilled water and then left to dry. 
For determining RVFV MP12delNSs:hRen titre, a focus forming assay was 
performed. Serial dilutions of virus inoculum in PBS/2% (v/v) FBS were applied to 
confluent BHK-21 cell monolayer. After 1 h incubation at 37°C, cell monolayer 
was overlaid with MEM overlay supplemented with 2% FBS and 0.6% Avicel. The 
assay was incubated for 5 days, after which was fixed with formaldehyde buffer 
for 1 h. After fixation, permeabilisation solution was applied to the monolayer 
and before further incubation of rabbit anti-RVFV N antibody (1:500 in standard 
blocking buffer) for 2 h. The monolayers were washed three times with washing 
buffer and incubated with anti-rabbit HRP-linked antibody (1:5000 in standard 
blocking buffer) for 1 h. Subsequently, cells were washed with PBS and foci 
detected by adding TrueBlue peroxidase substrate at room temperature for 30 
min. The plates were rinsed with distilled water and foci counted. 
Virus titres were calculated using the equation: 
 
𝑃𝐹𝑈 𝑜𝑟 𝐹𝐹𝑈
𝑚𝑙
=  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑜𝑟 𝑓𝑜𝑐𝑖
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑥 𝑉𝑜𝑙𝑢𝑚𝑒(𝑚𝐿) 
 
4.1.11 Immunofluroescence 
A549 or Huh7-T7-Lunet cells were seeded in glass-bottomed 24-well plates or 24 
well plates with 15 mm coverslips at a density of 1 x105 cells per well. 
Transfections (4.1.2) or infections (4.1.9) were carried out on the seeded cells 
as previously described. At the respective time points, cell culture supernatant 
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was removed and the cells were fixed with formaldehyde solution. Cells were 
subsequently permeabilised using permeabilisation solution (0.5% (v/v) Triton X-
100 in PBS) for 30 minutes. Following permeabilisation, cells were probed with 
primary antibody at the relevant concentration in 2% (v/v) FBS PBS and 
incubated overnight at 4 °C with gentle agitation. The following day, cells were 
washed three times with PBS 0.1% (v/v) Tween-20 before the addition of 
fluorescently-labelled secondary antibody in 2% (v/v) FBS PBS at the 
recommended concentration. The secondary antibody was incubated for 1 h at 
room temperature. Cells were subsequently washed twice with PBS 0.1% (v/v) 
Tween-20 before the addition of 1:100 DRAQ7™ DNA dye (BioStatus) in PBS. 
Samples were shaken for 10 minutes before washing once with distilled water 
and further mounting using hard set Prolong Diamond Antifade Mountant 
(Invitrogen).  
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4.2 Molecular Cloning 
4.2.1 DNA Amplification  
Polymerase chain reaction (PCR) was performed using KOD Hot Start polymerase 
for high fidelity reactions and GoTaq Flexi 2 polymerase for low fidelity 
reactions according to the manufacturer’s instructions. PCR mixes and cycling 
conditions are as follows; 
KOD Hot Start Polymerase 
PCR Components 
Amount PCR Component 
25 µl 2x KOD Master Mix  
1 µl 10 mM Forward Primer 
1 µl 10 mM Reverse Primer 
50 ng Template DNA 
Up to 50 µl total H2O 
 
Cycling Conditions 
Initial Denaturation: 95°C 2 min 
30 cycles:  
Denaturation: 95°C 1 min  
Annealing: Primer dependent 1 min  
Extension: 72°C 1 min/kb 
Final Extension: 72°C 5 min 
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Hold: 4°C 
GoTaq Flexi 2 polymerase 
PCR Components 
Amount PCR Component 
10 µl 5x GoTaq buffer 
4 µl 25 mM MgCl2 
1 µl 10 mM dNTPs 
1 µl 10 mM Forward Primer 
1 µl 10 mM Reverse Primer 
50 ng Template DNA 
0.25 µl GoTaq Flexi 2 DNA polymerase 
Up to 50 µl total H2O 
Cycling Conditions 
Initial Denaturation: 95°C 2 min 
30 cycles: 
Denaturation: 95°C 1 min 
Annealing:  Primer dependent 1 min 
Extension: 72°C 1 min/kb 
Final Extension:72°C 5 min 
Hold: 4°C 
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4.2.2 Site-directed mutagenesis 
Site-directed mutagenesis was performed with complementary primers designed 
for inverse PCR, where the desired point mutations were flanked by 
complementary plasmid sequence. The PCR was performed using KOD Hotstart 
polymerase with PCR mixes and cycling conditions as stated: 
PCR Components 
Amount PCR Component 
25 µl 2x KOD Master Mix  
1 µl 10 mM Forward Primer 
1 µl 10 mM Reverse Primer 
50 ng Template DNA 
Up to 50 µl total H2O 
Cycling Conditions 
Initial Denaturation: 95°C 2 min 
30 cycles: 
Denaturation: 95°C 20 seconds  
Primer Annealing: 61°C 10 seconds  
Extension: 70°C 2 min 
Final Extension: 70°C 7 min 
Hold: 4°C 
Following PCR amplification, samples were treated with 2 units of DpnI enzyme 
for 2 hours at 37°C digesting methylated input template plasmid. Products were 
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purified via gel electrophoresis and gel extraction (detailed in 4.2.4) before In-
fusion and bacterial transformation (detailed in 4.2.5). 
4.2.3 In-Fusion cloning 
Restriction free cloning was used as a primary method for gene insertion into 
specified vectors. The target vector was initially linearized using either 
restriction enzymes or through PCR. Primers were designed in a way to obtain 15 
base pair long complementary sequences between the insert and the vector at 
both the 5’ and 3’ ends. PCR products were purified as below before use in an 
In-Fusion reaction using the In-Fusion HD Cloning Plus kit (Clontech). The 
reaction was set up using equal moles of insert and linearized vector, 2 µl 5x In-
Fusion HD enzyme premix and a volume of ddH2O up to 10 µl total. The reaction 
was incubated for 15 min at 50 °C and subsequently placed on ice. 5 µl of the 
reaction mixture was used to transform 50 µl Stellar Competent cells (Clontech) 
as described in 4.2.5. 
4.2.4 Agarose gel electrophoresis 
PCR products and digested DNA products were visualised on gels consisting of 1-
2% (w/v) agarose, 0.04 µg/mL Ethidium bromide/Gel Red in either 1x TAE or 1x 
TBE buffer. Samples were mixed with 6x Gel loading dye and loaded on to the 
gel submerged in 1x TAE/TBE buffer. Additionally, Generuler 1kb+ DNA ladder 
was also loaded. Electrophoresis was performed at 100V to allow separation of 
desired fragments. If required, gel extraction was performed using the GE 
Healthcare gel extraction kit according to manufacturer’s instructions. 
4.2.5 Bacterial transformation 
50 µl Stellar Competent cells, DH5α or Bl21 Rosetta cells were incubated with 1-
5 µl plasmid on ice for 30 minutes before heat shock at 42 °C for 30 seconds. 
Cells were recovered on ice for 2 minutes before the addition of 500 µl S.O.C 
growth media. Transformed cells were subsequently placed at 37 °C and 
agitated at 180 revolutions per minute (RPM) for 1 hour. Cells were plated on LB 
agar plates containing antibiotic (100 µg/mL) and incubated at 37 °C overnight. 
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4.2.6 Plasmid isolation 
Single colonies were selected from LB agar plates using a pipette tip and were 
placed in 5 mL or 150 mL LB Broth containing 100 µg/mL antibiotic and 
incubated overnight shaking 180 RPM at 37 °C. Plasmid was isolated from the 
small-scale culture using the Miniprep kit or from the large-scale culture using 
the Maxiprep kit (Qiagen) according to the manufacturer’s instructions. To 
confirm successful cloning, plasmid was sent for Sanger sequencing (Source 
BioScience). Plasmid DNA concentration was quantified using a Nanodrop. 
4.2.7 Cellular RNA extraction 
Cell monolayers were harvested using 1x Trypsin in Versene before 
centrifugation at 2000 x G for 5 minutes. Cells were resuspended in 100 µl 
Versene before transfer into 1 mL Trizol LS reagent (Thermo Fisher Scientific). 
After which, 200 µl chloroform/mL Trizol was added and the sample vortexed for 
15 seconds. The sample was centrifuged for 15 min at 12,000 x G at 4°C. The 
upper aqueous phase was transferred to a clean Eppendorf tube then 500 µl 
isopropanol and 0.5 µl RNAse free glycogen (10 mg/ml) was added. The sample 
was incubated at room temperature for 10 min before centrifugation for 10 min 
at 12,000 x G at 4°C. The supernatant was removed and the RNA pellet washed 
with 500 µl 70% (v/v) ethanol and centrifuged for 15 min at 14,000 x G twice. 
The ethanol wash was then removed and the RNA pellet air dried before being 
resuspensed in 20 µl nuclease free H2O.  
4.2.8 cDNA synthesis 
Reverse transcription of cDNA from cellular RNA extraction was used for Real-
time qPCR analysis. SuperScript® III First-Strand Synthesis System for RT-PCR kit 
was used to synthesise cDNA. Firstly, the following components were combined 
in a 0.2 ml tube: 
 
 
Component Amount 
Total RNA ~1-5 µg 
Random primers 
50ng/µl 
2 µl 
10 mM dNTP mix 1 µl 
ddH2O Up to 10 µl 
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The reaction was incubated at 65°C for 5 min then placed on ice for 1 min, after 
which the following components were added: 
Component Amount 
5x RT buffer 4 µl 
0.1 M DTT 1 µl 
RNaseOUT™ (40 U/ 
µl) 
1 µl 
SuperScript® III RT 
(200 U/ µl) 
1 µl 
 
The sample was incubated for 5 min at 25°C, followed by 1 h at 50°C and then 
15 min at 70°C to inactivate the enzyme. Synthesised cDNA was stored at -20°C. 
4.3 Protein Analysis 
4.3.1 Co-immunoprecipitation 
4.3.1.1 Virus infection 
For proteomic analysis, A549 cells were seeded in a T225 flask (2.5x107 cells) 
and infected with rMP12 at MOI 5 in 2% FBS/PBS for 1 h before topping up of 
culture media. At 16 h post infection media was removed, cells were washed 
with 5 ml PBS and 5 ml IP lysis buffer added. After 5 min, cells were 
resuspended and transferred to a 15 ml falcon tube. The cell lysate was kept on 
ice for 20 min before centrifugation at 16,000 x G for 20 min. Meanwhile, the 
magnetic bead antibody complex was prepared by first washing 100 µl of the 
Protein A or G magnetic beads per sample in 500 µl IP wash buffer and vortexing 
for 15 seconds. Washing was repeated twice before resuspension in 200 µl IP 
wash buffer containing Halt protease inhibitors and addition of anti-RVFV N or 
anti-β-catenin antibody (details given in 3.1.5). Magnetic bead-antibody complex 
was rotated for 1 h and incubated at 4°C. Subsequently, the antibody-bead 
complex was washed with 500 µl wash buffer and rotated for 5 min at 4°C, this 
process was repeated twice. The antibody-bead complex was resuspended in 100 
µl IP wash buffer. The cell lysate and antibody-bead complex were combined 
and rotated for 2 h and incubated at 4°C. Following which, the sample was 
washed with 500 µl IP wash buffer and rotated for 5 min at 4°C, repeated three 
times. The sample was transferred to a fresh tube before the 
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immunoprecipitated protein was eluted from the beads through the addition of 
100 µl loading buffer containing 1x Bolt LDS sample buffer and 1x Bolt Reducing 
agent (Thermo Scientific) and incubation at 90°C for 10 min. Samples were 
further analysed via mass-spectrometry (4.3.3) or Western blot (4.3.2). 
4.3.1.2 Transfection 
For N protein interaction analysis, BSR-T7/5 cells were seeded in 6 well plates 
(1.2x106 cells) and transfected with 500 ng pTM1 L3V5 (expressing a V5-epitope 
tagged RVFV polymerase protein) and 1 µg pTM1 N or pTM1 N mutant. At 24 h 
post transfection, media was removed and 1 ml IP lysis buffer added. For Co-IP 
of transfected cells, 30 µl Pierce Protein A magnetic beads were used bound 
with anti-V5 antibody and protocol continued as 4.3.1.1. The 
immunoprecipitated protein was eluted through the addition of 50 µl loading 
buffer and incubation at 90°C for 10 min. Samples were analysed by Western 
blot (4.3.2). 
4.3.2 Western blotting analysis 
Samples were loaded on to precast Bolt 4-12% Bis-Tris (Thermo Scientific) gels 
for polyacrylamide gel electrophoresis (PAGE) under denaturing conditions and 
ran using 1x MES SDS running buffer at 100 V for 80 min. Using a Trans-Blot SD 
semi-dry transfer cell (BioRad) proteins were transferred on to a nitrocellulose 
membrane of 0.45 µm pore size (GE Healthcare) by soaking in 1x semi-dry 
transfer buffer and subjected to a constant voltage of 15V for 45 min. Following 
transfer, the membrane was blocked for 1 h at room temperature using Western 
blot blocking buffer. After blocking, antibodies (as specified in 3.2.4) were 
diluted in blocking buffer and incubated with the membrane overnight at 4°C or 
1 h at room temperature with mild rocking. The membrane was then washed 
three times with PBS-Tween washing buffer before the addition of secondary 
antibody diluted in blocking buffer for 45 min at room temperature. After 
incubation, the membrane was washed three times with PBS-Tween washing 
buffer and visualised using the Odyssey® CLx (LI-COR) or Pierce ECL Western 
blot substrate (Thermo Scientific) visualised on ChemiDoc MP Imaging system 
(BioRad). 
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4.3.3 Mass-spectrometry analysis  
A549 cells were infected and co-immunoprecipitated as previously described 
(4.3.1.1). Mass-Spectrometry of eluted immunoprecipitation samples was carried 
out at the FingerPrints Proteomics facility (Dundee) with an Ultimate 3000 
RSLCnano-system (Thermo Scientific) coupled to LTQ OrbiTrap Velos Pro 
(Thermo Scientific). In-Gel digestion was performed on samples to digest 
proteins into peptides for analysis via mass-spectrometry. This process was 
carried out at the Dundee facility by their standard protocol. The OrbiTrap Velos 
Pro was operating in data dependent acquisition mode using FT-MS and FT-
MS/MS. Detailed configuration provided below; 
FTMS Full AGC Target:1000000 
Ion Trap MSn AGC Target:5000.00 
Fill Time FTMS (ms): 500 
Fill Time ITMS (ms): 100 
Lock Mass: 445.120024 
FT-MS: 
        Resolution: 60000 
        Mass Range (m/z):335-1800 
        Scan Type: Full 
        Polarity:Positive 
        Data Type:Profile 
FT-MS/MS: 
        Resolution: 30000 
        Mass range: Normal 
        Data Type: Centroid 
       Activation Type:         CID 
       Min. Signal Required:    5000 
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       Isolation Width:         2.00 
       Normalized Coll. Energy: 35.0 
       Default Charge State:    2 
       Activation Q:            0.250 
       Activation Time:         10.00 
Progenesis LC-MS software was used to compare sample spectra and protein 
identification was performed using Mascot. MaxQuant software version 1.5.2.8 
was used downstream to obtain label free quantification intensity (LFQ) values 
used in label-free quantification. LFQ values are generated through MaxQuant by 
computing the sum of all identified protein intensities divided by the theoretical 
maximum number of peptides as calculated through in-silico digest. LFQ values 
undergo a process that reduces the need for “household” proteins that are 
unchanged during the experiment and maximises the information gained from 
signal ratios across samples through normalisation of intensity. The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository with the 
dataset identifier PXD010423 (Deutsch et al., 2017, Perez-Riverol et al., 2016). 
4.3.4 Luciferase assay 
Luciferase assays were carried out using either the Dual-Luciferase Reporter 
(Promega), SteadyGlo (Promega), or Luciferase Reporter systems (Promega) 
following the manufacturer’s instructions. Dual-Luciferase Reporter and 
Luciferase Reporter assays were measured using a GloMax 20/20 single tube 
luminometer (Promega), with a 10 second integration time for each reading. 
Luciferase assays performed under CL3 conditions used the SteadyGlo system 
and were measured without the use of injectors on a GloMax 20/20 system. 
 
4.3.4.1 Transfection 
Luciferase assays were carried out using Dual Luciferase (Promega), Steady Glo 
(Promega), Nano-Glo (Promgea) or Renilla-Glo (Promega) kits following the 
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manufacturer’s instructions. Renilla, firefly and Nano luciferase was measured 
on a Glomax luciferase machine with an integration time of 10 seconds. 
4.3.4.2 Gene modified SFV Infection 
Aag2, AF5 or AF319 cells were seeded at 1.5 x105 cells per well in 24 well plates. 
After 24 h, cells were infected with either SFV6 (3H)-FFLuc, SFV6(3H)-RLuc-2SG-
p19, SFV6(3H)-RLuc-2SG-ZIKA_C, SFV6(3H)-RLuc-2SG-RVFV_N, SFV6(3H)-RLuc-
2SG-BUNV_N or SFV6(3H)-RLuc-2SG-eGFP at MOI 0.01 or 0.001. Cells were lysed 
at 24, 48 and 72 h post infection with 100 µl passive lysis buffer and Rluc 
measured. 
4.3.4.3 siRNA/dsRNA Sensor Assay 
Aag2, AF5 or AF319 cells were seeded at 1.5 x105 cells per well in 24 well plates. 
After 24 h, cells were infected with either SFV6(3H)-FFLuc, SFV6(3H)-RLuc-2SG-
p19, SFV6(3H)-RLuc-2SG-ZIKA_C, SFV6(3H)-RLuc-2SG-RVFV_N, SFV6(3H)-RLuc-
2SG-BUNV_N or SFV6(3H)-RLuc-2SG-eGFP at MOI 1. At 24 h post infection, cells 
were transfected with 100 ng pIZ-Fluc and co-transfected with dsRNA against 
FLuc, dsFLuc, LacZ or dsLacZ. Alternatively, co-transfected with siRNAs against 
FLuc, siFLuc or Hygromycin B resistance gene, siHyg. using 1 µl Dharmafect per 
well. After 24 h, cells were lysed with 100 µl passive lysis buffer and firefly 
luciferase signal was measured within the cell monolayers. 
4.3.4.4 Cell Viability 
Cells were seeded in 96 well plates to 70% confluency. After 24 h, cells were 
infected with rMP12, rMP12delNSs:eGFP, mock infected or treated with (1 
µg/ml) puromycin (as a control). At 7 and 24 h post infection, cells were lysed 
for 10 min with 30 µl Cell Titre Glo buffer and substrate. Luciferase based cell 
viability assay was carried out using the Cell Titre-Glo luciferase kit (Promega) 
according to the manufacturer’s instructions. Luminescence was measured on a 
GloMax luciferase machine with an integration time of 5 seconds.  
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4.3.5 Protein purification 
4.3.5.1 Expression 
BL21 Rosetta2 competent bacterial cells were transformed with 50 ng p14 RVFV 
N or mutant N expressing plasmid and plated out as previously described (4.2.5). 
A colony was selected and placed in 3 ml LB broth containing ampicillin (100 
µg/ml). The culture was grown overnight at room temperature on a shaking 
incubator (180 rpm). The overnight cultures were transferred into a conical flask 
containing 200 ml fresh LB/ampicillin and grown at 37°C until the culture 
reached an A600 between 0.5-0.8. After which, the culture was cooled to room 
temperature and IPTG was added to a final concentration of 0.1 mM. The culture 
was placed on a shaker (150 rpm) for 18 h at room temperature. Subsequently, 
the cells were harvested by centrifugation at 3000 x G and stored at -20°C for up 
to a week. 
4.3.5.2 Purification  
The cell pellet was thawed, resuspended in 4 ml 1x lysis buffer per 50 ml 
pelleted culture B-PER Protein Extraction Reagent (Thermo Fisher Scientific) 
containing Halt EDTA-free protease inhibitor and DNase (50 µg/ml) and rotated 
at room temperature for 1 h. After which, 20 mM Imidazole, 0.3 M NaCl, 50 mM 
Tris pH 8.0 and 10% (v/v) glycerol final concentration was added. The cell lysate 
was centrifuged at 4000 x G for 30 min at 4°C. For a 50 ml culture, 300 µl Ni-
NTA resin was equilibrated with 2 ml Protein Equilibration buffer through 
rotation at 4 °C for 5 min twice. The clarified supernatant was added to the 
equilibrated Ni-NTA resin in a 15 ml falcon tube and incubated at 4°C with 
gentle rotation for 30 mins. The supernatant was discarded and Ni-NTA resin 
resuspended in 2 ml protein purification wash buffer. The sample was rotated at 
4°C for 5 minutes before centrifugation at 5000 x G for 1 minute and removal of 
supernatant. Washes were repeated at least 3 times. The purified protein was 
eluted using 500 µl protein purification elution buffer per 50 ml culture and with 
rotation at 4 °C for 15 mins. Finally, the sample was centrifuged at 5000 x G for 
1 minute and supernatant transferred to a fresh tube. Purified protein was 
buffer exchanged to protein storage buffer using Vivaspin® 500 Centrifugal 
Concentrator (molecular weight cut-off MWCO 10,000Da) according to 
manufacturer’s instructions. Protein samples were checked for purity using SDS-
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PAGE (4.3.2) and stained with SyproOrange (Sigma) according to manufacturer’s 
instructions. 
4.3.6 RNA binding assay 
Recombinant purified protein was examined for in vitro RNA-binding activity 
through dissociation of bound RNA from the sample. 2x RNA gel loading buffer 
was added to 5-10 µg of recombinant purified protein before visualisation on 2% 
NuSieve GTG agarose gel (Lonza) stained with GelRed (Biotium). 
4.3.7 Multimerisation assay 
Purified protein was buffer exchanged from protein storage buffer to 10% 
glycerol in PBS (v/v). Dithiobis(succinimidyl propionate)(DSP)(Thermo Fisher 
Scientific) was added to 5 µg of recombinant protein at 1 mM final concentration 
and incubated at 20°C for 30 min. The reaction was stopped through the 
addition of loading buffer containing 4x LDS sample buffer before analysis via 
SDS-Page (4.3.1.1) 
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Chapter 5 Mutagenesis of RVFV N protein to 
investigate N-N interactions 
5.1 Introduction 
N proteins within the Bunyavirales order are essential structural proteins for 
viral replication. Across the order, the protein largely performs the same 
important functions: the encapsidation of the viral genome, the formation of 
multimers, the association with the RdRp and the interaction with the 
glycoprotein Gn for packaging. The binding of the viral genomic RNAs by N is 
important for the formation of viral RNP complexes that subsequently   associate 
with L allowing transcription and replication to occur, and in addition function 
to protect the viral genome from harsh conditions found within the intracellular 
environment (Hornak et al., 2016). Secondly, the formation of multimeric 
structures of N is essential for the formation of RNP complexes in infected cells. 
The N-terminal arm binds adjacent N monomer in a globular hydrophobic groove 
that results in ring-shaped oligomers and allows the formation of filamentous 
RNPs required to replicate the viral genome (Ferron et al., 2011, Alfadhli et al., 
2001). The binding of RNA and the formation of multimeric rings allows the 
association and binding of the RdRp to the viral genomic RNAs to take place, and 
thus transcription and replication can occur (Leonard et al., 2005, Osborne and 
Elliott, 2000). Finally, the N-terminal of Gn has been shown to interact with N in 
the packaging process at the Golgi apparatus (Piper et al., 2011). 
Additionally, there are a number of studies focusing on the other members of 
the Bunyavirales order that have not been investigated within the context of 
RVFV. Orthohantavirus N protein is thought to have RNA chaperone activity, 
involving the dissociation of RNA duplexes allowing the binding of L protein to 
the 5’ end of the RNA for genome replication (Mir and Panganiban, 2006a, Mir 
and Panganiban, 2006b). Sin Nombre orthohantavirus N has also been shown to 
have cap-snatching activity through the binding and accumulation of mRNA caps 
in cytoplasmic processing bodies, the sequestered caps are then used as primers 
for the initiation of viral mRNA synthesis (Mir et al., 2008). Within the 
Peribunyaviridae, the order prototype virus Bunyamwera orthobunyavirus (BUNV) 
nucleocapsid has been shown to carry out largely the same functions as RVFV N 
(Panganiban and Mir, 2009, Eifan and Elliott, 2009). However, many members of 
82 
 
the Bunyavirales order have largely different N protein structures and thus may 
perform unrelated functions. For example, Crimean-Congo haemorrhagic fever 
orthonairovirus (CCHFV), a member of the Orthonairovirus genus within the 
Nairoviridae family, showed a structural alignment with other Bunyavirales N 
proteins that indicated CCHFV N was more closely related to the arenavirus 
Lassa virus than other members of Bunyavirales (Carter et al., 2012). Thus, 
other N functions may still be discovered. 
Previous studies have revealed a number of important residues essential for the 
primary functions of RVFV N. The RNA binding cleft has been identified as two 
distinct components: a) 18 core conserved residues at the centre of the protein 
and b) residues within the N-terminal arm hinge region. The inner surface of the 
RNA binding groove is lined with conserved hydrophobic amino acids; conversely 
the rim has conserved positively charged residues. Thus the core can bind RNA at 
a high affinity via contact with the hydrophobic amino acids and by base stacking 
(Raymond et al., 2012). Structurally, the RNA binding cleft showed no RNA 
sequence specificity or changes in binding affinity (Raymond et al., 2012) 
despite previous aptamer studies showing a slight preference for specifically 
designed RNA aptamers (Ellenbecker et al., 2012). Crystallisation of RVFV N 
allowed the structure to be solved, which showed ring-shaped hexamers, a 
structure mediated by the N-terminal arm of N binding to an adjacent subunit in 
the hydrophobic groove (Ferron et al., 2011). Additionally, a variation in the 
packing of subunits within the hexameric ring in the two crystal structures 
analysed indicates N’s ability to form varying subunit structures that would allow 
the formation of the serpentine-like RNP structures required for the 
encapsidation and replication of the viral genome (Ferron et al., 2011). The 
residues Y3, L7, I9, F11, V16, I21, Y24, V25, F28 and Y30 on the N-terminal arm 
of RVFV N are important residues for filling the hydrophobic groove (Table 5-1). 
Mutation of essential residues within the groove can prevent the formation of 
multimers and therefore stop the formation of viral RNPs (Le May et al., 2005). 
The link between RNA binding and N oligomerisation has been tentatively 
investigated. Electron microscopy (EM) of only N protein showed small 
oligomers, conversely the EM sample containing both N and RNA showed the 
typical circular multimeric structures expected from N crystallography (Ferron et 
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al., 2011). Thus, it has been suggested that in the absence of RNA, the N-
terminal arm of N subunits binds to its own oligomerisation groove, resulting in a 
closed “low-energy” conformation (Ferron et al., 2011). In the presence of RNA, 
it is predicted that the N-terminal arm opens and stabilises, allowing the further 
recruitment of N subunits and the formation of higher order structures (Ferron 
et al., 2011). 
There have been several studies that identify important functions of named 
amino acid residues, summarised in Table 5-1. These residues were all found to 
be involved in multimerisation or RNA binding and as such, were used as a 
reference in selection of residues for a mutagenesis study. 
The primary aim of this study was to inform on and characterise amino acids 
that are not associated with the multimerisation and RNA binding function of 
RVFV N yet are conserved within the Phlebovirus genus and thus are likely to be 
important and may reveal unknown functions. 
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Table 5-1. Summary of known RVFV N residue functions. 
A table compiling the predicted and known functions of RVFV N protein residues 
from studies primarily focused on the RNA binding capabilities. Information 
compiled from (Ferron et al., 2011),(Raymond et al., 2012) and (Raymond et al., 
2010)  
Residue Function Reference 
M1 Contacts Trp125 dimer interface  (Raymond et al., 2010) 
Y3 Project from N terminal arm - interact with hydrophobic groove  (Ferron et al., 2011) 
Y4 Observed loss of dimer formation (destabilisation of helix a1)  (Raymond et al., 2010) 
Q5 Contacts Trp125 dimer interface  (Raymond et al., 2010) 
L7 Project from N terminal arm - interact with hydrophobic groove  (Ferron et al., 2011) 
I9 
Contacts Trp125 dimer interface, Project from N terminal arm - interact 
with hydrophobic groove  
(Raymond et al., 2010, 
Ferron et al., 2011) 
F11 
Observed loss of dimer formation (destabilisation of helix a1), Project 
from N terminal arm - interact with hydrophobic groove  
(Raymond et al., 2010, 
Ferron et al., 2011) 
A12 Intersubunit van der waals contacts  (Raymond et al., 2010) 
V16 Project from N terminal arm - interact with hydrophobic groove  (Ferron et al., 2011) 
I21 Project from N terminal arm - interact with hydrophobic groove (Ferron et al., 2011) 
Y24 Project from N terminal arm - interact with hydrophobic groove  (Ferron et al., 2011) 
V25 Project from N terminal arm - interact with hydrophobic groove  (Ferron et al., 2011) 
F28 Project from N terminal arm - interact with hydrophobic groove  (Ferron et al., 2011) 
Y30 
Project from N terminal arm - interact with hydrophobic groove, Hinge 
region stacks with 5'most base in RNA binding (base 1)  
(Ferron et al., 2011) 
F33 "Back pocket" of RNA binding slot interacts with base 2  (Raymond et al., 2012) 
R64 Predicted RNA binding cleft, loss of RNA binding in triple mutant*  (Ferron et al., 2011) 
G65 Interacts with base 5 in narrow pocket   (Raymond et al., 2012) 
K67 Predicted RNA binding cleft, loss of RNA binding in triple mutant* (Ferron et al., 2011) 
K74 Predicted RNA binding cleft, loss of RNA binding in triple mutant*  (Ferron et al., 2011) 
A109 Lines RNA binding slot interacts with base 3 and 4  (Raymond et al., 2012) 
A110 Lines RNA binding slot interacts with base 3 and 4  (Raymond et al., 2012) 
V120 Intersubunit van der Waals contacts  (Raymond et al., 2010) 
V121 Intersubunit van der Waals contacts  (Raymond et al., 2010) 
E124 Intersubunit van der Waals contacts  (Raymond et al., 2010) 
W125 
Contacts Met1, Gln5, Ile9 and Trp125 of second monomer. Critical for 
dimer formation  
(Raymond et al., 2010) 
L126 Interacts with base 5 in narrow pocket  (Raymond et al., 2012) 
P127 Interacts with base 5 in narrow pocket  (Raymond et al., 2012) 
T131 Intersubunit van der Waals contacts  (Raymond et al., 2010) 
P147 Lines RNA binding slot interacts with base 3 and 4  (Raymond et al., 2012) 
F176 Interacts with base 5 in narrow pocket  (Raymond et al., 2012) 
R178 Forms salt bridge with Ala245  (Raymond et al., 2010) 
I180 Lines RNA binding slot interacts with base 3 and 4  (Raymond et al., 2012) 
P199 Lines RNA binding slot interacts with base 3 and 4  (Raymond et al., 2012) 
A202 Lines RNA binding slot interacts with base 3 and 4  (Raymond et al., 2012) 
A245 Forms salt bridge with Arg178  (Raymond et al., 2010) 
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5.2 Results 
5.2.1 N Protein Conservation and Mutagenesis 
To assess the conservation of the N protein sequence between members of the 
Phlebovirus genus, 14 Phlebovirus N sequences in GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) were aligned using a pairwise 
alignment in Geneious (Appendix 9.2) and conserved residues were identified 
(Figure 5-1). The conservation of N between RVFV and other species of 
Phlebovirus varies greatly, at 48% aa similarity between RVFV and TOSV and as 
little as 36% between RVFV and UUKV. The alignment of phleboviruses forms into 
two distinct groups, phleboviruses transmitted by an insect vector or transmitted 
by ticks. From this alignment five amino acids were selected for alanine 
substitution and downstream functional analysis. Alanine substitution was chosen 
due to its biochemical nature, as it retains the shape of the structure via the 
beta carbon; however it has no further side chain chemistry. This small selection 
of mutants was selected based upon sequence conservation between 
phleboviruses, targeting those residues that were most likely to have a 
significant conserved function. Additionally, residues were included that are 
presented on the surface of the N protein, and not close to previously known 
functional areas such as the RNA binding pocket therefore excluding some of the 
more highly conserved residues within the alignment. Thus a targeted approach 
was used; fewer mutants were selected due to time constraints and to allow for 
complete downstream experimental evaluation and confirmation of residue 
functions. Residue F11, a previously analysed residue found on the N-terminal 
arm of N, is highly conserved between the insect-borne phleboviruses, with the 
exception of Candiru virus (CDUV). In the UUKV-like tick-borne virus group 
however the phenylalanine is often substituted with an isoleucine. While the 
function of F11 had been previously identified, unpublished work from the Elliott 
laboratory indicating it is possible to rescue a functional N-terminal arm deletion 
mutant may have shed doubt on the residues structural functions.  Residue Y30 
of RVFV has been previously analysed and is conversed across both phlebovirus 
groups. Residues D34, F149 and N181 are conserved across the Phlebovirus genus 
and have no associated functions. Additionally, as mentioned previously, the 
prior unpublished work from the Elliott laboratory had indicated that it is 
possible to rescue a RVFV virus with an N-arm deletion, and thus would be a 
86 
 
valuable tool with which to generate an RVFV N tagged virus that does not affect 
the globular formation of N. This would also allow us to examine the impact of 
N-N interactions on N protein functions. To test this, two N-arm mutants, a 
deletion of amino acids 1-14 and 1-31, were also introduced to the panel of 
mutants (Figure 5-2).  
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Figure 5-1. Alignment of Phlebovirus sequences and indicated point mutations. 
Rift Valley fever phlebovirus (RVFV), Toscana phlebovirus (TOSV), sandfly fever 
Naples phlebovirus (SFNV), sandfly fever Turkey phlebovirus (SFTV), Salehabad 
phlebovirus (SALV), Candiru virus (CDUV), Granada phlebovirus (GRV), Heartland 
phlebovirus (HRTV), Ixcanal phlebovirus (IXCV), Punta Toro phlebovirus (PTV), 
SFTS phlebovirus (SFTSV), Uukuniemi phlebovirus (UUKV), Lone Star phlebovirus 
(LSV), Bhanja phlebovirus (BHAV) Genbank sequences were aligned, conserved 
regions identified and cross referenced with previous literature. Amino acid 
positioning is relative to the RVFV N sequence. The tick-borne phleboviruses are 
highlighted in yellow. 
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Figure 5-2. Chimera 3D Model of RVFV N protein monomer with highlighted mutant 
residues. 
(A) RVFV N protein with highlighted mutations in ribbon view, F11A purple, Y30A 
red, D34A yellow, F149A green, N181A blue (top image)and corresponding 
surface view (bottom image). (B) Alternative orientation of RVFV N with 90° 
offset to (A). (C) RVFV N protein with highlighted N-terminal arm deletion 
mutations, 1-14 in red and 15-31 in blue. (D) Mutant RVFV N with the full delN1-
31 mutation and corresponding surface view. Figure based on data generated in 
a previous study (PDB: 3LYF) (Raymond et al., 2010). 
  
89 
 
5.2.2 Effect of N mutants on reporter systems 
To test the functionality of each RVFV N mutant we employed a minigenome 
system. As N is under differential expression from the S segment via an 
ambisense coding strategy, a plasmid containing only the N coding sequence was 
used to study N in isolation and avoid any deleterious effects that NSs may have 
on the functions of N or on the minigenome activity (Brennan et al., 2011a). The 
minigenome system involves the expression of the N protein ORF (pTM1-N) as 
opposed to plasmids that express full mRNA copies of the viral S segment such as 
pTVT7 RVFV MP12 S Segment. In addition to pTM1-N, the minigenome system 
requires the viral RdRp expressed in a pTM1-L plasmid, both under the 
expression of a T7 RNA polymerase promoter. Together, the N and L plasmids 
transfected into T7 RNA polymerase expressing cells bind to the mRNA generated 
from a third plasmid, a virus genome segment analogue with the viral coding 
sequence replaced with the Rluc ORF leaving the viral M segment UTRs intact 
(Figure 5-3). The viral N and L proteins form RNP complexes that recognise M 
segment UTRs and transcribe Rluc gene resulting in luminescent signal. The level 
of luminescence correlates to the efficiency of viral RNP formation through the 
measurement of transcriptional activity. The pTM1-N plasmids were used as a 
basis in this study to express mutant N proteins. As shown in Figure 5-4, both 
delN1-14 and delN1-31 N arm mutants have no activity in the minigenome 
system. Interestingly, the conserved mutants showed a wide variation in their 
minigenome activities. The mutants F11A and F149 had no transcription activity, 
whereas Y30A and N181A both showed significantly increased activity and D34A 
showed reduced activity, all relative to the wildtype (WT) N (Figure 5-4). A 
previous mutagenesis study of BUNV N showed that inconsistent protein 
expression levels can significantly impact minigenome system activity (Eifan and 
Elliott, 2009), and therefore a Western blot assay was performed on cell lysates 
from the minigenome assay to determine the expression levels of the N protein 
mutants. The expression of transiently expressed N protein mutants was 
consistent, however, mutant delN1-31 showed greatly reduced expression levels. 
Furthermore, through the generation and utilisation of BSR-T7/5 CL21, a single 
cell clone of BSR-T7 cells with increased expression of T7 RNA polymerase, 
delN1-31 expression was detected (Figure 5-5).  
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Figure 5-3. Schematic of pTVT7–GM:hRen  
The pTVT7 backbone contains a T7 promoter followed by RVFV viral UTRs 
flanking both the 5’ and 3’ end of the Renilla luciferase ORF. The Renilla ORF is 
in the anti-sense orientation and thus does not produce mRNA transcripts from 
T7 polymerase activity. Furthermore there is a Hepatitis δ virus ribozyme to 
allow self-cleavage and generation of the correct 3’UTR end, allowing 
recognition by RVFV RNP complexes. Finally, the cassette contains a T7 
terminator sequence.  
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Figure 5-4. Minigenome activity of RVFV N mutants and western blot of expression levels.  
BSR-T7/5 cells were transfected with pTM1-N (wildtype [WT] N, mutant N) or 
empty pTM1 plasmid as a negative control (Con), pTM1-L, pTVT7-GM:hRen and 
pTM1-FF-Luc as a transfection control. (A) Cells were lysed 24 hours post 
transfection to measure the minigenome activity with the presence of WT RVFV 
N or its mutant version. Experiments were performed in triplicate and values 
calculated by dividing Rluc activity by Fluc activity to normalise variable 
transfection efficiency. Mean values together with standard error are shown, 
*denotes p<0.05, ** for p<0.001 using Student’s T-test. (B) Western blot analysis 
of cell lysates, probed with RVFV anti-N antibody (top panel) and anti-actin 
(bottom panel) as loading control.  
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Figure 5-5. Relative expression levels of delN1-31 mutant. 
BSRT7/5 CL21 cells were transfected with pTM1-N and delN1-31 mutant 
plasmids, followed by cells lysis 24 hpt. Western blot probing for anti-actin (top 
panel) and anti-RVFV N (bottom panel) antibodies. Four times more cell lysate 
from delN1-31 transfected cells was loaded for expression analysis.   
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Furthermore, Fluc transfection control values were evaluated for any significant 
changes in general cellular transcription/translation upon the transfection and 
expression of RVFV N or mutant N proteins. As shown in Figure 5-6, there was no 
significant difference due to the presence of the mutants or WT N.  
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Figure 5-6. Effect of N protein on Fluc expression.  
The Firefly luciferase (Fluc) values for the minigenome experiment described in 
Figure 5-4. Mean values together with standard error of triplicate experiments 
are shown, Student’s T test showed no significant difference as compared to 
control plasmid. 
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One of RVFV N’s described functions is the interaction with the N-terminal 
glycoprotein tail of Gn that mediates the packaging of viral RNPs into virions 
before budding at the Golgi apparatus. To assess the capacity for N mutants to 
form virus-like particles we employed an assay based upon packaging the 
minigenome system into VLPs with the addition of the plasmid expressing 
glycoproteins. BSR-T7/5 CL21 cells were transfected with RVFV M segment 
minigenome reporter pTVT7-GM:hRen, pTM1-N or mutant N, pTM1-L and 
additionally pTM1-M encoding the glycoprotein precursor of RVFV M segment. At 
48 h post transfection, cell culture media of the donor cells containing the 
produced VLPs was clarified by centrifugation and nuclease treated to prevent 
the reporter plasmid carry over, thereby reducing background luciferase levels. 
The nuclease-treated supernatant was used to inoculate recipient BSR-T7/5 CL21 
cells pre-transfected with pTM1-L and WT pTM1-N plasmids. The supplementary 
plasmids express stable RNP complexes that can, in the case of functional 
packaging, transcribe reporter template released into the cells from virus-like 
particles resulting in translation and Rluc expression. The VLP data corroborated 
data shown in the minigenome assay presented in Figure 5-7. The WT N and its 
mutants Y30A, D34A and N181A showed functional packaging of the reporter 
template into the VLPs. 
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Figure 5-7. RVFV N mutant activity in a VLP assay  
BSR-T7/5 CL21 cells were transfected with pTVT7-GM:hRen, pTM1-L, pTM1-M, 
pTM1-FF-Luc and WT or mutant pTM1-N. In case of control cells pTM1-N was 
replaced with pTM1. At 48 hours post transfection, the supernatant was 
harvested and treated with Benzonase. The treated supernatant was applied to 
recipient BSR-T7/5 CL21 cells pre-transfected with pTM1-L and WT pTM1 N. Rluc 
activity was measured 24 h post-infection. Experiments were performed in 
triplicate and repeated three times, mean values together with standard error 
are shown. Mean values together with standard error are shown, *denotes p<0.05 
using Student’s T-test. 
  
97 
 
5.2.3 N mutant proteins- assessment of functional properties  
RVFV N has a number of key functions: encapsidation of viral RNA, 
multimerisation of N into functional higher order structures and the association 
and binding of the viral RdRp (Ferron et al., 2011, Raymond et al., 2010, 
Raymond et al., 2012), all of these functions are required for the successful 
formation of viral RNPs. Thus, it was important to assess each mutant for their 
ability to perform each of these functions. To assess the encapsidation and RNA 
binding capacity, we utilised the N protein’s ability to non-specifically bind any 
cellular RNA (Raymond et al., 2010, Dong et al., 2013). During the protein 
purification process from E. coli, purified N binds non-specific bacterial RNA 
(Figure 5-8A). This RNA can be dissociated by using formamide-containing RNA 
loading buffer, which denatures N and thus, it releases bound RNA fragments 
(Figure 5-8B). The RNA binding activity was evident for the delN1-14, F11A, 
D34A, F149A and N181A mutants, however the full arm mutant delN1-31 and 
mutant Y30A had no detectable RNA bound. This was consistent with the 
measurement of 260nm/280nm ratios for all these purified protein samples.  
RVFV N, sized 27kDa, has been shown to form higher order structures: 
tetramers, pentamers and hexamers. Therefore, it was important to assess if the 
mutant’s capacity to multimerise was impaired, which could explain the results 
of the minigenome system. To capture the multimerisation states of N we 
employed a DSP chemical crosslinking assay on purified N protein from the 
bacterial expression system (Figure 5-8C). The arm mutant delN1-31 had 
impaired capacity to form higher order structures, however the other mutants 
all showed normal multimerisation properties. 
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Figure 5-8. Purified RVFV N protein RNA binding capacity and multimerisation properties. 
(A) InstantBlue staining was performed to confirm the purification of N protein 
or its mutants. (B) The in vitro RNA binding activity of WT and mutant N proteins 
was determined by dissociation of non-specifically bound bacterial RNA with a 
buffer containing formamide. Representative image of three repeats shown and 
260nm/280nm ratios for this experiment indicated below the image. (C) DSP 
chemical cross-linking was used to determine the multimerisation capacity of 
purified mutant proteins, cross-linked samples were analysed by Western blot 
using anti-RVFV N antibodies. β-mercaptoethanol was added to the control 
(WT(R)) to reduce the di-sulfide bonds after multimerisation; representative 
image of three independent experiments.   
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The interaction between N and the viral L protein is essential for the formation 
of replication-active RNP complexes. Through the use of a construct expressing a 
V5-tagged L protein (L3V5) (Brennan et al., 2011a) we performed a co-
immunoprecipitation (co-IP) to assess the direct interaction between the 
polymerase and the N mutants (Figure 5-9). pTM1-L3V5 and pTM1-N (or its 
mutant variants) were co-transfected into BSR T7/5 CL21 cells 24 hours before 
subsequent immunoprecipitation. To reduce the effect of bound RNA influencing 
the interaction, the experiment was performed in the presence of RNase A. To 
note, due to the encapsidation ability of N, RNA pre-bound within the N binding 
cleft would not be removed under these conditions as it would be protected 
from cleavage by RNAse A. The co-IP with an anti-V5 antibody was followed by 
western blotting with anti-N and anti-V5 sera to identify the capacity for N to 
bind to the L protein. As expected, the mutants Y30A, D34A and N181A that had 
activity in the minigenome assay interacted with the L protein. Interestingly, 
mutants delN1-14, delN1-31, F11A and F149A also showed binding ability despite 
showing no functional RNP complexes. Thus, we suggested that any functional 
deficiencies observed are irrespective of the N-L interaction, however, L 
polymerase processivity could be affected.   
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Figure 5-9. RVFV L3V5 polymerase interaction with WT and mutant N proteins. 
BSR-T7/5 CL21 cells were transfected with pTM1-L3V5 and pTM1-N (or its mutant 
version). For a negative control, the pTM1-L3V5 plasmid was replaced with 
empty pTM1 (Con). At 24 h post transfection, the cells were lysed and lysate 
applied to magnetic beads bound with anti-V5 antibody. The bound proteins 
were dissociated from the beads and analysed by Western blot using anti-V5 and 
anti-RVFV N antibodies. Following the treatment with secondary antibodies the 
membranes were visualised using LI-COR. The image is representative of three 
independent repeats.  
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5.3 Discussion 
This study aimed to inform on previously unknown conserved phlebovirus N 
residues in order to gain an understanding into the fundamental biology of RVFV 
and its replication cycle. The highly conserved nature of RVFV N within 
identified isolates, as evidenced by multiple sequence alignment (Appendix 9.2), 
indicates the propensity for conserved residues to confer essential functions. 
RVFV MP12, an attenuated strain of RVFV generated by serial passage under 
chemical mutagen, was used in this study. The RVFV MP12 N has no non-
synonymous mutations compared with the pathogenic parental strain ZH548 and 
thus, the data on functional amino acids is applicable both for MP12 studies and 
natural RVFV isolates. 
This study identified two residues, F11A and F149A, to have unknown essential 
functions in the formation of viral RNP complexes and/or transcription or 
replication of the viral genome. The F149A mutant in particular had no activity 
in the minigenome assay and had lost the ability to form VLPs, however 
performed all functions previously identified as essential for RVFV N protein. The 
surface exposed nature of F149A and location at a predicted protein binding 
cleft has lead us to hypothesise that this residue may be involved in the 
interaction with host cellular factors important for normal N processes. Further 
study of this mutant was out of the scope of this study, however an explorative 
experiment using immunoprecipitation followed by proteomics to identify 
interactors of F149A comparative to WT N may reveal impacted host processes 
that are important for RVFV N function. Furthermore, this avenue of study can 
be widened to assess host protein interactions with other members of the 
Phlebovirus genus. The mutant D34A showed slightly reduced activity in the 
minigenome system yet performed all known functions, thus may also be 
involved in host protein interactions, particularly considering its surface exposed 
nature.  
The F11A mutant shows no activity in the minigenome system. A previous study 
has identified a F11G mutant to be involved in the loss of N-N dimer formation, 
through the use of a GST-fused N protein. They hypothesise that the disruption 
involves misfolding of the N-terminal region and disruption of the N-N 
interaction (Le May et al., 2005). Interestingly F11A showed full multimerisation 
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capability within our cross-linking system and additionally still associated with 
the viral L protein and encapsidated the genome. As the G residue can be more 
flexible than A, it could explain the discrepancy in results between F11G and 
F11A. Testing the F11G mutant within the DSP crosslinking assay, or through 
immunoprecipitation of a GST fused F11A mutant would provide confirmation 
regarding the nature of these two mutants. It is clear that the F11A mutant is 
essential for N protein function; it may impact a function other than N-N dimer 
formation. For example, the processivity of RNA synthesis could be affected, or 
binding of further host factors required. By assessing the generation of Renilla 
RNA transcripts it would be possible to assess whether the effect is on 
transcription or on translation. 
Two mutants, Y30 and N181, were shown to have increased activity in our 
minigenome system (Figure 5-4). The N181A residue has no previously described 
function yet showed increased activity in the minigenome assay and formed 
functional VLP complexes. This indicates that N181A must retain the capacity to 
interact with Gn in the formation of VLPs. Interestingly; Y30 had previously been 
identified as an essential residue, involved in the multimerisation of N protein 
and base stacking of RNA within the RNA binding groove. Additionally Y30 is 
thought to be a key residue in the hinge region of the N-terminal arm, allowing 
flexibility and thus facilitating the binding of N into various multimeric 
structures (Raymond et al., 2012). The Y30A mutant in this study however 
appeared to have reduced RNA binding capacity yet still formed multimeric 
structures. A previous study indicated that the Y30A mutation did not disrupt N-
N interactions and thus, it retained its multimerisation capability (Le May et al., 
2005). Additionally, a mutagenesis study in UUKV, also of the Phlebovirus genus, 
identified Y30A as active within a minigenome reporter system (Katz et al., 
2010b) though the study did not assess its RNA binding capacity. The reduced 
RNA binding capacity did not negatively affect the expression of the minigenome 
reporter Rluc or packaging into VLPs.  
The nature of N proteins ability to non-specifically bind cellular RNAs has been 
proposed as a mechanism for preventing translation of cellular transcripts, 
however, the levels of Firefly luciferase from transfection  control plasmid in the 
minigenome assay showed no significant change in the presence of N signifying 
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no general shutdown of translation (Figure 5-6). There may however be an 
inverse relationship between minigenome activity and RNA binding, this would 
require further confirmation. We hypothesise that the reduced RNA binding 
capacity may positively affect RNA replication by a looser binding of RNA into 
the binding pocket allowing increased processivity of the L protein in the 
transcription and replication of the genome, at the expense of genome 
protection. The testing of this hypothesis was outside the scope of this study.  
The delN1-14 and delN1-31 arm mutants showed no activity in the minigenome 
assay. A study on UUKV N N-terminal mutants showed no activity on CAT signal 
based minigenome system (Katz et al., 2010a). This study supports the 
hypothesis that phleboviral N protein N-terminal arm is functionally essential. 
Interestingly, in our study the delN1-14 mutant retained the ability to form 
multimers and encapsidate RNA. Thus, these data suggest that the removal of 
the 1st helix of the n-terminal arm does not impair multimerisation and RNA 
binding, yet these functions are impaired with the removal of the 2nd helix. The 
delN1-31 arm mutant showed impaired multimerisation. While able to form 
dimers and tetramers, delN1-31 showed impaired formation of higher order 
structures indicating an importance for the 2nd helix in successful N-N binding in 
a functional conformation. We hypothesise that the removal of the 1st alpha 
helix reduces the stability of binding into N subunits oligomerisation groove, 
however the 2nd helix provides enough stability to identify the interaction in a 
cross-linking assay. Comparatively, a delN1-19 mutant in UUKV N showed 
approximately 25% N-N binding capacity (Katz et al., 2010a), thus indicating a 
reduced level of multimerisation, this supports our hypothesis for RVFV delN1-
14. The loss of function may also be due to the impairment of the RNA-
dependent RNA-polymerase L to track along the viral RNP, or the resulting N 
protein multimeric structures having an unfavourable orientation or 
configuration conducive to successful transcription or replication. The delN1-31 
arm mutants lack of activity is likely due to its inability to from higher order 
multimeric structures and bind viral RNA. Interestingly, delN1-31 still showed 
interaction with the polymerase L (Figure 5-9), therefore it is highly likely that 
the interaction domain with L is not within the N-terminal arm, and L interaction 
does not require functional formation of the RNP complexes. 
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In conclusion, this study indicates the importance of identifying essential 
residues for understanding the fundamental processes of RVFV N protein while 
also informing on residues conserved across the phleboviruses and thus may have 
wider importance within the genus. The availability of mutational information is 
an important resource for further study, particularly for the investigation of 
RVFV N interaction with the host proteins and other essential functions, for 
example, the multimerisation capacity, the link between non-specific RNA 
binding and minigenome activity and L protein processivity. Through 
understanding of these processes, we may identify potential therapeutic targets 
against RVFV as there is currently no specific antiviral treatment available. 
The functional similarity of phlebovirus N proteins, as evidenced by the 
mutagenesis of Y30A and the delN1-14 mutants similarity with UUKV, indicates 
that the mutagenesis data may be relevant for informing on functional residues 
of other phleboviruses. The residues identified can be used as a basis for 
determining interaction domains of newly identified phlebovirus N – host protein 
interactions. Additionally, this mutagenesis study can be used as a basis for 
influencing therapeutic or vaccine design. Further analysis of replication 
deficient RVFV N mutants and the rescue of mutant RVFV viruses may reveal 
significant attenuation that can be used in vaccine trials. A significant issue with 
vaccination of ruminants across the African continent is the inability to 
distinguish between seropositive and vaccinated animals. To continue this study, 
an attenuated N mutant RVFV strain maybe be distinguished from active RVFV 
infection by generation of monoclonal antibodies to specific mutant residues and 
thus may be a candidate for an effective veterinary vaccine. These findings may 
also influence structure-based drug design, designed to disrupt interactions such 
as binding the interaction domains of the N-terminal arm via P11 or more 
accessible residues such as F149. This study will provide a significant basis with 
which to expand the understanding of RVFV N biology. 
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5.4 Summary 
 A panel of mutants targeting residues conserved across the phlebovirus 
genus was generated. 
 Mutant F149A was essential yet still performed all known functions of N 
protein indicating unknown protein-protein interaction effected. 
 Mutant F11A had no minigenome activity yet also performed all known 
functions. F11A showed activity in multimerisation despite previous 
evidence indicating it as an essential residue for multimerisation. 
 Mutant Y30A showed increased activity yet reduced RNA binding capacity. 
Y30A also had multimerisation capacity yet Y30A had been implicated as 
an important residue for both RNA binding and multimerisation. Mutant 
N181 also showed increased minigenome activity and reduced RNA 
binding, indicating inverse relationship between RNA binding and 
minigenome activity. 
 D34A had reduced minigenome activity and performed all known 
functions. The residue being surface exposed may indicate a disrupted 
host protein interaction. 
 delN1-14 showed no minigenome activity but retained multimerisation 
capacity. delN1-31 lost the ability to form higher order multimers, thus 
the stability of N-N interactions is likely centred around the 2nd alpha 
helix within the N-terminal arm.  
 This panel of mutants has provided a strong basis for future studies, 
informing on conserved residues that have revealed the complexities of 
RNP formation and successful transcription and replication capacity of 
RVFV N.  
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Chapter 6 RVFV and the WNT Signalling 
Pathway 
6.1 Introduction 
Understanding the interaction between host cell proteins and viruses is 
exceptionally important; disrupting these interactions may unveil novel 
intervention strategies for both drug treatment and vaccination. All viruses 
require the interaction of host cell machinery to replicate but also require host 
proteins for receptor binding, entry, penetration of the endosome, budding and 
release. A whole genome siRNA screen identifying host interactors of the 
phlebovirus UUKV had over 370 candidate genes. Many of the interactors were 
with the components of ribosomal machinery and RNA-binding proteins, as 
expected for an RNA virus, however, there were further interactions highlighted 
involved in entry, endosomal acidification and trafficking (Meier et al., 2014). 
Proteomics studies designed to assess bunyavirus host protein interactions are 
limited. Previous studies are often broad in scope and focus primarily on host 
proteins found packaged within the virion or directly interacting with the non-
structural protein NSs (Nuss et al., 2014). These studies most commonly 
identified cytoskeletal proteins within the RVFV virions, such as integrin subunits 
and integrin regulatory proteins. These integrins have a predicted involvement 
with viral budding and egress, however, further study is limited. Additionally, 
proteins from the Ras superfamily were found within the virion correlating 
evidence for RVFV’s use of caveola-mediated endocytosis for viral entry (Harmon 
et al., 2012).  
Within RVFV research, the nucleocapsid protein N has not been the subject of 
focus for host protein interactions. The non-structural proteins of many viruses 
are involved in interactions disrupting innate immune pathways important for 
the successful replication of the virus. Influenza virus replication for example, 
can be disrupted by the targeting of host-virus interactions; such as the 
inhibition of the Raf/MEK/ERK signalling cascade resulted in reduction of virus 
production (Pleschka et al., 2001). There have been over 80 compounds 
identified as potent inhibitors of influenza host-virus interactions (De Chassey et 
al., 2014). This highlights the efficacy of targeting host protein interactions for 
viral therapeutics. Nucleoproteins may also have antagonistic properties. The 
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arenavirus Junín virus (JUNV) nucleoprotein was shown to associate with the 
double-stranded RNA activated protein kinase (PKR) by sequestering PKR into 
viral factories preventing the phosphorylation of eIF2α and thus inhibiting a key 
antiviral pathway (King et al., 2017). A previous study using a proteomics 
approach to assess Crimean-Congo haemorrhagic fever virus (CCHFV), of the 
Nairovirus genus, Bunyavirales order, identified an important interaction with 
cellular chaperons of the HSP70 family. The inhibition of HSP70 function resulted 
in a significant titre reduction for Hazara virus, a distinct virus of the CCHFV 
serogroup (Surtees et al., 2016).  
The primary aim of this study was to identify host protein interactions of RVFV 
nucleocapsid protein and to further elucidate the importance of said 
interactions on the replication efficiency of the virus. Furthermore, I wished to 
assess the impact of RVFV infection on the interactions, determining 
relocalisation of proteins and impact on cellular pathways with the outlook of 
informing on possible therapeutic targets. The WNT signalling pathway had 
previously been shown to have a role in RVFV infection, however the mechanism 
behind this function and its importance within the wider context of virus 
infection was unknown. Additionally, the wealth of molecular tools available for 
studying WNT allowed for more in depth study into the pathway. Thus WNT was 
the primary focus of this study.  
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6.1.1 Human WNT signalling pathway 
The WNT (wingless/integrated) pathway is an important pathway in embryonic 
development, involved in numerous cell cycle and cell proliferation activities. 
While there are a number of minor WNT signalling pathways, the most critical 
and most studied signalling pathway is the canonical WNT signalling pathway 
involving the effector molecule β-catenin which localises to the nucleus to act as 
a key transcriptional activator for numerous downstream developmental genes 
(Clevers and Nusse, 2012).  
In the absence of the signalling molecule WNT at the surface of the cell, 
cytoplasmic β-catenin is targeted for degradation by the Axin complex in the 
cytoplasm (Figure 6-1A). The Axin complex is composed of the scaffold protein 
Axin, glycogen synthase kinase 3 (GSK3), casein kinase 1 (CK1) and adenomatous 
polyposis coli gene product (APC). This complex binds β-catenin, phosphorylating 
the terminal region, thereby allowing recognition by the E3 ubiquitin ligase 
subunit Trcp resulting in subsequent ubiquination and further proteosomal 
degradation (Aberle et al., 1997). This results in significantly reduced levels of 
cytoplasmic β-catenin preventing transition to the nucleus. WNT activated genes 
are repressed by DNA-bound T cell factor/lymphoid enhancer factor (TCF/LEF) 
including the proteins Transducin-like-Enhancer (TLE) and histone deacetylase-1 
(HDAC) that form a co-repressor complex functioning to remove the acetyl 
groups from the chromatin resulting in transcriptional repression (Daniels and 
Weis, 2005). 
Conversely, extracellular WNT ligand will bind to the cell surface 
transmembrane receptor Frizzled (Fz) and its co-receptor low-density 
lipoprotein receptor-related protein 5 (LRP5) or LRP6. The generation of this 
complex recruits the scaffold protein Dishevelled (Dv1) which in turn 
phosphorylates LRP5/6 resulting in the further recruitment of the Axin complex 
to the receptor, preventing the degradation of cytoplasmic β-catenin. The 
accumulation of β-catenin allows migration into the nucleus where β-catenin 
complexes with TCF/LEF promotor sites allowing transcription (Daniels and Weis, 
2005).  
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The β-catenin independent WNT signalling pathway (non-canonical) does not 
involve LRP5/6 sensors or β-catenin yet still activates various signalling cascades 
involved in gene transcription. Two common non-canonical pathways are 
WNT/Ca2+ and WNT/PCP (planar cell polarity) also referred to as the Frizzled-
PCP pathway. These pathways have cross-talk with the canonical signalling 
pathway, often inhibiting the pathway (Mcneill and Woodgett, 2010). 
Overexpression of Wnt5a, an activator of the non-canonical signalling pathway 
can block stabilization of β-catenin (Torres et al., 1996). Conversely, inhibition 
of the canonical pathway can result in a potential activation of PCP (Rousset et 
al., 2001). Thus it is important to be aware the consequences of affecting one 
pathway on the other.  
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Figure 6-1. Canonical WNT signalling pathway. 
A schematic representation of the canonical (β-catenin dependent) WNT 
signalling pathway. (A) Signalling pathway in the absence of a WNT activator, 
resulting in the formation of the destruction complex and proteasomal 
degradation of β-catenin preventing activation of downstream promoters. (B) 
Signalling pathway in the presence of a WNT activator (e.g. WNT3a) resulting in 
the stabilisation of β-catenin and subsequent nuclear localisation binding to 
TCF/LEF promoters within the nucleus.   
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6.1.2 WNT in health and disease 
The dysregulation of WNT is known to be involved in carcinogenesis and other 
diseases (Table 6-1). Most prominently, the APC gene, a suppressor of WNT 
signalling is commonly mutated in human cancers resulting in stabilisation of β-
catenin and subsequent activation of the pathway (Polakis, 2007). Additionally, 
Axin1 and Axin2 are also mutated in a number of human cancers, again due to 
the negative regulatory nature of the proteins on the WNT pathway, thus their 
dysregulation results in a subsequent activation of the pathway (Salahshor and 
Woodgett, 2005). One such Axin1 mutant showed a reduced binding of GSK3b 
preventing the formation of the destruction complex and another Axin1 
substitution mutation interfered with Axin’s interaction with Disheveled 
(Webster et al., 2000).  
WNT has also been implicated in a number of bone diseases (Table 6-1). WNT 
activates osteoblasts and thus the inhibition or over activation of the pathway 
can result in abnormally low or high bone mass. This is evidenced by a loss-of-
function mutation in LRP6 linked to osteoporosis (Mani et al., 2007), or a deleted 
Frizzled in patients diagnosed with Williams-Beuren syndrome, a disease 
characterised by low bone density (Wang et al., 1999). WNT dysregulation has 
also been associated in metabolic disease, particularly type II diabetes. Single 
nucleotide polymorphisms (SNPs) in TCF7L2 are a strong risk determinant for the 
disease (Tong et al., 2009).  
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Protein   Mutation 
Type 
Associated Disease 
PORCN Loss-of-
function 
X-linked focal dermal hypoplasia 
WNT3 Loss-of-
function 
Tetra-amelia 
WNT4 Loss-of-
function 
Mullerian duct regression and virilisation 
WNT5B Loss-of-
function 
Type II diabetes 
WNT7A Loss-of-
function 
Fuhrmann syndrome 
WNT10A Loss-of-
function 
Odonto-onchyo-dermal hypoplasia 
WNT10B Loss-of-
function 
Obesity 
RSPO1 Loss-of-
function 
XX sex reversal with palmoplantar hyperkeratosis 
RSPO4 Loss-of-
function 
Autosomal-recessive anonychia and hyponychia 
congenital 
SOST Loss-of-
function 
High bone mass, sclerosteosis, Van Buchem disease 
Norrin 
(NDP) 
Loss-of-
function 
Famililal exudative vitreoretinopathy 
LRP5 Gain-of-
function 
Hyperparathyroid tumors, High bone mass 
LRP5 Loss-of-
function 
Osteoporosis-pseudoglioma, eye vascular effects 
LRP6 Loss-of-
function 
Early coronary disease and osteoporosis 
FZD4 Loss-of-
function 
Familial exudative vitreoretinopathy 
FZD9 Loss-of-
function 
Williams-Beuren Syndrome 
TSPAN12 Loss-of-
function 
Familial exudative vitreoretinopathy 
APCDD1 Loss-of-
function 
Hereditary hypothrochosis simplex 
Axin1 Loss-of-
function 
Caudal duplication, cancer 
Axin2 Loss-of-
function 
Tooth agenesis, cancer 
APC  Loss-of-
function 
Familial adenomatous polyposis, cancer 
WTX Loss-of-
function 
Wilms tumour, OCTS 
Β-catenin Gain-of-
function 
Cancer 
LEF1 Loss-of-
function 
Sebaceous skin tumour 
TCF4 Gain-of-
function 
Type II diabetes, colon cancer 
Table 6-1. Diseases associated with WNT component dysfunction.  
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6.1.3 Viral response to WNT signalling 
While there are many studies implicating the WNT pathways importance in 
various viral infections, how these viruses utilise and interact with the WNT 
pathway to facilitate their replication and transmission is relatively unknown. 
There are however a number of proposed ways with which viruses can interact 
with the WNT pathway. The first is cellular or viral miRNAs targeting WNT genes. 
It has been shown that miR-34 family of miRNAs repress the WNT/β-catenin 
signalling pathway and furthermore this repression has demonstrated strong 
anti-viral effects against a number of viruses including dengue virus (DENV), 
West Nile virus (WNV), ZIKV, alphaviruses and herpesviruses (Smith et al., 2017). 
There is indication that the WNT signalling pathway can influence the type-1 
interferon pathway in response to viral infection. This cross-talk between 
signalling pathways occurs with phosphorylated GSK3β interacting with TBK1, 
however in the activation of the WNT pathway, GSK3 βs recruitment to the cell 
surface receptors prevents further phosphorylation of TBK1, reducing 
downstream IRF3 phosphorylation and a reduction in IFN stimulation (Wang et 
al., 2008). This is hypothesised to function as a negative feedback loop 
preventing overstimulation of the host inflammatory response. Inhibition of WNT 
signalling, in the case of the microRNA miR-34, enhances IFN stimulation (Smith 
et al., 2017). Furthermore, inhibition of GSK3β by LiCl leads to the enhancement 
of IFN-β (Marcato et al., 2016). However, a further study has indicated this is 
mediated through TCF/ β-catenin complexes rather than IRF3 previously 
suggested (Wang et al., 2013).  
The second method in which viruses can affect WNT signalling is through 
inhibition or activation at the epigenetic level. Aberrant WNT signalling caused 
by many viruses including hepatitis B virus (HBV) and Epstein-Barr viruses are 
thought to be a key component in carcinogenesis. In HBV infection, the 
downregulation of secreted frizzled-related proteins (SFRPs), antagonists of WNT 
signalling, facilitated through the binding of hepatitis B X protein (HBx) resulted 
in the activation of WNT pathway and further hepatocarcinogenesis (Xie et al., 
2014). 
Viruses can also relocalise β-catenin or other WNT pathway components 
preventing or increasing downstream activation. In porcine circovirus-like virus 
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P1 infection, WNT is inhibited through expression of a VP1 protein that prevents 
β-catenin from entering the nucleus and accessing the TCF/LEF promoters (Zhu 
et al., 2018). Additionally hepatitis C virus (HCV) core protein and non-structural 
4B protein (NS4B) were shown to enhance the nuclear translocation of β-catenin 
thereby enhancing WNT gene transcription (Jiang et al., 2017). 
Finally, viruses can also directly interact with WNT pathway components, 
inhibiting or activating downstream WNT. In Karposi-Sarcoma Herpesvirus (KSHV) 
it has been shown that the viral protein kinase (vPK) interacts with β-catenin 
directly reducing its affinity to bind to TCF binding sites resulting in reduced 
mRNA of downstream WNT products (Cha et al., 2018). 
There are a number of other studies that have not identified a mechanism for 
the interaction of the virus with the WNT pathway, however, have determined 
that the pathway is important for viral replication. Influenza A virus has been 
shown to have significantly increased replication with WNT activated by Wnt3a, 
and has been shown to have a marked reduction in replication in β-catenin 
knockout cells or with the use of iCRT14 Wnt inhibitor, an inhibitor that targets 
the interaction between β-catenin and TCF4 (More et al., 2018). 
The interactions between RVFV nucleocapsid protein and host proteins are a 
promising target for antiviral therapies due to the decreased likelihood of 
resistance developing. The low rate of genetic change within host cells, coupled 
with the highly conserved nature of the nucleocapsid protein may result in a 
longer period of effectiveness for targeting therapeutics. Additionally, by 
targeting host proteins it massively increases the repertoire of therapeutic 
targets and may allow the discovery of broad acting drugs that disrupt 
interactions across different virus genus or families. 
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6.2 Results 
6.2.1 RVFV N proteomics studies reveals new interactions 
To investigate the interaction partners of RVFV N, an immunoprecipitation of N 
using an anti-N antibody was performed 16 hours post infection from RVFV MP12- 
infected A549 cells. The control immunoprecipitation was performed on 
uninfected cells using the same anti-N antibody (Brennan et al., 2011b). 
Following pulldown, triplicate samples were analysed by mass spectrometry to 
identify host proteins captured by RVFV N. Using a label free quantification 
approach, analysed by MaxQuant, we identified 24 potential protein interactors 
(Table 6-2), determined by the presence of at least two peptides of the 
potential interactor in 3 or more infected samples and absent or reduced 
quantities in control samples. Along with host protein interactions, N also 
interacted with the viral proteins L, Gn and NSs to varying degrees, as was 
expected. By using the protein-protein interaction database STRING to analyse 
any potential complexes or interactions between the identified proteins we 
selected a smaller panel of proteins to investigate further (Figure 6-2). Many of 
the host interactors included ribosomal proteins and heat shock proteins that are 
often found in proteomic studies of RNA viruses. The smaller selected panel of 
proteins included: Scaffold attachment factor B (SAFB), Annexin A1 (ANXA1), 
Annexin A2 (ANXA2), Polyadenylate binding protein 1 (PABP1), Polyadenylate 
binding protein 4 (PABP4) and β-catenin (CTNB1). 
  
116 
 
Protein Interactor Abbreviation  Average 
RVFV LFQ 
Intensity 
Average 
Negative 
Control LFQ 
Intensity 
Ratio 
Annexin A1 ANXA1 7545908.333 0 N/A  
Protein S100-A8 S100A8 3629366.667 0 N/A  
Heat shock protein beta-1 HSPB1 2456790 0 N/A  
Zinc finger protein Rlf RLF 1472300 0 N/A  
Protein S100-A9 S100A9 1256713.333 0 N/A  
Heterogeneous nuclear 
ribonucleoprotein H 
HRNRPH1 898650 0 N/A  
Dermcidin DCD 805200 0 N/A  
Histone H3.2 HIST2H3A 664940 0 N/A  
Annexin A2 ANXA2 487846.6667 0 N/A  
Histone H3.3 H3F3A 450430 0 N/A  
60S ribosomal protein L15 RPL15 412100 0 N/A  
Polyadenylate-binding protein 
4 
PABPC4 
(PABP4) 
395853.3333 0 N/A  
Catenin beta-1 CTNNB1 
(CTNB1) 
393190 0 N/A  
Scaffold attachment factor B1 SAFB2 294216.6667 0 N/A  
Polyadenylate-binding protein 
1 
PABPC1 
(PABP1) 
11668633 313250 37.25023 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
HNRNPA2/B1 1012630 267973.3 3.778846 
Putative uncharacterized 
protein PSMG3-AS1 
PSMG3-AS1 10661000 5119400 2.082471 
Histidine-rich glycoprotein HRG 3766067 1826967 2.061377 
Uncharacterized protein 
KIAA1671 
KIAA1671 4.59E+08 2.7E+08 1.702327 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
HNRNPC1/C2 10039533 6163383 1.6289 
Heterogeneous nuclear 
ribonucleoprotein M 
HNRNPM 2412933 1557940 1.548797 
 
Table 6-2. Potential interaction partners of RVFV N protein. 
Protein interactions identified by Mass-spectrometry using a label-free 
quantification approach. LFQ intensities shown are the average of three 
experimental repeats. Full proteomics data available via ProteomeXchange 
(Project accession: PXD010423). 
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Figure 6-2. Cytoscape interaction diagram of RVFV N protein.  
A549 cells were infected with RVFV MP12 at MOI 5 and immunoprecipitated using 
anti-N rabbit polyclonal antibody 16 hpi. Potential interactors were determined 
by evaluating LFQ intensities 30 fold or greater in infected samples compared 
with samples from uninfected cells. Interactions were assessed by STRING 
analysis, with each link representing a potential interaction identified through 
experimentation. The size of nodes indicates relative abundance of protein.  
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6.2.2 siRNA screen of potential interactors 
The effect of potential protein interactions on viral replication was assessed by 
utilising an siRNA screen targeted against the panel of interactors. A549 cells 
were transfected with siRNA targeting each protein interactor, 72 hours post 
transfection cells were infected with Renilla luciferase expressing RVFV 
MP12delNSs:hRen at MOI 0.01. Luciferase values were assessed 24 hours post 
infection. The interactions with CTNB1, ANXA1, ANXA2, PABP1 and SAFB were all 
important for the replication of the virus and showed significant reduction in 
luciferase, however the silencing of PABP4 and DCD showed no effect on the 
reporter virus (Figure 6-3). 
Additionally, an siRNA screen was performed using the T7 RNA polymerase based 
minigenome system in Huh-T7-Lunet cells to evaluate the impact of protein 
interactions on the formation of RNP complexes specifically (Figure 6-4). Huh-
T7-Lunet cells were transfected with siRNAs targeting each protein interactor. 
After 24 hours, cells were transfected with pTM1 N, pTM1 L, pTVT7-GM:hRen and 
pTM1-FF-Luc. At 24 hours post transfection, cells were harvested and luciferase 
measured. The variability of the minigenome activity resulted in no significance 
of knockdown interactors; however, there was a trend for silencing of Anxa1, 
PABP4 and SAFB to have a reducing effect on the luciferase levels in the 
minigenome system.   
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Figure 6-3. siRNA screen of potential N protein interactors infected with RVFV reporter 
A549 cells were transfected with gene specific siRNAs or negative siRNA (-ve) for 
72 hours before infection with RVFV MP12delNSs:Rluc reporter virus at MOI 0.01. 
Values of triplicate experiments were normalised to scrambled siRNA control. 
*denotes p<0.05, **p<0.001 using Student’s T-test.   
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Figure 6-4. siRNA screen of potential N protein interactors utilising an RVFV minigenome 
system.  
Huh-T7-Lunet cells were transfected with gene specific siRNAs or negative siRNA 
(-ve). At 24 hours post transfection with siRNA, cells were further transfected 
with RVFV pTM1 N, pTM1 L, pTVT7-GM:hRen and pTM1-FF-Luc. After 24 hours, 
cells were lysed and luciferase values measured. Values of triplicate 
experiments presented were normalised to negative siRNA control. Significance 
was determined by Student t-test were * denotes p<0.05.   
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6.2.3 RVFV impact on the Wnt pathway  
Evaluation of previous literature and β-catenin’s impact in the siRNA screen on 
RVFV replication indicated that β-catenin indeed does play a role in RVFV 
infection (Harmon et al., 2016). Thus, to investigate RVFV’s role and influence 
on the canonical Wnt signalling pathway, of which β-catenin is the main effector 
molecule (6.1.1), a TOPFlash (TF) system was employed. TOPFlash reporter 
plasmid utilises a pTA-Luc (Clontech) backbone with 7 TCF/LEF (AGATCAAAGG) 
binding sites, with a 5 nucleotide (GGGTA) spacer between each site driving the 
expression of the firefly luciferase gene (Veeman et al., 2003). Stable β-catenin, 
upon WNT pathway activation, binds to TCF/LEF promoters driving firefly 
expression resulting in measurable luciferase.  
A549, Huh-T7-Lunet and HEK 293FT cells were transfected with TF for 24 hours 
and subsequently infected with RVFV MP12 or eGFP expressing RVFV 
MP12delNSs:eGFP at MOI 1. The MP12delNSs:eGFP was used to determine the 
effects of NSs on the WNT pathway and to reduce the effects of general host 
transcriptional shut down on the assay. Cells were lysed and luminescence 
measured at 7 and 24 hours post infection. All three cell lines showed reduction 
in luciferase activity after both 7 and 24 hours (Figure 6-5). A549 cells displayed 
moderate reduction in activity after 7 hours and had significantly reduced 
activity compared with uninfected cells 24 hours post infection using both RVFV 
MP12 and RVFV MP12delNSs:eGFP, the former displaying slightly higher reduction 
in activity. Infection in both Huh-T7-Lunet and HEK 293FT cells resulted in 
significant inhibition of the WNT pathway at 7 and 24 hours post infection with 
both RVFV MP12 and RVFV MP12delNSs:eGFP.  
Furthermore, to determine if the inhibition of WNT was an RVFV specific effect 
or could be a characteristic of bunyaviruses in general, A549, Huh-T7-Lunet and 
HEK 293FT cells were transfected with TF for 24 hours and subsequently infected 
with BUNV or BUNVdelNSs at MOI 1. At 7 and 24 hours post infection, cells were 
lysed, and luciferase measured (Figure 6-6). Interestingly, there was a more 
varied cell specific effect. In A549 infection, BUNV showed significant reduction 
in the WNT pathway only after 24 hours, and this effect was not observed with 
BUNVdelNSs. However, in Huh-T7-Lunets there appeared to be a discreet 
activation of the pathway for BUNVdelNSs after 7 hours, however after 24 hours 
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both BUNV and BUNVdelNSs showed significant inhibition of the WNT pathway. In 
HEK 293FT cells, neither BUNV nor BUNVdelNSs showed significant inhibition of 
the pathway after 7 or 24 hours.   
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Figure 6-5. RVFV infection inhibits TOPFlash reporter activity in multiple cell types. 
(A) A549, (B) Huh-T7-Lunet and (C) HEK 293FT cells were transfected with 
TCF/LEF WNT pathway reporter plasmid TOPFlash. At 24 hours post transfection, 
cells were infected with RVFV MP12 (RVFV), RVFV MP12delNSs:eGFP (RVFVeGFP) 
or mock (C) at MOI 1. Cells were lysed at 7 h (left panel) and 24 h (right panel) 
post infection and luciferase measured. Values of triplicate experiments were 
normalised to mock infected cells. *denotes p<0.05, **p<0.001, ***p<0.0001 using 
Student’s T test.   
124 
 
 
Figure 6-6. BUNV- specific inhibition of TOPFlash activity.  
The three cell types, A549s (A), Huh-T7-Lunets (B) and HEK 293FTs (C) were 
transfected with the TOPFlash WNT activity reporter plasmid. At 24 hours post 
transfection cells were infected with BUNV, BUNVdelNSs or mock infected (C). 
At 7 h (left panel) and 24 h (right panel) post infection the cells were harvested 
and luciferase measured. Values of triplicate experiments were normalised to 
mock infected (C). *denotes P<0.05, **P<0.001, ****P<0.00001 determined by 
Student’s T-test.   
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By utilising RVFV MP12delNSs:hRen, a reporter virus expressing Renilla luciferase 
in place of the NSs gene, it was possible to further determine the importance of 
β-catenin for RVFV replication. Additionally, the generation of β-catenin KO 
A549 cells provides confirmation of knockout and thus additional evidence that 
RVFV requires β-catenin for successful replication. A549 β-catenin KO and A549 
control cells were treated with PBS/FBS or Wnt3a recombinant activator 1 hour 
pre-infection. Subsequently, cells were infected with RVFV MP12delNSs:hRen at 
MOI 0.01 (Figure 6-7). After 7, 24 and 48 hours cells were lysed and 
luminescence measured. After 7 hours, there was no effect on the replication of 
RVFV MP12delNSs:hRen by either the pre-activation or inhibition of the WNT 
pathway. At 24 hours post infection, RVFV showed reduced Renilla luciferase 
activity in A549 β-catenin KO cells as compared to control. However, the 
activation with Wnt3a did not affect viral replication. Interestingly, at 48 hours 
post infection, there was a further decrease in viral replication in β-catenin KO 
cells compared with control but also there was a significant yet mild increase in 
replication within cells treated with Wnt3a. 
Furthermore, it was important to assess the effect of β-catenin knockdown or 
activation on BUNV, to evaluate if the effect seen in RVFV is virus specific or can 
be seen in another virus family (Figure 6-8). A549 cells were transfected with 
siRNA targeting β-catenin or treated with Wnt3a recombinant activator. At 72 
hours post transfection, cells were infected with BUNV-expressing Nanoluc 
luciferase at MOI 1. At 24 hours post infection, cells were lysed and luciferase 
measured. Interestingly, the knockdown of β-catenin or the activation of the 
WNT pathway had no effect on BUNV viral replication.   
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Figure 6-7. β-catenin knockout reduces RVFV reporter infection  
(A) Western blot of A549 β-catenin KO and A549 β-catenin KO control cells. β-
catenin was knocked out using CRISPR/Cas9 and single cell populations selected. 
Negative control cells contain non-functional lentiviral cassette.   
Representative image of three experimental repeats shown. (B) A549 β-catenin 
knockout or control cells were pre-treated 1 hour prior to infection with Wnt3a 
activator or with PBS/FBS mix. Cells were subsequently infected with RVFV 
MP12delNSs:hRen at MOI 0.01. After 7, 24 or 48 hours post infection cells were 
lysed and luciferase measured. Values of triplicate experiments were normalised 
to mock treated A549 β-catenin KO control cells separately for each time point. 
*denotes p<0.05, **p<0.001 using Student’s T-test. 
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Figure 6-8. Effects of Knockdown or activation of WNT on BUNV infection 
A549 cells were transfected with siRNA, negative siRNA or treated with Wnt3a 
activator or PBS/FBS mix (Neg) 24 hours prior to infection. Cells were 
subsequently infected with BUNV Nanoluc and at 24 hours post infection, cells 
were lysed and luciferase measured. Values of triplicate experiments were 
normalised to Wnt3a negative control.   
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It has been hypothesised that RVFVs inhibition of the WNT pathway may be an 
effect of general cell death rather than specific pathway inhibition. Thus, a cell 
viability assay was performed (Figure 6-9). A549, Huh-T7-Lunet and HEK 293FT 
cells were infected with RVFV MP12, RVFV MP12delNSs:eGFP, Mock or treated 
with 2 µg/ml puromycin. At 7 hours and 24 hours post infection, luciferase based 
cell viability assay was measured. After 7 hours, there was no evidence of cell 
death in A549s, Huh-T7-Lunets or HEK293 FTs infected with either RVFV MP12 or 
the delNSs virus. At 24 hours post infection, there was evidence of gradual minor 
cell death in A549s and Huh-T7-Lunets infected with RVFV MP12 and RVFV 
MP12delNSs:eGFP. There appeared to be more significant cell death in HEK 
293FT cells when infected with RVFV MP12 however the effect was less 
pronounced in RVFV MP12delNSs:eGFP infected cells.   
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Figure 6-9. Viability of RVFV and RVFVdelNSs:eGFP infected cells 
(A) A549s, (B) Huh-T7-Lunets and (C) HEK 293FTs were infected with RVFV MP12, 
RVFV MP12delNSs:eGFP, Mock infected at MOI 1 or treated with Puromycin. After 
7 h (left panel) or 24 h (right panel) cells were harvested and luciferase 
measured. Values of triplicate experiments shown. No significance was 
determined by Student t-test.   
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The interaction between β-catenin and RVFV appears to have a proviral effect 
on replication, in addition to proteomics data suggesting a direct interaction 
with the nucleoprotein, suggested that there may be co-localisation between 
RVFV N, RNP complexes and β-catenin. A549 cells were infected with RVFV MP12 
or RVFV MP12delNSs:eGFP at MOI 1. At 24 hours post infection, cells were fixed 
and probed with anti-N rabbit polyclonal antibody and anti-β-catenin mouse 
monoclonal antibody. There was no evidence of direct co-localisation between 
β-catenin and RVFV N (Figure 6-10). There was however distinct relocalisation of 
β-catenin from the plasma membrane to a diffuse pattern across the cytoplasm. 
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Figure 6-10. β-catenin localisation during RVFV infection.  
(A) A549 cells infected with RVFV MP12 at MOI 1, cross-section displaying side by 
side comparison of infected and uninfected cells. (B) A549 cells infected with 
RVFV MP12delNSs:eGFP at MOI 1. (C) Uninfected A549 cells. RVFV MP12 N shown 
in red, β-catenin is shown in green and DRAQ7 DNA nuclear dye in blue. 
Representative images shown of three experiments.  
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6.3 Discussion 
The mutagenesis study carried out during this project indicated there may be 
novel protein-protein interactions between N and host proteins that may involve 
residues located on surface of N. The proteomics study here identified a number 
of interesting and intriguing interactions. Annexin A1 (ANXA1) is involved in the 
innate immune response as an effector of glucocorticoid-mediated responses and 
as a regulator of the inflammatory response. Additionally, ANXA1 contributes to 
the adaptive immune response by enhancing signalling cascades triggered by T-
cell activation, and further T-cell differentiation and proliferation. ANXA1 has 
also been implicated in the reorganization of the actin cytoskeleton, endosomal 
trafficking and apoptosis. ANXA1 has been implicated as an important host 
protein interactor for a number of viruses. For example, influenza A replication 
is enhanced in the presence of ANXA1. ANXA1 co-localises with early and late 
endosomes near the nucleus and has been shown to enhance trafficking of the 
virus to the nucleus evidenced from increased nuclear accumulation of viral 
nucleoprotein (Arora et al., 2016). ANXA1 was also identified in a proteomic 
screen of HIV infected cells, however there was no further study about its 
effects (Pathak et al., 2009). Interestingly, a study of HCV susceptibility of 
different liver cell types showed that HCV virus production was significantly 
reduced in cell lines stably expressing exogenous ANXA1. The study further 
demonstrated that ANXA1 specifically inhibits HCV RNA replication (Hiramoto et 
al., 2015). This indicates that ANXA1 does not have a specific proviral or 
antiviral function and therefore each viral species may interact with ANXA1 in 
different ways. 
Annexin A2 (ANXA2) was also a potential interactor of RVFV N as evidenced from 
the proteomic study. It has a wide array of functions, primarily the linking of 
membrane complexes with the actin cytoskeleton and the exocytosis of 
intracellular proteins. ANXA2 has been shown to form complexes with S100A10 
on the cell surface of macrophages and is important for HIV-1 infection of 
macrophages through the binding of HIV-1 gag proteins. The silencing of ANXA2 
by RNAi significantly inhibits HIV-1 infection (Ryzhova et al., 2006, Woodham et 
al., 2016). In HPV-16 infection, the S100A10 heterotetramer with ANXA2 is 
required for entry into HeLa cells, as evidenced by small molecule inhibitors 
ability to block this interaction (Woodham et al., 2015). ANXA2 was shown to 
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interact with classical swine fever virus (CSFV) glycoprotein E2 and the silencing 
of ANXA2 reduced viral replication whereas overexpression enhanced replication. 
However, RNA replication was not affected and the binding to CSFV NS5A 
implicated ANXA2 as being involved in viral assembly (Sheng et al., 2015). 
ANXA2s interaction has also been hypothesised to be associated with CSFV 
cellular entry (Yang et al., 2015). ANXA2 has also been identified as a RNA 
binding protein involved in modulating frameshift activity in Infectious Bronchitis 
Virus (IFV) infection (Kwak et al., 2011).  
Poly(A) binding protein 1 (PABP1) has been previously identified as an important 
protein within RVFV infection. PABP1 was shown to relocalise to the nucleus 
upon RVFV infection through the interaction with non-structural protein S (NSs). 
An siRNA screen showed no change in RVFV positive cells, however, the 
sequestration of PABP1 was hypothesised to influence the cellular environment 
to promote viral protein production (Copeland et al., 2013). This relocalisation is 
considered to block mRNA export, an important host cell process and targeted 
by many viruses (Copeland et al., 2015). The mechanism of interaction between 
NSs, PABP1 and host cell mRNA relocalisation has not been elucidated, however, 
it was observed that N alone was able to alter mRNA localisation though this was 
hypothesised to be an artefact (Copeland et al., 2015). With further evidence of 
direct PABP1 and N interaction, there may be another avenue of study to assess 
mRNA export mechanisms during RVFV infection.  
The interaction with Poly(A) binding protein 4 (PABP4), eukaryotic initiation 
factor (eIF4E) and eukaryotic initiation factor 4G (eIF4G) is important for 
efficient translation of 5’ capped and 3’ poly(A) tailed cellular mRNAs. Viruses 
often have distinct mechanisms to initiate translation within host cells, such as 
the utilisation of a highly structured 3’ untranslated region (UTR) that 
functionally replaces the poly(A) tail of some positive stranded RNA viruses 
(Edgil et al., 2003). The UTR regions of the negative-stranded BUNV have also 
been shown to mediate efficient translation of viral mRNAs though this 
interaction is independent of PABP (Blakqori et al., 2009). 
Scaffold attachment factor B (SAFB) functions as a nuclear matrix protein (NMP) 
that binds to scaffold or matrix attachment region DNA elements (S/MAR DNA), 
thus, it is thought to be important in assembling a transcriptome complex near 
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actively transcribed genes (Debril et al., 2005). They have also been implicated 
in a number of cellular processes including chromatin organization, 
transcriptional regulation, stress response and RNA splicing (Oesterreich, 2003). 
There is limited documentation on any interaction between viral infections and 
SAFB, however, it has been shown to be a target of the immediate-early protein 
BICP22 in bovine herpesvirus 1 infection (Saydam et al., 2006).  
The antimicrobial peptide Dermicidin (DCD) was found to be an interactor, 
though likely to be a contaminant, and was thus chosen as a likely negative 
control for further interaction studies. DCD is an antimicrobial peptide secreted 
by sweat glands and transported to the epidermal surface to disrupt the 
colonization of early skin pathogens (Schittek et al., 2001). DCD has been found 
previously in viral proteomics of HIV host protein interactors, though no further 
study was conducted (Pathak et al., 2009). Additionally, DCD was found to be 
upregulated in influenza A infection of A549 cells (Coombs et al., 2010). 
Lastly, the effector molecule of the WNT signalling pathway, β-catenin, was 
identified within this proteomics study as an interactor of RVFV N protein. As 
mentioned previously, the WNT signalling pathway is important for a number of 
key cellular processes such as cell homeostasis and it affects over 100 
downstream genes. The disruption of the WNT pathway has been implicated in 
cancer, tumorigenesis and metabolic diseases (Reya and Clevers, 2005, 
Kanazawa et al., 2004). 
The identification of β-catenin, ANXA1, ANXA2, PABP1, PABP4 and SAFB as 
important for viral infection was a significant finding. The previous identification 
of PABP4 and β-catenin as being involved in RVFV replication validates the 
proteomic results whilst uncovering new information. This provides a number of 
avenues with which to pursue elucidating the interactions of RVFV N protein. A 
comparison between the RVFV reporter virus siRNA screen and the minigenome 
screen may indicate a more significant involvement of PABP4 and SAFB on the 
actual formation of the RNP complexes, whereas it is more likely ANXA2 is 
involved in entry/exit processes not evaluated in the minigenome assay. The 
minigenome siRNA screens general lack of significance may be a result of a 
number of factors worthy of further investigations. The siRNA transfection was 
performed for 24 hours, which may not be sufficient time for full knockdown, as 
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evidenced from siRNA of β-catenin which required a minimum of 70 hours post 
transfection of siRNAs to reach a sufficient level of knockdown. Additionally, the 
difference in cell types may further suggest cell specific interactions identified. 
The focus of this study on β-catenin was primarily due to previous studies 
identifying the importance of the protein for RVFV infection, and the abundance 
of high quality molecular tools to help evaluate the interaction. A whole genome 
siRNA screen identified the knockdown of β-catenin to result in a significant 
reduction in viral replication (Harmon et al., 2016). Thus, the full knockout of β-
catenin and siRNA screen knockdown provided further evidence that β-catenin 
plays a role in the RVFV replication cycle. Additionally, Harmon et al identified 
small molecule inhibitors IWR-1 and JW67 that stabilise the β-catenin 
destruction complex and through this action reduce β-catenin levels and 
therefore reduce RVFV replication. In our study, we showed that activation of 
the pathway has a minor effect on RVFV replication after 48 hours. Further 
assessment of RVFV MP12 viral titre in the presence of WNT3a may be important. 
Particularly as there may be a more pronounced positive effect on viral 
replication, due to the increased inhibition of the WNT pathway of RVFV 
compared to RVFVdelNSs:eGFP. Interestingly, this effect is RVFV specific and 
does not extend to the Orthobunyavirus genus, as BUNV shows no change in 
replication dynamics in β-catenin knockdown cells or upon activation of the WNT 
pathway with Wnt3a activator (Figure 6-8). Further study may investigate other 
members of the Phlebovirus genus, such as the closely related TOSV or members 
of the tick-borne group, UUKV or SFTSV. Evaluating the effect on other 
phleboviruses may provide opportunities to test WNT pathway inhibitors as 
therapeutics upon phlebovirus infection, or may be a factor differentiating 
phleboviruses from other members of the Phenuviridae family.  
Another study on WNT in RVFV infection utilised a mouse model to investigate 
RVFV ZH548 effect on IFN-β production and the WNT pathway (Marcato et al., 
2016). This study found no significant fold change in the mRNA production of β-
catenin and differing profiles of WNT gene regulation between infection with 
RVFV MP12 and RVFV ZH548. In contrast, Harmon et al using a HEK 293T cell 
model infected with RVFV MP12 found a small but significant 1.8 fold 
upregulation of β-catenin mRNA. This indicates that RVFVs effect on the WNT 
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pathway may be virus strain or cell specific. Further study could investigate the 
variation in general expression levels of β-catenin within different tissue or cell 
types and investigate a correlation between RVFV infectivity. It has been 
proposed that the importance of β-catenin in the context of viral infection 
involves the activation of IFN-β however this is contradictory to the knockout of 
β-catenin reducing RVFV replication and thus, it is likely to be a more complex 
mechanism.  
This study identified RVFV MP12 and RVFV MP12delNSs:eGFP inhibit the TOPFlash 
WNT reporter system and thus, inhibit the WNT pathway at 7 and 24 hours post 
in infection in three distinct cell types. In contrast, Harmon et al showed a 
distinct activation of the WNT pathway by these viruses up to 7 hours post 
infection in HEK 293T cells. The inhibition of the WNT pathway is not an artefact 
of general cell death (Figure 6-9). The RVFV non-structural protein S (NSs) has 
been shown to bind to WNT pathway genes through use of a CHIP-seq assay. This 
binding includes WNT ligands, negative regulators of β-catenin (such as GSK3b) 
and β-catenin itself amongst others (Benferhat et al., 2012). This may contribute 
to WNTs inhibition, however the inhibition effect is seen in the NSs deletion 
mutant RVFV MP12delNSs:eGFP, thus NSs effect is likely non-specific to WNT 
signalling and performs other primary functions. The inhibition of WNT by RVFV 
MP12delNSs:eGFP also indicates that the effect is not due to general host 
translational shutoff by NSs. Additionally, BUNV and BUNVdelNSs showed cell 
specific inhibition of the WNT pathway, with BUNV inhibiting WNT in A549 cells 
after 24 hours but BUNVdelNSs having no significant effect. The inhibition by 
both BUNV and BUNVdelNSs after 24 hours in Huh-T7-Lunet cells and no 
inhibition in HEK 293FT cells indicates a cell specific inhibition of the WNT 
pathway that may be a non-specific effect of BUNV infection (Figure 6-6). The 
interplay between RVFVs use of β-catenin for efficient replication and RVFVs 
inhibition of the WNT pathway is unclear. It may be inhibition of WNT signalling 
is a side effect of RVFVs interaction with β-catenin, or that the modulation of 
WNT signalling itself is important for replication. 
β-catenin has been implicated as a target in a number of viral infections. The 
herpesvirus human cytomegalovirus (HCMV) inhibits the β-catenin signalling 
pathway and relocalises β-catenin to form aggregates at a central juxtanuclear 
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location (Angelova et al., 2012). Furthermore, HIV-1 tat protein has been shown 
to induce an inhibitory effect on the canonical WNT signalling pathway in 
astrocytes (Henderson et al., 2012), however, the activation of β-catenin 
reduces HIV-1 replication (Narasipura et al., 2012). Thus, it is clear that there 
are no overall anti-viral or pro-viral effects portrayed by β-catenin, and viruses 
impact the pathway in a multitude of different ways.  
This study also found that β-catenin loses its distinct localisation at the plasma 
membrane upon infection with RVFV MP12 or RVFV MP12delNSs:eGFP. RVFV may 
therefore sequester β-catenin early in infection and thus interfere with β-
catenin’s localisation to the nucleus upon activation. β-catenin was not found to 
co-localise with RVFV N at 24 hours post infection (Figure 6-10), however, the 
speed of activation with WNT activator Wnt3a may indicate this interaction 
occurs earlier in infection. The diffuse nature of RVFV N throughout the 
cytoplasm may obscure any specific β-catenin interaction. Additionally, this 
interaction may not be a direct interaction with the nucleocapsid, and could be 
in complex with other viral proteins such as L or Gn. Further investigation into 
the interaction dynamics of N and β-catenin is required. 
The important nature of the identified protein interactors, and their implication 
in other viral-host protein interactions make each target an interesting point of 
study. An understanding of these interactions may reveal new targets for 
antiviral therapy. This is evident from the impact of WNT inhibitors on RVFV 
infection (Harmon et al., 2016), and thus by understanding the mechanism 
behind the interaction, it provides a platform with which to discover new 
inhibitors or improve existing drugs. Additionally, this study uncovered more 
RVFV N protein interactors, informing on the basic molecular biology of the virus 
with which further studies can investigate the therapeutic potential of targeting 
these interactions. 
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6.4 Summary 
 A proteomics study was performed on RVFV N protein in A549 cells, 
revealing potential host-pathogen protein-protein interactions. 
 Knockdown of host proteins CTNB1, ANXA1, ANXA2, PABP1 and SAFB 
reduced RVFV replication. Minigenome activity was reduced in PABP4 and 
SAFB knockdown cells. 
 RVFV and RVFVdelNSs:eGFP inhibit the WNT pathway in A549, Huh-T7-
Lunet and HEK 293FT cell lines. The effect seen in RVFVdelNSs:eGFP 
indicates this is not general transcriptional shutdown.  
 BUNV inhibitions the WNT pathway in A549 and Huh-T7-Lunet cells after 
24 hours but not HEK 293FTs. This is likely a non-specific effect of BUNV 
NSs.  
 Knockout of β-catenin reduces RVFV replication, activation of WNT shows 
a moderate increase in RVFV replication after 48 hours.  
 Inhibition or activation of WNT has no effect on BUNV. 
 RVFV infection delocalises β-catenin from the plasma membrane resulting 
in a diffuse staining pattern throughout the cytoplasm, likely resulting in 
the inhibition of the WNT pathway. 
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Chapter 7 Bunyavirales N effect on exo-siRNA 
pathway 
7.1 Introduction 
Arbovirus infection of arthropod vectors requires an important balance between 
viral replication and survival of the vector. Replication of such viruses does not 
cause obvious pathogenesis within the vector allowing a long duration infection, 
maximising the virus transmissibility. It is hypothesised that the innate immune 
response of the invertebrate host is essential for controlling viremia and thus a 
stable and persistent infection. There are a number of important innate immune 
responses identified in mosquitos, particularly; the exogeneous siRNA pathway 
(exo-siRNA) of different RNA interference (RNAi) mechanisms are very efficient 
against viruses. Briefly, the siRNA pathway functions by identification of long 
(viral) dsRNA within the cytoplasm by an endo-ribonuclease known as Dicer 2 
(Dcr2). Dcr2 cleaves the dsRNA into short interfering RNA (siRNA) fragments of 
21 nucleotides (nt) in length which are loaded to the RNA-induced silencing 
complex (RISC) made up of the Argonaut 2 (Ago2) protein and a complex of Dcr2, 
R2D2 and other associated proteins (Hammond et al., 2000, Dana et al., 2017, 
Liu et al., 2004). The passenger strand of the siRNA duplex is degraded and the 
RISC complex remains bound to the guide strand. This RISC complex recognises 
(viral) RNA fragments complementary to the bound fragment and targets these 
for cleavage. The guide strand is thought to be retained allowing degradation of 
subsequent targets. The result is a knockdown of RNA transcripts that can 
disrupt viral replication. Research into antiviral RNAi pathways in insects has 
predominantly focussed on the model organism Drosophila melanogaster, 
however key parts of these pathways are also present in aedine mosquitos (Blair 
and Olson, 2015, Kemp and Imler, 2009). 
The effect of RNAi silencing on viral replication in vector systems has been 
extensively investigated. RVFV infection of Aedes albopictus and Aedes aegypti 
based cell lines, U4.4 and Aag2 respectively, revealed the siRNA response to 
infection was partially responsible for establishing persistence of the virus (Léger 
et al., 2013). A similar effect was shown in dengue type 2 (DENV2) infection of 
the Aag2 cell line, with DENV2 circumventing the RNAi pathway without 
completely evading it, thus indicating RNAi is involved in the balance of viral 
140 
 
persistence within the vector to aid successful transmission (Sánchez-Vargas et 
al., 2009). This is further evident by assessment of mosquito fitness upon 
suppression of RNAi effector molecules and subsequent infection with the 
alphavirus Sindbis virus (SINV), which showed a marked decrease in mosquito 
fitness, again showing the importance of the siRNA pathway for viral 
maintenance within the viral vector (Myles et al., 2008). Another key piece of 
evidence supporting RNAi as a regulator of virus infection in the vector is the 
rapid evolutionary arms race of RNAi genes, indicating the importance of RNAi as 
an antiviral mechanism (Campbell et al., 2008, Obbard et al., 2006). Regarding 
Phenuiviridae, virus specific small RNAs have been shown to be produced in 
mosquito cells during RVFV infection (Dietrich et al., 2017). Additionally, 
knocking out the RNAi components enhances RVFV replication, however no viral 
suppressor of RNAi was identified (Dietrich et al., 2017). 
The nature of RVFV N protein’s ability to non-specifically bind RNA lead to the 
hypothesis that N may non-specifically bind siRNA or precursors thereof, 
resulting in the suppression but not complete reduction of the siRNA pathway 
required for the persistence of RVFV within the mosquito vector. The 
nucleocapsid could also directly interact with siRNA machinery. The capsid 
protein of Flavivirus yellow fever virus (YFV) has recently been identified as a 
viral suppressor of siRNA through potential inhibition of Dicer-2s cleavage ability 
by non-specifically binding double stranded RNA (dsRNA) (Samuel et al., 2016). 
Additionally, it has previously been shown that BUNV NSs does not function to 
suppress the RNAi response in Ae. aegypti suggesting any suppression by BUNV 
may come from the nucleocapsid or other viral proteins (Samuel et al., 2016). 
The capability of YFV capsid to interfere with the siRNA pathway suggested that 
the function may utilised by other members of the Flavivirus genus, within the 
Flaviviridae family, such as the Zika virus (ZIKV). ZIKV was first isolated in 
Uganda in 1947 (Dick et al., 1952), however, a recent epidemic that started in 
South America in 2015 signalled a need for thorough investigation from the 
research community (Petersen et al., 2016). ZIKV has a typical flavivirus genome 
organization, a single-stranded positive sense RNA molecule with a single open 
reading frame encoding three structural proteins; precursor membrane (prM) 
protein, envelope (E) and capsid (C) protein, along with seven non-structural 
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proteins (Shi and Gao, 2017). The prM protein is thought to be involved in E 
protein folding before subsequent cleavage in the golgi network into the pr 
peptide and M protein (Tian et al., 2016). Zika E protein is the major virion 
surface protein involved in binding to host cell receptors and membrane fusion 
(Dai et al., 2016). The Zika C protein comprises the viral capsid in an icosahedral 
shape surround by a lipid bilayer derived from the host cell. The non-structural 
proteins primary function is to form the replicative complex and to antagonise 
the host immune response. NS1 and NS4A are involved in viral replication 
(Lindenbach and Rice, 1999). NS2A, NS2B and NS4B have currently unknown 
functions (Zhu et al., 2016). NS3 is involved in polyprotein processing and is 
important for viral replication. NS5 functions as an RNA-dependent RNA 
polymerase with cap snatching functions while also suppressing IFN signalling 
(Grant et al., 2016, Faye et al., 2014). 
Infection with ZIKV primarily results in asymptomatic infection though can cause 
mild febrile illness as seen with other flaviviruses such as dengue fever. 
However, there has been an association between incidences of microcephaly, 
Guillain-Barré Syndrome and other congenital abnormalities in infants born from 
ZIKV infected mothers during ZIKV outbreaks (Cao-Lormeau et al., 2016, Brasil et 
al., 2016). This suggests ZIKV specific neural tropism not found in other 
flaviviruses and the ability to cross the placental barrier (Wang et al., 2017).  
Semliki Forest Virus (SFV) is a mosquito-borne alphavirus of the Togaviridae 
family. SFV is closely related to Chikungunya virus and is often used as a model 
system for viral pathogenesis and viral encephalitis (Atkins et al., 1999). SFV 
encodes for 4 non-structural proteins in addition to the structural proteins under 
a subgenomic promotor. A designed reporter SFV contains a second duplicated 
subgenomic promotor which allows for further expression of proteins of interest 
(Varjak et al., 2017a). The virulent SFV6 strain (Ferguson et al., 2015), a mutant 
of the prototype SFV4 strain, was used as a model virus in this study for its 
ability to grow to high titres and susceptibility to genetic manipulation.  
The expression of ZIKV C by recombinant SINV was shown to cause a significant 
disease phenotype in infected mosquitos, though the mechanism behind this 
phenotype has not been established (Samuel et al., 2016). Elucidating the 
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suppression of the RNAi response in vector systems may provide avenues for 
generation of suitable vaccine candidates.  
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7.2 Results 
The replication enhancing effect of flavivirus C proteins has been previously 
described (Samuel et al., 2016), though this effect has not been observed with 
members of the Bunyaviridae family. Thus, to test the hypothesis that RVFV N, 
BUNV N or ZIKV C proteins inhibited the antiviral response in mosquitos we first 
cloned the full length ORF of RVFV N, BUNV N and ZIKV C behind the duplicated 
subgenomic promoter in the alphavirus Semliki Forest Virus (SFV) genome. 
Additionally, the tombusvirus p19 protein, known to bind siRNAs (Attarzadeh-
Yazdi et al., 2009, Silhavy et al., 2002), was cloned into SFV as a positive control 
and eGFP expressing SFV was used as a negative control. These viruses also 
expressed Renilla luciferase, which was cloned together with duplicated 
cleavage sites between the non-structural proteins nsP3 and nsP4 within the 
viral genome. Aag2 cell line was infected at a low MOI (0.01) with recombinant 
SFV expressing each protein of interest to monitor the spread of SFV by 
measurement of Renilla levels (RLuc) (Figure 7-1). The expression of ZIKV C 
resulted in enhanced replication of SFV, interestingly this effect was 
significantly greater than resulted from the expression of the RNAi suppressor 
p19. Both RVFV N and BUNV N showed inhibition of viral replication, with 
reduced replication compared with the SFV eGFP control. 
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Figure 7-1. Increased replication efficiency of recombinant SFV expressing Zika C. 
Aag2 cells were infected with SFV6(3H)-RLuc-2SG-p19, SFV6(3H)-RLuc-2SG-
ZIKV_C, SFV6(3H)-RLuc-2SG-RVFV_N, SFV6(3H)-RLuc-2SG-BUNV_N or SFV6(3H)-
RLuc-2SG-eGFP at MOI 0.01. Replication of recombinant SFV was determined by 
measurement of Renilla luciferase (RLuc) activity at each time point. 
Experiment was performed three times in quadruplicate. Significance 
determined by Student’s t-test, where * denotes p<0.05.   
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The lack of viral enhancement of SFV expressing BUNV N or RVFV N changed the 
focus of investigation to p19 and ZIKV C To further assess the replication 
enhancing activity of ZIKV C, AF319 cells (a derivate cell line of Aag2 cells with 
the key RNAi effector molecule Dicer2 knocked out (Varjak et al., 2017b)) and 
its parental cell line AF5 cells (Varjak et al., 2017b) were infected at MOI 0.01 
(Figure 7-2) or MOI 0.001 (Figure 7-3) to assess the replication of ZIKV C in RNAi 
defective cells. p19 expressing SFV showed increased replication in AF5 cells, 
however, lost the enhancing effect in RNAi deficient AF319 cells. SFV expressing 
ZIKV C showed increased replication in AF5 cells as expected. Surprisingly, the 
virus also showed significantly increased replication in AF319 cells indicating 
that the infection enhancing activity of ZIKV C is not related to or active against 
the antiviral RNAi response within the mosquito cells. The enhanced replication 
was more pronounced at MOI 0.001 compared with MOI 0.01. 
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Figure 7-2. Infection of AF5 and AF319 cells with recombinant SFV6 at MOI 0.01 
AF319 (A) and AF5 (B) cells were infected with SFV6(3H)-RLuc-2SG-p19, 
SFV6(3H)-RLuc-2SG-ZIKV_C or SFV6(3H)-RLuc-2SG-eGFP at MOI 0.01. Cells were 
harvested at respective time points and Renilla luciferase levels measured. 
Experiments were repeated three times in quadruplicate. Mean values are shown 
and error bars depict standard error. Significance determined by Student’s t-
test, where * denotes p<0.05.   
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Figure 7-3. Infection of AF5 and AF319 cells with recombinant SFV6 at MOI 0.001 
AF319 (A) and AF5 (B) cells were infected with SFV6(3H)-RLuc-2SG-p19, 
SFV6(3H)-RLuc-2SG-ZIKV_C or SFV6(3H)-RLuc-2SG-eGFP at MOI 0.001. Cells were 
harvested at respective time points and Renilla luciferase measured. 
Experiments were repeated three times in quadruplicate. Mean values are shown 
and error bars depict standard error. Significance determined by Student’s t-
test, where * denotes p<0.05.   
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Although RVFV N did not show any enhancing effects on reporter virus, it was of 
interest to determine if ZIKV C has any effect on the RNAi pathway. For this, 
Aag2 cells were infected with recombinant SFV expressing ZIKV C, p19 or eGFP. 
At 24 hours post infection, cells were transfected with a plasmid expressing 
firefly luciferase (Fluc) and Fluc specific dsRNAs or siRNAs, dsRNAs against LacZ 
or siRNAs against Hygromycin B resistance gene were used as control, 
respectively. In the case of an active RNAi system, the transfection of Fluc 
specific dsRNA or siRNA will result in the targeted destruction of Fluc 
transcripts. The transfection of dsRNA resulted in knockdown of Fluc transcripts 
for both p19 and ZIKV C. The transfection of siRNA and subsequent knockdown of 
Fluc transcripts was inhibited by p19, which showed approximately 20% activity 
compared with 5% activity in the eGFP control. The Fluc activity in the presence 
of ZIKV C interestingly showed similar knockdown to eGFP, thus showing ZIKV C’s 
replication enhancing activity is unlikely to be related to the RNAi response.  
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Figure 7-4. ZIKV capsid C has no effect on the exo-siRNA pathway 
Aag2 cells were infected with SFV6(3H)-RLuc-2SG-p19, SFV6(3H)-RLuc-2SG-
ZIKV_C or SFV6(3H)-RLuc-2SG-eGFP at MOI 1. At 24 hours post infection, cells 
were transfected with (A) siRNAs against Fluc (siFluc) or Hygromycin B resistance 
gene (siHyg) (B) dsRNA against Fluc (dsFluc) or LacZ (dsLacZ), in addition to an 
Fluc-expressing reporter plasmid. Cells were lysed 24 hours post-transfection 
and Fluc activity measured. Experiment was repeated three times in 
quadruplicate and mean shown with error bars indicating the standard error. 
Significance was determined by two-way ANOVA with * denoting p<0.05.   
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7.3 Discussion 
It is important for viruses to balance supressing host antiviral responses and host 
survivability for the successful transmission of the pathogen. There are a number 
of proteins encoded by viruses that function to counter the RNAi defence known 
as Viral suppressors of RNA silencing (VSRs) (Wu et al., 2010, Csorba et al., 
2015). VSRs have diverse mechanisms in suppressing the RNAi response. The 
primary mechanism appears to be the binding of dsRNA by VSRs and this is 
evident in a number of VSRs including influenza A virus NS1 (Bucher et al., 
2004). Interestingly, tombusvirus p19s mode of action is unique, where p19 has a 
high affinity for duplexed siRNA and has much weaker affinity for dsRNA longer 
than 22 nt, implying size specific recognition and binding of siRNA (Vargason et 
al., 2003, Ye et al., 2003). There is some evidence for VSRs expressed by 
arboviruses; the dengue non-structural protein NS4B is described to interact with 
RNAi machinery resulting in inhibition of the pathway (Kakumani et al., 2013), 
the sfRNA encoded by flaviviruses also has RNAi inhibitory activity (Schnettler et 
al., 2012) and YFV C is a candidate VSR (Samuel et al., 2016). 
RVFV N and BUNV N both bind ssRNA and dsRNA in an unspecific manner, with 
limited evidence of preference to either (Osborne and Elliott, 2000). However, 
there was no evidence for a proviral effect in comparison to eGFP expressing 
SFV. In fact, both RVFV N and BUNV N showed distinct antiviral properties which 
may be a result of the non-specific binding of SFV transcripts preventing 
efficient viral replication, however, this requires further study, alternatively, 
the effect could be an artefact. The replication enhancing effect of SINV 
expressing ZIKV C had previously been described and was suggested to be the 
result of RNAi silencing as seen for YFV (Samuel et al., 2016). YFV C was shown 
to bind dsRNA in vitro and thus interfere with cleavage by Dicer thereby 
inhibiting the RNAi response. Interestingly, ZIKV C proviral effect was evident in 
Dicer2 knockout A319 cells and an RNAi reporter assay showed ZIKV C had no 
effect on dsRNA or siRNA mediated silencing. Therefore, the mechanism of ZIKV 
C replication enhancing effect is unknown. This highlights that despite the 
evidence that many flavivirus C proteins provide replication enhancing effects to 
alphaviruses, their means can be different. 
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Interestingly, p19 had no silencing effect upon the transfection of dsRNA into the 
reporter system. This is likely due to p19s mechanism of specifically binding 
duplexed siRNA, and thus the silencing effect was more pronounced when siRNA 
was transfected directly, resulting in an abundance of available targets for p19s 
inhibitory activity. ZIKV C replication enhancing activity was significantly higher 
than the effect provided by p19, suggesting that the ZIKV C enhancement of 
infection by an unknown mechanism has a more significant effect than 
overcoming the antiviral properties of RNAi.  
Understanding the mechanisms governing persistence of viruses within their 
vectors allows the exploitation of interactions, particularly those which impact 
the innate immune system. These interactions can be investigated as 
therapeutic targets or as mechanisms for vector control.  
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7.4 Summary 
 Recombinant SFV reporter viruses expressing RVFV N, BUNV N and ZIKV C 
proteins along with positive and negative controls were generated.  
 RVFV N and BUNV N reduced replication of SFV in Aag2 mosquito cells and 
are not likely to display RNAi-antagonistic activities.  
 ZIKV C significantly increased replication of SFV in Aag2 cells. 
 ZIKV C showed significantly increased replication of SFV in AF5 cells with 
functional siRNA pathway and in A319 cells with impaired Dcr2. This 
effect was more pronounced in low MOI infections.  
 ZIKV C showed no inhibitory effect on the siRNA pathway  
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Chapter 8 General Discussion 
8.1 Project Outcomes 
The main focus and primary aim of this project was to inform on the 
fundamental processes involved in the replication cycle of RVFV with particular 
focus on the nucleocapsid protein N, and its potential interactions within host 
cells during infection. 
At the beginning of the project, we sought to identify conserved regions of the 
nucleocapsid protein that may act as interaction domains between the 
nucleocapsid and RVFV or host proteins. By performing a sequence alignment 
and assessment of the 3D structure, five residues were selected for further 
investigation (Chapter 5). I used a site-directed mutagenesis approach to 
perform alanine substitutions for these key nucleocapsid residues, as well as two 
N-terminal arm deletions that had previously been indicated as functional 
(unpublished data). By performing crosslinking, RNA binding, 
immunoprecipitation assays and utilising minigenome reporter systems, I 
identified two novel functional residues, F11 and F149 that, despite performing 
all known functions of RVFV N, showed no activity in the minigenome assay when 
mutated to alanine. Unfortunately, despite multiple attempts of virus rescue it 
was not possible within the project’s timeframe to utilise reverse genetics 
systems to rescue RVFV containing each mutation.  This was due to laboratory 
wide issues rescuing wildtype RVFV. Ultimately, by informing on the RVFV N 
functional residues we provided useful data for further study, particularly with 
regards to potential interaction sites of RVFV with host proteins. Furthermore, 
the discovery of the mutant Y30A with increased replication capacity, despite 
reduced RNA binding, could open avenues for replication competent attenuated 
vaccines.  
Previous studies investigating RVFV host protein interactions have mostly been 
limited to RVFV NSs and understanding its antagonistic properties. I was 
interested in elucidating the interactions of RVFV N protein with an aim to 
identify interactions essential for the RVFV life cycle. Using a proteomics-based 
approach, I identified 23 potential host protein interactors with RVFV N in A549 
cells during infection, 2 of which had been previously identified as having a role 
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in RVFV virus-host interaction and 21 were newly identified. This initial study 
provides a basis for further investigation into RVFV N roles. After testing each 
interaction by siRNA knockdown, I identified interactions involved in RVFV 
replication. This screen allowed me to make an informed decision on which 
interactions would be most relevant for further investigations. The large body of 
previous research on the WNT pathway, the availability of molecular tools and a 
prior indication of the WNT pathway’s importance in RVFV infection made β-
catenin a prime candidate for further experiments. 
By employing a TOPFlash reporter assay, I informed on RVFV’s inhibition of the 
WNT pathway and by developing a CRISPR-Cas9 β-catenin knockout cell line I 
provided a useful tool for further study of interactions between RVFV and WNT 
pathway. Using the knockout A549 cell line, I highlighted the impact of β-catenin 
for efficient RVFV replication. Additionally, I identified a small but enhancement 
of RVFV replication upon WNT pathway activation. Utilising a confocal 
microscopy-based approach, I identified a change in localisation of β-catenin 
from the plasma membrane during the infection to a cytoplasmic disperse 
localisation. This study has identified β-catenin as an important interactor of 
RVFV N protein that is involved in modulating replication of RVFV. The disruption 
of this interaction or the WNT pathway itself may provide therapeutic potential 
to RVFV infection. 
During the course of this PhD, a study on YFV revealed dsRNA binding properties 
of its capsid protein that allowed YFV to evade the RNAi response in mosquito 
cells (Samuel et al., 2016). In light of this, it was hypothesised that RVFV and 
BUNVs non-specific binding of RNA may also influence the RNAi response in a 
similar manner. I cloned RVFV N, BUNV N and ZIKV C into the subgenomic region 
of a reporter SFV. By utilising these reporter viruses, I identified RVFV N and 
BUNV N both provided a fitness disadvantage, however, ZIKV C showed greatly 
increased viral replication. I continued investigation into ZIKV C and identified 
its replication enhancing activity unrelated to the RNAi antagonistic activity. 
Uncovering the mechanism behind the replication enhancing activity of ZIKV C 
will increase our understanding of ZIKV C’s modulation of viral replication within 
the mosquito vector. Hover, clearly bunyavirus N proteins are not likely to have 
RNAi antagonistic activity.  
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8.2 Future Studies 
The importance of RVFV is highlighted by the constant threat of outbreaks across 
the continent of Africa. This is evidenced by a significant outbreak in Niger in 
2016 that infected both humans and ruminants and most recently, evidence of 
ongoing human infection in Uganda, July 2018. The lack of therapeutics and 
vaccines is an ever-present issue that will be amplified by the potential spread 
of RVFV vector mosquitos into southern Europe. 
The identification of essential functional residues within RVFV N opens many 
avenues for future research. In particular, the generated panel of mutants can 
be combined with the siRNA screen designed from the proteomics screen, 
focusing on mutants F11A and F149A. The cloning of mutants F11A and F149A 
into a plasmid backbone containing a mammalian promoter such as a CMV 
promoter would allow expression within A549 cells and other mammalian cell 
systems. Overexpression of these mutants within A549 cells, application of the 
siRNA screen and subsequent immunoprecipitation of RVFV N mutants, followed 
by probing using antibodies against potential interactors such as β-catenin would 
inform on whether these residues disrupt specific interactions. Alternatively, 
using a proteomics approach on immunoprecipitated mutant N proteins and 
comparing between the wildtype interaction panel one can make an informed 
decision on any interactions that may be disrupted, which can lead to 
therapeutic targets or viruses/replicons that can be manipulated or selected for 
via specific interactions. This could lead to novel restricted vaccination strains. 
The lack of licenced RVFV vaccines is a persistent issue. While RVFV MP12 is a 
well-studied attenuated vaccine candidate, RVFV MP12 retains some virulence 
and has been shown to result in fetal death in sheep (Morrill et al., 2013). Thus, 
recombinant RVFV MP12 N mutants with specific cell ranges may unveil potential 
vaccine candidates that might reduce issues of virulence.  
The siRNA experiment itself allows a number of interesting leads for follow up 
studies. Annexin A1 and A2 have been shown to be important in many viral 
infections. Annexin A2 knockout reduced virus reporter activity however it did 
not affect the formation of viral RNPs or viral replication directly (Chapter 6). As 
ANXA2 has RNA binding activity and has been shown to be involved in the 
frameshift efficiency of viral proteins (Kwak et al., 2011), it may be involved in 
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altering the balance of GnGc expression and its various cleavage products, 
resulting in reduced particle formation. ANXA2 may also interact with the 
formation of viral particles directly at the Golgi apparatus. By employing VLP 
assays, one can elucidate ANXA2s interaction with RVFV during the virus life 
cycle. Additionally, the use of immunoprecipitation to pulldown ANXA2 from 
RVFV infected cells may reveal if the interaction with N is direct or mediated by 
viral glycoproteins. Additionally, by dissociating and sequencing the RNA bound 
to ANXA2, we may uncover specific RVFV bound sequence motifs.  
The identification of PABP1 and PABP4 are also significant and can be 
investigated further. Investigating the direct interaction of RVFV N and PABP1 
may be important. The overexpression of PABP1 promotes human 
cytomegalovirus (HCMV) protein synthesis (Perez et al., 2011), thus, it may 
support a similar function in RVFV infection. A recent study generated and 
characterized an RNA substrate that binds to PABP with high specificity 
impairing PABP function (Barragán-Iglesias et al., 2018). Utilising such a 
substrate would allow investigation into the mechanism of interaction with RVFV 
N and its impact on RVFV replication. 
The limited study on SAFBs interaction within virus infection implies a more 
explorative study to untangle the importance of SAFB for RVFV replication. 
SAFBs function in healthy cells is binding of DNA elements for transcription and 
its involvement in RNA splicing may play a role in RVFV infection. Using confocal 
microscopy to identify the intracellular localisation of SAFB in relation to RVFV N 
at varying timepoints during RVFV infection would inform on the relationship 
during RVFV replication. 
During this study, I focused on one specific interactor, and I identified β-catenin 
to be important for RVFV replication. The presence of β-catenin is required for 
efficient viral replication. Currently the downstream effect of RVFV infection on 
the WNT pathway is not clearly understood. By utilising qPCR, one can assess 
many of the downstream genes for which β-catenin is a transcription factor for. 
In turn, each of these downstream genes may also influence RVFV infection. 
Furthermore, RNASeq of A549 cells after infection by RVFV would provide a 
global overview of RNA transcription that may allow the identification of new 
co-factors related to β-catenin and the regulation of the WNT pathway. The 
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relocalisation of β-catenin during RVFV infection can be studied further, in 
particular using confocal microscopy combined with live cell imaging to assess 
earlier timepoints during RVFV infection. Confocal imagery of RVFV N and β-
catenin at early timepoints may allow observation of the direct infection 
between these two proteins. A more thorough analysis of WNT pathway 
activation and the dynamics of RVFV infection would inform on the observed 
RVFV replication enhancing effect of WNT activation. Such an effect may be 
timepoint specifc or cell specific. The relocalisation may be due to the 
invagination of the plasma membrane during the virus particles entry into 
endosomes, or by some other mechanism. Understanding this process would 
allow specific targeting of the β-catenin – RVFV interaction at timepoints where 
the interaction is the most important for the virus lifecycle.  
The identification of RVFV N and BUNV N not acting as RNAi antagonists indicates 
that non-specific binding of RNA transcripts is not sufficient as a mechanism for 
RNAi antagonism. Additionally, the discovery of ZIKV C as a significant proviral 
protein that also does not work through the antagonism of the RNAi response in 
mosquitos implies that capsid or nucleocapsid proteins may not have general 
RNAi antagonistic properties. Further work is required to evaluate RVFVs 
interaction with mosquito cell proteins that allow the balance between efficient 
viral replication and mosquito cell fitness.  
Work from this PhD provided new insights into the mechanisms, molecular 
characterisations and host protein interactions of RVFV nucleocapsid protein. By 
expanding the knowledge of RVFVs interaction with host cell pathways, I have 
provided a strong basis for future study and the potential development of 
therapeutics. The interaction of β-catenin with RVFV is a strong candidate for 
intervention strategies. Understanding these processes is important as RVFV 
continues to be a public health threat.  
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Chapter 9 Appendices 
9.1 Oligonucleotides  
Table 9-1. Oligonucleotide primers used for generation of RVFV nucleocapsid mutant 
plamsids 
Primer Sequence (5’ → 3’) Purpose 
PTM1 Plus ATG Rev 
PTM1 N-2-15-Fwd 
PTM1 N2-30 Fwd 
[Phos]CATGGTATTATCGTGTTTTTCAAAGGAAAAC 
GTGGACCGCAATGAGATTGAACAGTGGGTC  
AAGGGTTTGATGCCCGTAGAGTTATCGAAC 
Site directed 
mutagenesis of 
pTM1-RVFV_N 
sequence 
PTM1 P11A Fwd 
PTM1 P11A Rev 
GCCGCTGCTCAAGCAGTGGACCGC 
[Phos]CTGGATCGCAAGCTCTTGATAG 
 
Site directed 
mutagenesis of 
pTM1-RVFV_N 
sequence 
Y30 Fwd 
Y30 Rev  
GGTCCGAGAGTTTGCTGCTCAAGGGTTTGA 
TCAAACCCTTGAGCAGCAAACTCTCGGACC 
Site directed 
mutagenesis of 
pTM1-RVFV_N 
sequence 
Asp34Ala Fwd 
Asp34Ala Rev 
CCGCCCGTAGAGTTATCGAAC 
CAAACCCTTGATAAGCAAACTC 
Site directed 
mutagenesis of 
pTM1-RVFV_N 
sequence 
Phe149Ala Fwd 
Phe149Ala Rev 
GCCGCTGGCATGGTGGATCCTTC 
GCTGGGGTGCATCATATGCCTC 
 
Site directed 
mutagenesis of 
pTM1-RVFV_N 
sequence 
Asp181Ala Fwd 
Asp181Ala Rev 
GCCCCAAACCTCCGAGGTAGAAC 
GATGACCCGGGAGAACTGCAGC 
Site directed 
mutagenesis of 
pTM1-RVFV_N 
sequence 
 
159 
 
 
Primer Sequence (5’ → 3’) Purpose 
p14 P11A Fwd 
p14 P11A Rev 
CAAGAGCTTGGATCCAGGCCGCTGCTCAAGCAGTGGAC 
 
 
GTCCACTGCTTGAGCAGCCGGCTGGATCGCAAGCTCTTG 
Site directed 
mutagenesis of p14-
RVFV_N sequence 
p14 Asp34Ala Fwd 
p14 Asp34Ala Rev 
CCGCCCGTAGAGTTATCGAAC 
[Phos]CAAACCCTTGATAAGCAAACTC 
Site directed 
mutagenesis of p14-
RVFV_N sequence 
p14 Phe149Ala Fwd 
p14 Phe149Ala Rev 
GCCGCTGGCATGGTGGATCCTTC 
 
[Phos]GCTGGGGTGCATCATATGCCTC 
 
Site directed 
mutagenesis of p14-
RVFV_N sequence 
p14 Asp181Ala Fwd 
p14 Asp181Ala Rev 
GCCCCAAACCTCCGAGGTAGAAC 
[Phos]GATGACCCGGGAGAACTGCAGC 
Site directed 
mutagenesis of p14-
RVFV_N sequence 
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Table 9-2. Oligonucleotide primers used for generation of SFV6 constructs. 
Primer Sequence (5’ → 3’) Purpose 
Zika_C 
Fwd 
Zika_C 
Rev 
CGTTAATACAGGATCCATGAAAAACCCAAAAAAGAAATCC 
CTACCCTAACGGATCCTTATGCCATAGCTGTGGTCAGCAG 
Insertion of ZIKV C 
sequence before 
subgenomic region 
of SFV6 plasmid 
Bun_N 
Fwd 
Bun_N 
Rev 
CGTTAATACAGGATCCATGATTGAGTTGGAATTTCATGATG 
CTACCCTAACGGATCCTTACATGTTGATTCCGAATTTAG 
Insertion of BUNV 
N sequence before 
subgenomic region 
of SFV6 plasmid 
Rift_N 
Fwd 
Rift_N 
Rev 
CGTTAATACAGGATCCATGGACAACTATCAAGAGCTTGCG 
CTACCCTAACGGATCCTTAGGCTGCTGTCTTGTAAGCCTG 
Insertion of RVFV N 
sequence before 
subgenomic region 
of SFV6 plasmid 
eGFP Fwd 
eGFP Rev 
CGTTAATACAGGATCCATGGTGAGCAAGGGCGAGGAGCTG 
CTACCCTAACGGATCCTTACTTGTACAGCTCGTCCATGCC 
Insertion of eGFP 
sequence before 
subgenomic region 
of SFV6 plasmid 
P19 Fwd 
P19 Rev 
CGTTAATACAGGATCCATGGAACGAGCTATACAAGGA 
CTACCCTAACGGATCCTTACTCGCTTTCTTTTTCGAAG 
Insertion of P19 
sequence before 
subgenomic region 
of SFV6 plasmid 
 
  
161 
 
9.2 Sequence Alignment  
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Figure 9-1. Complete sequence alignment of Phlebovirus N sequences  
Phlebovirus N Genbank sequences were aligned using Geneious. Conserved amino 
acids are colour highlighted. Amino acid positioning relative to UUKV N.  
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